<?xml-stylesheet type="text/xsl" href="varreports_v3.xsl"?><data_table name="afucomposite" dataset_id="pht006416.v2" study_name="Atherosclerosis Risk in Communities (ARIC) Cohort" study_id="phs000280.v5" participant_set="1" date_created="2018/11/19"><description>Annual Follow-up Form. Participants with or without atherosclerosis and cardiovascular disease and involved in the "Atherosclerosis Risk in Communities (ARIC) Cohort" project.</description><variable id="phv00294620.v2.p1" var_name="SUBJECT_ID" calculated_type="string" reported_type=""><description>Subject ID</description><total><subject_profile><sex><male>6633</male><female>7854</female></sex></subject_profile><stats><stat n="312826" nulls="0"/></stats></total></variable><variable id="phv00294620.v2.p1.c1" var_name="SUBJECT_ID" calculated_type="string" reported_type=""><description>Subject ID</description><total><subject_profile><sex><male>6626</male><female>7846</female></sex></subject_profile><stats><stat n="312439" nulls="0"/></stats></total></variable><variable id="phv00294620.v2.p1.c2" var_name="SUBJECT_ID" calculated_type="string" reported_type=""><description>Subject ID</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="387" nulls="0"/></stats></total></variable><variable id="phv00294621.v2.p1" var_name="AFUcomp2_A" calculated_type="string" reported_type=""><description>A. Vital Status. FINAL STATUS Q2 IN AFUA-M; Q1 IN AFU V1-V3, SAF1 V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6633</male><female>7854</female></sex></subject_profile><stats><stat n="312402" nulls="424"/><enum count="289434">C</enum><enum count="6322">R</enum><enum count="6201">U</enum><enum count="5574">D</enum><enum count="2870">F</enum><enum count="2001">W</enum></stats></total></variable><variable id="phv00294621.v2.p1.c1" var_name="AFUcomp2_A" calculated_type="string" reported_type=""><description>A. Vital Status. FINAL STATUS Q2 IN AFUA-M; Q1 IN AFU V1-V3, SAF1 V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6626</male><female>7846</female></sex></subject_profile><stats><stat n="312015" nulls="424"/><enum count="289048">C</enum><enum count="6322">R</enum><enum count="6201">U</enum><enum count="5574">D</enum><enum count="2869">F</enum><enum count="2001">W</enum></stats></total></variable><variable id="phv00294621.v2.p1.c2" var_name="AFUcomp2_A" calculated_type="string" reported_type=""><description>A. Vital Status. FINAL STATUS Q2 IN AFUA-M; Q1 IN AFU V1-V3, SAF1 V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="387" nulls="0"/><enum count="386">C</enum><enum count="1">F</enum></stats></total></variable><variable id="phv00294622.v2.p1" var_name="AFUcomp3_A" calculated_type="string" reported_type=""><description>A. Vital Status. STATUS INFORMATION  Q3 IN AFUA-M [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6633</male><female>7854</female></sex></subject_profile><stats><stat n="272660" nulls="40166"/><enum count="263393">A</enum><enum count="4120">G</enum><enum count="3695">D</enum><enum count="668">B</enum><enum count="358">I</enum><enum count="272">H</enum><enum count="102">F</enum><enum count="34">E</enum><enum count="18">C</enum></stats></total></variable><variable id="phv00294622.v2.p1.c1" var_name="AFUcomp3_A" calculated_type="string" reported_type=""><description>A. Vital Status. STATUS INFORMATION  Q3 IN AFUA-M [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6626</male><female>7846</female></sex></subject_profile><stats><stat n="272329" nulls="40110"/><enum count="263062">A</enum><enum count="4120">G</enum><enum count="3695">D</enum><enum count="668">B</enum><enum count="358">I</enum><enum count="272">H</enum><enum count="102">F</enum><enum count="34">E</enum><enum count="18">C</enum></stats></total></variable><variable id="phv00294622.v2.p1.c2" var_name="AFUcomp3_A" calculated_type="string" reported_type=""><description>A. Vital Status. STATUS INFORMATION  Q3 IN AFUA-M [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="331" nulls="56"/><enum count="331">A</enum></stats></total></variable><variable id="phv00294623.v2.p1" var_name="AFUcomp6_A" calculated_type="string" reported_type=""><description>C. General Health. HEALTH COMPARED TO OTHERS? Q6 IN AFUA-M; Q17 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6551</male><female>7818</female></sex></subject_profile><stats><stat n="277710" nulls="35116"/><enum count="141292">G</enum><enum count="75845">E</enum><enum count="48450">F</enum><enum count="12123">P</enum></stats></total></variable><variable id="phv00294623.v2.p1.c1" var_name="AFUcomp6_A" calculated_type="string" reported_type=""><description>C. General Health. HEALTH COMPARED TO OTHERS? Q6 IN AFUA-M; Q17 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6544</male><female>7810</female></sex></subject_profile><stats><stat n="277351" nulls="35088"/><enum count="141037">G</enum><enum count="75770">E</enum><enum count="48423">F</enum><enum count="12121">P</enum></stats></total></variable><variable id="phv00294623.v2.p1.c2" var_name="AFUcomp6_A" calculated_type="string" reported_type=""><description>C. General Health. HEALTH COMPARED TO OTHERS? Q6 IN AFUA-M; Q17 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="359" nulls="28"/><enum count="255">G</enum><enum count="75">E</enum><enum count="27">F</enum><enum count="2">P</enum></stats></total></variable><variable id="phv00294624.v2.p1" var_name="AFUcomp7_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN SINCE LAST CONTACT Q7 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6549</male><female>7818</female></sex></subject_profile><stats><stat n="134682" nulls="178144"/><enum count="112759">N</enum><enum count="21923">Y</enum></stats></total></variable><variable id="phv00294624.v2.p1.c1" var_name="AFUcomp7_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN SINCE LAST CONTACT Q7 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6542</male><female>7810</female></sex></subject_profile><stats><stat n="134531" nulls="177908"/><enum count="112629">N</enum><enum count="21902">Y</enum></stats></total></variable><variable id="phv00294624.v2.p1.c2" var_name="AFUcomp7_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN SINCE LAST CONTACT Q7 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="151" nulls="236"/><enum count="130">N</enum><enum count="21">Y</enum></stats></total></variable><variable id="phv00294625.v2.p1" var_name="AFUcomp8_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN WHEN WALK UPHILL Q8 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3182</male><female>4173</female></sex></subject_profile><stats><stat n="21900" nulls="290926"/><enum count="14833">N</enum><enum count="6713">Y</enum><enum count="354">H</enum></stats></total></variable><variable id="phv00294625.v2.p1.c1" var_name="AFUcomp8_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN WHEN WALK UPHILL Q8 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3177</male><female>4168</female></sex></subject_profile><stats><stat n="21879" nulls="290560"/><enum count="14815">N</enum><enum count="6710">Y</enum><enum count="354">H</enum></stats></total></variable><variable id="phv00294625.v2.p1.c2" var_name="AFUcomp8_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN WHEN WALK UPHILL Q8 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>5</male><female>5</female></sex></subject_profile><stats><stat n="21" nulls="366"/><enum count="18">N</enum><enum count="3">Y</enum></stats></total></variable><variable id="phv00294626.v2.p1" var_name="AFUcomp9_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN WHEN WALK AT AN ORDINARY PACE Q9 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1239</male><female>1689</female></sex></subject_profile><stats><stat n="7043" nulls="305783"/><enum count="4221">N</enum><enum count="2822">Y</enum></stats></total></variable><variable id="phv00294626.v2.p1.c1" var_name="AFUcomp9_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN WHEN WALK AT AN ORDINARY PACE Q9 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1237</male><female>1688</female></sex></subject_profile><stats><stat n="7040" nulls="305399"/><enum count="4218">N</enum><enum count="2822">Y</enum></stats></total></variable><variable id="phv00294626.v2.p1.c2" var_name="AFUcomp9_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN WHEN WALK AT AN ORDINARY PACE Q9 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>2</male><female>1</female></sex></subject_profile><stats><stat n="3" nulls="384"/><enum count="3">N</enum></stats></total></variable><variable id="phv00294627.v2.p1" var_name="AFUcomp10_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. WHAT DO YOU DO IF YOU GET CHEST PAIN Q10 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1235</male><female>1682</female></sex></subject_profile><stats><stat n="7023" nulls="305803"/><enum count="6075">S</enum><enum count="948">C</enum></stats></total></variable><variable id="phv00294627.v2.p1.c1" var_name="AFUcomp10_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. WHAT DO YOU DO IF YOU GET CHEST PAIN Q10 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1233</male><female>1681</female></sex></subject_profile><stats><stat n="7020" nulls="305419"/><enum count="6073">S</enum><enum count="947">C</enum></stats></total></variable><variable id="phv00294627.v2.p1.c2" var_name="AFUcomp10_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. WHAT DO YOU DO IF YOU GET CHEST PAIN Q10 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>2</male><female>1</female></sex></subject_profile><stats><stat n="3" nulls="384"/><enum count="2">S</enum><enum count="1">C</enum></stats></total></variable><variable id="phv00294628.v2.p1" var_name="AFUcomp11_A" calculated_type="string" reported_type=""><description>C. General Health. WHAT HAPPENS TO CHEST PAIN IF STAND STILL Q11 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1081</male><female>1471</female></sex></subject_profile><stats><stat n="6073" nulls="306753"/><enum count="5558">R</enum><enum count="515">N</enum></stats></total></variable><variable id="phv00294628.v2.p1.c1" var_name="AFUcomp11_A" calculated_type="string" reported_type=""><description>C. General Health. WHAT HAPPENS TO CHEST PAIN IF STAND STILL Q11 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1080</male><female>1470</female></sex></subject_profile><stats><stat n="6071" nulls="306368"/><enum count="5556">R</enum><enum count="515">N</enum></stats></total></variable><variable id="phv00294628.v2.p1.c2" var_name="AFUcomp11_A" calculated_type="string" reported_type=""><description>C. General Health. WHAT HAPPENS TO CHEST PAIN IF STAND STILL Q11 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="2">R</enum></stats></total></variable><variable id="phv00294629.v2.p1" var_name="AFUcomp12_A" calculated_type="string" reported_type=""><description>C. General Health. HOW SOON CHEST PAIN RELIEVED Q12 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1030</male><female>1386</female></sex></subject_profile><stats><stat n="5555" nulls="307271"/><enum count="4610">L</enum><enum count="945">M</enum></stats></total></variable><variable id="phv00294629.v2.p1.c1" var_name="AFUcomp12_A" calculated_type="string" reported_type=""><description>C. General Health. HOW SOON CHEST PAIN RELIEVED Q12 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1029</male><female>1385</female></sex></subject_profile><stats><stat n="5553" nulls="306886"/><enum count="4608">L</enum><enum count="945">M</enum></stats></total></variable><variable id="phv00294629.v2.p1.c2" var_name="AFUcomp12_A" calculated_type="string" reported_type=""><description>C. General Health. HOW SOON CHEST PAIN RELIEVED Q12 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="2">L</enum></stats></total></variable><variable id="phv00294630.v2.p1" var_name="AFUcomp13a_A" calculated_type="string" reported_type=""><description>C. General Health. STERNUM (UPPER OR MIDDLE) PAIN Q13A IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>910</male><female>1238</female></sex></subject_profile><stats><stat n="4587" nulls="308239"/><enum count="3625">Y</enum><enum count="962">N</enum></stats></total></variable><variable id="phv00294630.v2.p1.c1" var_name="AFUcomp13a_A" calculated_type="string" reported_type=""><description>C. General Health. STERNUM (UPPER OR MIDDLE) PAIN Q13A IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>909</male><female>1237</female></sex></subject_profile><stats><stat n="4585" nulls="307854"/><enum count="3624">Y</enum><enum count="961">N</enum></stats></total></variable><variable id="phv00294630.v2.p1.c2" var_name="AFUcomp13a_A" calculated_type="string" reported_type=""><description>C. General Health. STERNUM (UPPER OR MIDDLE) PAIN Q13A IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="1">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294631.v2.p1" var_name="AFUcomp13b_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. STERNUM (LOWER) PAIN Q13B IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>910</male><female>1234</female></sex></subject_profile><stats><stat n="4574" nulls="308252"/><enum count="3644">N</enum><enum count="930">Y</enum></stats></total></variable><variable id="phv00294631.v2.p1.c1" var_name="AFUcomp13b_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. STERNUM (LOWER) PAIN Q13B IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>909</male><female>1233</female></sex></subject_profile><stats><stat n="4572" nulls="307867"/><enum count="3643">N</enum><enum count="929">Y</enum></stats></total></variable><variable id="phv00294631.v2.p1.c2" var_name="AFUcomp13b_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. STERNUM (LOWER) PAIN Q13B IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="1">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294632.v2.p1" var_name="AFUcomp13c_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. LEFT ANTERIOR CHEST PAIN Q13C IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>910</male><female>1235</female></sex></subject_profile><stats><stat n="4578" nulls="308248"/><enum count="2785">N</enum><enum count="1793">Y</enum></stats></total></variable><variable id="phv00294632.v2.p1.c1" var_name="AFUcomp13c_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. LEFT ANTERIOR CHEST PAIN Q13C IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>909</male><female>1234</female></sex></subject_profile><stats><stat n="4576" nulls="307863"/><enum count="2783">N</enum><enum count="1793">Y</enum></stats></total></variable><variable id="phv00294632.v2.p1.c2" var_name="AFUcomp13c_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. LEFT ANTERIOR CHEST PAIN Q13C IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="2">N</enum></stats></total></variable><variable id="phv00294633.v2.p1" var_name="AFUcomp13d_A" calculated_type="string" reported_type=""><description>C. General Health. LEFT ARM PAIN Q13D IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>908</male><female>1231</female></sex></subject_profile><stats><stat n="4571" nulls="308255"/><enum count="3527">N</enum><enum count="1044">Y</enum></stats></total></variable><variable id="phv00294633.v2.p1.c1" var_name="AFUcomp13d_A" calculated_type="string" reported_type=""><description>C. General Health. LEFT ARM PAIN Q13D IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>907</male><female>1230</female></sex></subject_profile><stats><stat n="4569" nulls="307870"/><enum count="3525">N</enum><enum count="1044">Y</enum></stats></total></variable><variable id="phv00294633.v2.p1.c2" var_name="AFUcomp13d_A" calculated_type="string" reported_type=""><description>C. General Health. LEFT ARM PAIN Q13D IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="2">N</enum></stats></total></variable><variable id="phv00294634.v2.p1" var_name="AFUcomp13e_A" calculated_type="string" reported_type=""><description>C. General Health. OTHER PAINS Q13E IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>907</male><female>1227</female></sex></subject_profile><stats><stat n="4552" nulls="308274"/><enum count="3559">N</enum><enum count="993">Y</enum></stats></total></variable><variable id="phv00294634.v2.p1.c1" var_name="AFUcomp13e_A" calculated_type="string" reported_type=""><description>C. General Health. OTHER PAINS Q13E IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>906</male><female>1226</female></sex></subject_profile><stats><stat n="4550" nulls="307889"/><enum count="3558">N</enum><enum count="992">Y</enum></stats></total></variable><variable id="phv00294634.v2.p1.c2" var_name="AFUcomp13e_A" calculated_type="string" reported_type=""><description>C. General Health. OTHER PAINS Q13E IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="1">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294635.v2.p1" var_name="AFUcomp13f_A" calculated_type="string" reported_type=""><description>C. General Health. SPECIFY IF OTHER PAINS Q13F IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>317</male><female>433</female></sex></subject_profile><stats><stat n="1082" nulls="311744" mean_count="3.502" sd="10.17" median_count="1" min_count="1" max_count="98" distinct_vals="309"/><example count="98">RIGHT ARM</example><example count="89">BACK</example><example count="66">NECK</example><example count="58">CHEST</example><example count="56">SHOULDER</example><example count="35">THROAT</example><example count="32">RIGHT SIDE</example><example count="31">RT ARM</example><example count="21">JAW</example><example count="20">STOMACH</example></stats></total></variable><variable id="phv00294635.v2.p1.c1" var_name="AFUcomp13f_A" calculated_type="string" reported_type=""><description>C. General Health. SPECIFY IF OTHER PAINS Q13F IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>316</male><female>433</female></sex></subject_profile><stats><stat n="1081" nulls="311358" mean_count="3.498" sd="10.16" median_count="1" min_count="1" max_count="98" distinct_vals="309"/><example count="98">RIGHT ARM</example><example count="89">BACK</example><example count="66">NECK</example><example count="58">CHEST</example><example count="56">SHOULDER</example><example count="34">THROAT</example><example count="32">RIGHT SIDE</example><example count="31">RT ARM</example><example count="21">JAW</example><example count="20">STOMACH</example></stats></total></variable><variable id="phv00294635.v2.p1.c2" var_name="AFUcomp13f_A" calculated_type="string" reported_type=""><description>C. General Health. SPECIFY IF OTHER PAINS Q13F IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">THROAT</enum></stats></total></variable><variable id="phv00294636.v2.p1" var_name="AFUcomp14_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN ANYWHERE ELSE Q14 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>909</male><female>1237</female></sex></subject_profile><stats><stat n="4571" nulls="308255"/><enum count="3605">N</enum><enum count="966">Y</enum></stats></total></variable><variable id="phv00294636.v2.p1.c1" var_name="AFUcomp14_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN ANYWHERE ELSE Q14 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>908</male><female>1236</female></sex></subject_profile><stats><stat n="4569" nulls="307870"/><enum count="3603">N</enum><enum count="966">Y</enum></stats></total></variable><variable id="phv00294636.v2.p1.c2" var_name="AFUcomp14_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. CHEST PAIN ANYWHERE ELSE Q14 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="2">N</enum></stats></total></variable><variable id="phv00294637.v2.p1" var_name="AFUcomp15_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. SEE DOCTOR BECAUSE OF THE PAIN Q15 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>912</male><female>1240</female></sex></subject_profile><stats><stat n="4596" nulls="308230"/><enum count="3247">Y</enum><enum count="1349">N</enum></stats></total></variable><variable id="phv00294637.v2.p1.c1" var_name="AFUcomp15_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. SEE DOCTOR BECAUSE OF THE PAIN Q15 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>911</male><female>1239</female></sex></subject_profile><stats><stat n="4594" nulls="307845"/><enum count="3245">Y</enum><enum count="1349">N</enum></stats></total></variable><variable id="phv00294637.v2.p1.c2" var_name="AFUcomp15_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. SEE DOCTOR BECAUSE OF THE PAIN Q15 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="2">Y</enum></stats></total></variable><variable id="phv00294638.v2.p1" var_name="AFUcomp16_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. WHAT DID THE DOCTOR SAY THE PAIN WAS? Q16 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>757</male><female>910</female></sex></subject_profile><stats><stat n="3206" nulls="309620"/><enum count="1741">O</enum><enum count="694">A</enum><enum count="654">D</enum><enum count="117">H</enum></stats></total></variable><variable id="phv00294638.v2.p1.c1" var_name="AFUcomp16_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. WHAT DID THE DOCTOR SAY THE PAIN WAS? Q16 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>756</male><female>909</female></sex></subject_profile><stats><stat n="3204" nulls="309235"/><enum count="1741">O</enum><enum count="694">A</enum><enum count="653">D</enum><enum count="116">H</enum></stats></total></variable><variable id="phv00294638.v2.p1.c2" var_name="AFUcomp16_A" calculated_type="string" reported_type=""><description>D. Chest Pain on Effort. WHAT DID THE DOCTOR SAY THE PAIN WAS? Q16 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="2" nulls="385"/><enum count="1">H</enum><enum count="1">D</enum></stats></total></variable><variable id="phv00294639.v2.p1" var_name="AFUcomp17_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. SEVERE CHEST PAIN SINCE LAST CONTACT Q17 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3184</male><female>4168</female></sex></subject_profile><stats><stat n="21811" nulls="291015"/><enum count="18675">N</enum><enum count="3136">Y</enum></stats></total></variable><variable id="phv00294639.v2.p1.c1" var_name="AFUcomp17_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. SEVERE CHEST PAIN SINCE LAST CONTACT Q17 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3179</male><female>4163</female></sex></subject_profile><stats><stat n="21790" nulls="290649"/><enum count="18654">N</enum><enum count="3136">Y</enum></stats></total></variable><variable id="phv00294639.v2.p1.c2" var_name="AFUcomp17_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. SEVERE CHEST PAIN SINCE LAST CONTACT Q17 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>5</male><female>5</female></sex></subject_profile><stats><stat n="21" nulls="366"/><enum count="21">N</enum></stats></total></variable><variable id="phv00294640.v2.p1" var_name="AFUcomp18_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. SEE DOCTOR BECAUSE OF THE SEVERE CHEST PAIN Q18 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>890</male><female>1084</female></sex></subject_profile><stats><stat n="3141" nulls="309685"/><enum count="2417">Y</enum><enum count="724">N</enum></stats></total></variable><variable id="phv00294640.v2.p1.c1" var_name="AFUcomp18_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. SEE DOCTOR BECAUSE OF THE SEVERE CHEST PAIN Q18 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>890</male><female>1084</female></sex></subject_profile><stats><stat n="3141" nulls="309298"/><enum count="2417">Y</enum><enum count="724">N</enum></stats></total></variable><variable id="phv00294640.v2.p1.c2" var_name="AFUcomp18_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. SEE DOCTOR BECAUSE OF THE SEVERE CHEST PAIN Q18 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294641.v2.p1" var_name="AFUcomp19_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. WHAT DID THE DOCTOR SAY THE SEVERE PAIN WAS? Q19 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>748</male><female>878</female></sex></subject_profile><stats><stat n="2374" nulls="310452"/><enum count="1975">O</enum><enum count="399">H</enum></stats></total></variable><variable id="phv00294641.v2.p1.c1" var_name="AFUcomp19_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. WHAT DID THE DOCTOR SAY THE SEVERE PAIN WAS? Q19 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>748</male><female>878</female></sex></subject_profile><stats><stat n="2374" nulls="310065"/><enum count="1975">O</enum><enum count="399">H</enum></stats></total></variable><variable id="phv00294641.v2.p1.c2" var_name="AFUcomp19_A" calculated_type="string" reported_type=""><description>E. Possible Infraction. WHAT DID THE DOCTOR SAY THE SEVERE PAIN WAS? Q19 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294642.v2.p1" var_name="AFUcomp20_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN ON WALKING SINCE LAST CONTACT Q20 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6549</male><female>7818</female></sex></subject_profile><stats><stat n="134666" nulls="178160"/><enum count="103512">N</enum><enum count="31154">Y</enum></stats></total></variable><variable id="phv00294642.v2.p1.c1" var_name="AFUcomp20_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN ON WALKING SINCE LAST CONTACT Q20 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6542</male><female>7810</female></sex></subject_profile><stats><stat n="134515" nulls="177924"/><enum count="103398">N</enum><enum count="31117">Y</enum></stats></total></variable><variable id="phv00294642.v2.p1.c2" var_name="AFUcomp20_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN ON WALKING SINCE LAST CONTACT Q20 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="151" nulls="236"/><enum count="114">N</enum><enum count="37">Y</enum></stats></total></variable><variable id="phv00294643.v2.p1" var_name="AFUcomp21_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN WHEN STANDING STILL Q21 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3822</male><female>5330</female></sex></subject_profile><stats><stat n="31142" nulls="281684"/><enum count="21595">Y</enum><enum count="9547">N</enum></stats></total></variable><variable id="phv00294643.v2.p1.c1" var_name="AFUcomp21_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN WHEN STANDING STILL Q21 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3817</male><female>5325</female></sex></subject_profile><stats><stat n="31105" nulls="281334"/><enum count="21565">Y</enum><enum count="9540">N</enum></stats></total></variable><variable id="phv00294643.v2.p1.c2" var_name="AFUcomp21_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN WHEN STANDING STILL Q21 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>5</male><female>5</female></sex></subject_profile><stats><stat n="37" nulls="350"/><enum count="30">Y</enum><enum count="7">N</enum></stats></total></variable><variable id="phv00294644.v2.p1" var_name="AFUcomp22_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT PART OF THE LEG DO YOU FEEL THE PAIN Q22 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>2301</male><female>3074</female></sex></subject_profile><stats><stat n="9542" nulls="303284"/><enum count="5837">N</enum><enum count="3705">C</enum></stats></total></variable><variable id="phv00294644.v2.p1.c1" var_name="AFUcomp22_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT PART OF THE LEG DO YOU FEEL THE PAIN Q22 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>2298</male><female>3073</female></sex></subject_profile><stats><stat n="9535" nulls="302904"/><enum count="5831">N</enum><enum count="3704">C</enum></stats></total></variable><variable id="phv00294644.v2.p1.c2" var_name="AFUcomp22_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT PART OF THE LEG DO YOU FEEL THE PAIN Q22 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>3</male><female>1</female></sex></subject_profile><stats><stat n="7" nulls="380"/><enum count="6">N</enum><enum count="1">C</enum></stats></total></variable><variable id="phv00294645.v2.p1" var_name="AFUcomp23_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN IF WALK UPHILL Q23 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>960</male><female>1312</female></sex></subject_profile><stats><stat n="3695" nulls="309131"/><enum count="2019">Y</enum><enum count="1510">N</enum><enum count="166">H</enum></stats></total></variable><variable id="phv00294645.v2.p1.c1" var_name="AFUcomp23_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN IF WALK UPHILL Q23 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>959</male><female>1312</female></sex></subject_profile><stats><stat n="3694" nulls="308745"/><enum count="2019">Y</enum><enum count="1509">N</enum><enum count="166">H</enum></stats></total></variable><variable id="phv00294645.v2.p1.c2" var_name="AFUcomp23_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN IF WALK UPHILL Q23 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294646.v2.p1" var_name="AFUcomp24_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN WHEN WALK AT AN ORDINARY PACE Q9 IN AFUA-F</description><total><subject_profile><sex><male>585</male><female>695</female></sex></subject_profile><stats><stat n="2184" nulls="310642"/><enum count="1250">Y</enum><enum count="934">N</enum></stats></total></variable><variable id="phv00294646.v2.p1.c1" var_name="AFUcomp24_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN WHEN WALK AT AN ORDINARY PACE Q9 IN AFUA-F</description><total><subject_profile><sex><male>585</male><female>695</female></sex></subject_profile><stats><stat n="2184" nulls="310255"/><enum count="1250">Y</enum><enum count="934">N</enum></stats></total></variable><variable id="phv00294646.v2.p1.c2" var_name="AFUcomp24_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN WHEN WALK AT AN ORDINARY PACE Q9 IN AFUA-F</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294647.v2.p1" var_name="AFUcomp25_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN EVER DISAPPEAR WHILE WALKING Q25 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>585</male><female>694</female></sex></subject_profile><stats><stat n="2183" nulls="310643"/><enum count="1333">N</enum><enum count="850">Y</enum></stats></total></variable><variable id="phv00294647.v2.p1.c1" var_name="AFUcomp25_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN EVER DISAPPEAR WHILE WALKING Q25 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>585</male><female>694</female></sex></subject_profile><stats><stat n="2183" nulls="310256"/><enum count="1333">N</enum><enum count="850">Y</enum></stats></total></variable><variable id="phv00294647.v2.p1.c2" var_name="AFUcomp25_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. LEG PAIN EVER DISAPPEAR WHILE WALKING Q25 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294648.v2.p1" var_name="AFUcomp26_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT DO YOU DO IF YOU GET LEG PAIN WHEN WALKING Q26 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>388</male><female>388</female></sex></subject_profile><stats><stat n="1332" nulls="311494"/><enum count="1088">S</enum><enum count="244">C</enum></stats></total></variable><variable id="phv00294648.v2.p1.c1" var_name="AFUcomp26_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT DO YOU DO IF YOU GET LEG PAIN WHEN WALKING Q26 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>388</male><female>388</female></sex></subject_profile><stats><stat n="1332" nulls="311107"/><enum count="1088">S</enum><enum count="244">C</enum></stats></total></variable><variable id="phv00294648.v2.p1.c2" var_name="AFUcomp26_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT DO YOU DO IF YOU GET LEG PAIN WHEN WALKING Q26 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294649.v2.p1" var_name="AFUcomp27_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT HAPPENS TO LEG PAIN IF STAND STILL? Q27 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>309</male><female>279</female></sex></subject_profile><stats><stat n="1086" nulls="311740"/><enum count="982">R</enum><enum count="104">N</enum></stats></total></variable><variable id="phv00294649.v2.p1.c1" var_name="AFUcomp27_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT HAPPENS TO LEG PAIN IF STAND STILL? Q27 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>309</male><female>279</female></sex></subject_profile><stats><stat n="1086" nulls="311353"/><enum count="982">R</enum><enum count="104">N</enum></stats></total></variable><variable id="phv00294649.v2.p1.c2" var_name="AFUcomp27_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. WHAT HAPPENS TO LEG PAIN IF STAND STILL? Q27 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294650.v2.p1" var_name="AFUcomp28_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. HOW SOON LEG PAIN RELIEVED Q28 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>290</male><female>232</female></sex></subject_profile><stats><stat n="982" nulls="311844"/><enum count="855">L</enum><enum count="127">M</enum></stats></total></variable><variable id="phv00294650.v2.p1.c1" var_name="AFUcomp28_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. HOW SOON LEG PAIN RELIEVED Q28 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>290</male><female>232</female></sex></subject_profile><stats><stat n="982" nulls="311457"/><enum count="855">L</enum><enum count="127">M</enum></stats></total></variable><variable id="phv00294650.v2.p1.c2" var_name="AFUcomp28_A" calculated_type="string" reported_type=""><description>F. Intermittent Claudication. HOW SOON LEG PAIN RELIEVED Q28 IN AFUA-F [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294651.v2.p1" var_name="AFUcomp29_A" calculated_type="string" reported_type=""><description>G. Stroke/TIA. DOCTOR -STROKE, TIA SINCE LAST CONTACT Q29 IN AFUA-F; Q8 IN AFUG-J; Q8A IN AFUK; Q22A IN AFUL-M; Q48 IN AFU V1-V3; Q16 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6551</male><female>7817</female></sex></subject_profile><stats><stat n="291294" nulls="21532"/><enum count="287507">N</enum><enum count="3780">Y</enum><enum count="7">U</enum></stats></total></variable><variable id="phv00294651.v2.p1.c1" var_name="AFUcomp29_A" calculated_type="string" reported_type=""><description>G. Stroke/TIA. DOCTOR -STROKE, TIA SINCE LAST CONTACT Q29 IN AFUA-F; Q8 IN AFUG-J; Q8A IN AFUK; Q22A IN AFUL-M; Q48 IN AFU V1-V3; Q16 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6544</male><female>7809</female></sex></subject_profile><stats><stat n="290908" nulls="21531"/><enum count="287122">N</enum><enum count="3779">Y</enum><enum count="7">U</enum></stats></total></variable><variable id="phv00294651.v2.p1.c2" var_name="AFUcomp29_A" calculated_type="string" reported_type=""><description>G. Stroke/TIA. DOCTOR -STROKE, TIA SINCE LAST CONTACT Q29 IN AFUA-F; Q8 IN AFUG-J; Q8A IN AFUK; Q22A IN AFUL-M; Q48 IN AFU V1-V3; Q16 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="386" nulls="1"/><enum count="385">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294652.v2.p1" var_name="AFUcomp31_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. OTHER OVERNIGHT HOSPITALIZATION SINCE LAST CONTACT Q31 IN AFUA-F; Q10 IN AFUG-K; Q24 IN AFUL-M; Q10 OR Q51 IN AFU V1-V3; Q19 IN SAF V1-V3; Q8 IN DEC V1 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6618</male><female>7844</female></sex></subject_profile><stats><stat n="300059" nulls="12767"/><enum count="260385">N</enum><enum count="38002">Y</enum><enum count="1672">U</enum></stats></total></variable><variable id="phv00294652.v2.p1.c1" var_name="AFUcomp31_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. OTHER OVERNIGHT HOSPITALIZATION SINCE LAST CONTACT Q31 IN AFUA-F; Q10 IN AFUG-K; Q24 IN AFUL-M; Q10 OR Q51 IN AFU V1-V3; Q19 IN SAF V1-V3; Q8 IN DEC V1 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6611</male><female>7836</female></sex></subject_profile><stats><stat n="299673" nulls="12766"/><enum count="260017">N</enum><enum count="37984">Y</enum><enum count="1672">U</enum></stats></total></variable><variable id="phv00294652.v2.p1.c2" var_name="AFUcomp31_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. OTHER OVERNIGHT HOSPITALIZATION SINCE LAST CONTACT Q31 IN AFUA-F; Q10 IN AFUG-K; Q24 IN AFUL-M; Q10 OR Q51 IN AFU V1-V3; Q19 IN SAF V1-V3; Q8 IN DEC V1 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="386" nulls="1"/><enum count="368">N</enum><enum count="18">Y</enum></stats></total></variable><variable id="phv00294653.v2.p1" var_name="form" calculated_type="string" reported_type=""><description>AFU: Annual Follow up; SAF: Semi-Annual Follow up</description><total><subject_profile><sex><male>6633</male><female>7854</female></sex></subject_profile><stats><stat n="312826" nulls="0"/><enum count="298671">AFU</enum><enum count="14155">SAF</enum></stats></total></variable><variable id="phv00294653.v2.p1.c1" var_name="form" calculated_type="string" reported_type=""><description>AFU: Annual Follow up; SAF: Semi-Annual Follow up</description><total><subject_profile><sex><male>6626</male><female>7846</female></sex></subject_profile><stats><stat n="312439" nulls="0"/><enum count="298311">AFU</enum><enum count="14128">SAF</enum></stats></total></variable><variable id="phv00294653.v2.p1.c2" var_name="form" calculated_type="string" reported_type=""><description>AFU: Annual Follow up; SAF: Semi-Annual Follow up</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="387" nulls="0"/><enum count="360">AFU</enum><enum count="27">SAF</enum></stats></total></variable><variable id="phv00294654.v2.p1" var_name="AFUcomp30_deceased_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. DECEASED HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT  Q30 IN AFUA-F; Q9 IN AFUG-K, Q23 IN AFUL-M [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>2510</male><female>2079</female></sex></subject_profile><stats><stat n="4589" nulls="308237"/><enum count="3682">N</enum><enum count="660">U</enum><enum count="247">Y</enum></stats></total></variable><variable id="phv00294654.v2.p1.c1" var_name="AFUcomp30_deceased_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. DECEASED HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT  Q30 IN AFUA-F; Q9 IN AFUG-K, Q23 IN AFUL-M [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>2510</male><female>2079</female></sex></subject_profile><stats><stat n="4589" nulls="307850"/><enum count="3682">N</enum><enum count="660">U</enum><enum count="247">Y</enum></stats></total></variable><variable id="phv00294654.v2.p1.c2" var_name="AFUcomp30_deceased_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. DECEASED HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT  Q30 IN AFUA-F; Q9 IN AFUG-K, Q23 IN AFUL-M [Annual Follow-up Questionnaire Form, Version A]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294655.v2.p1" var_name="AFUcomp30non_deceased_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. NON-DECEASED HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT Q30 IN AFUA-F; Q9 IN AFUG-K, Q23 IN AFUL-M; Q37 in AFU V1-V3; Q11 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6555</male><female>7820</female></sex></subject_profile><stats><stat n="267832" nulls="44994"/><enum count="264257">N</enum><enum count="2302">Y</enum><enum count="1273">U</enum></stats></total></variable><variable id="phv00294655.v2.p1.c1" var_name="AFUcomp30non_deceased_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. NON-DECEASED HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT Q30 IN AFUA-F; Q9 IN AFUG-K, Q23 IN AFUL-M; Q37 in AFU V1-V3; Q11 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>6548</male><female>7812</female></sex></subject_profile><stats><stat n="267501" nulls="44938"/><enum count="263926">N</enum><enum count="2302">Y</enum><enum count="1273">U</enum></stats></total></variable><variable id="phv00294655.v2.p1.c2" var_name="AFUcomp30non_deceased_A" calculated_type="string" reported_type=""><description>H. Hospitalizations. NON-DECEASED HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT Q30 IN AFUA-F; Q9 IN AFUG-K, Q23 IN AFUL-M; Q37 in AFU V1-V3; Q11 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version A]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="331" nulls="56"/><enum count="331">N</enum></stats></total></variable><variable id="phv00294656.v2.p1" var_name="AFUcomp36b_D" calculated_type="decimal" reported_type=""><description>I. Functional Status. NO. DAYS MISSED FOR HLTH REASONS Q36B IN AFUD, F; Q27B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1283</male><female>1753</female></sex></subject_profile><stats><stat n="4848" nulls="307978" mean="4.827" sd="6.845" median="2" min="0" max="62"/><example count="1760">1</example><example count="1052">2</example><example count="531">3</example><example count="267">4</example><example count="258">28</example><example count="237">5</example><example count="172">7</example><example count="143">14</example><example count="108">10</example><example count="74">6</example></stats></total></variable><variable id="phv00294656.v2.p1.c1" var_name="AFUcomp36b_D" calculated_type="decimal" reported_type=""><description>I. Functional Status. NO. DAYS MISSED FOR HLTH REASONS Q36B IN AFUD, F; Q27B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1282</male><female>1750</female></sex></subject_profile><stats><stat n="4840" nulls="307599" mean="4.832" sd="6.85" median="2" min="0" max="62"/><example count="1757">1</example><example count="1049">2</example><example count="530">3</example><example count="267">4</example><example count="258">28</example><example count="237">5</example><example count="171">7</example><example count="143">14</example><example count="108">10</example><example count="74">6</example></stats></total></variable><variable id="phv00294656.v2.p1.c2" var_name="AFUcomp36b_D" calculated_type="decimal" reported_type=""><description>I. Functional Status. NO. DAYS MISSED FOR HLTH REASONS Q36B IN AFUD, F; Q27B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1</male><female>3</female></sex></subject_profile><stats><stat n="8" nulls="379" mean="2.375" sd="1.996" median="2" min="1" max="7"/><enum count="3">1</enum><enum count="3">2</enum><enum count="1">7</enum><enum count="1">3</enum></stats></total></variable><variable id="phv00294657.v2.p1" var_name="AFUcomp38b_D" calculated_type="decimal" reported_type=""><description>I. Functional Status. NO. DAYS CUT DOWN ON ACTIVITIES Q38B IN AFUD, F; Q29B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1930</male><female>3062</female></sex></subject_profile><stats><stat n="8648" nulls="304178" mean="10.45" sd="9.736" median="6" min="0" max="30"/><example count="1587">28</example><example count="1230">2</example><example count="929">3</example><example count="775">14</example><example count="769">1</example><example count="737">4</example><example count="626">7</example><example count="508">5</example><example count="352">10</example><example count="231">21</example></stats></total></variable><variable id="phv00294657.v2.p1.c1" var_name="AFUcomp38b_D" calculated_type="decimal" reported_type=""><description>I. Functional Status. NO. DAYS CUT DOWN ON ACTIVITIES Q38B IN AFUD, F; Q29B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1927</male><female>3056</female></sex></subject_profile><stats><stat n="8632" nulls="303807" mean="10.45" sd="9.736" median="6" min="0" max="30"/><example count="1584">28</example><example count="1228">2</example><example count="927">3</example><example count="773">14</example><example count="767">1</example><example count="735">4</example><example count="626">7</example><example count="507">5</example><example count="350">10</example><example count="231">21</example></stats></total></variable><variable id="phv00294657.v2.p1.c2" var_name="AFUcomp38b_D" calculated_type="decimal" reported_type=""><description>I. Functional Status. NO. DAYS CUT DOWN ON ACTIVITIES Q38B IN AFUD, F; Q29B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>3</male><female>6</female></sex></subject_profile><stats><stat n="16" nulls="371" mean="9.813" sd="9.961" median="4.5" min="1" max="28"/><enum count="3">28</enum><enum count="2">14</enum><enum count="2">1</enum><enum count="2">2</enum><enum count="2">10</enum><enum count="2">3</enum><enum count="2">4</enum><enum count="1">5</enum></stats></total></variable><variable id="phv00294658.v2.p1" var_name="AFUcomp39b_D" calculated_type="integer" reported_type=""><description>I. Functional Status. HOW MUCH LOWER IS THE WEIGHT THAN A YEAR AGO? Q39B IN AFUD, F; Q32B IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2325</male><female>3047</female></sex></subject_profile><stats><stat n="8842" nulls="303984" mean="17.85" sd="12.09" median="15" min="0" max="180"/><example count="1236">15</example><example count="1085">20</example><example count="1057">10</example><example count="850">12</example><example count="823">11</example><example count="453">30</example><example count="397">25</example><example count="386">0</example><example count="223">13</example><example count="222">14</example></stats></total></variable><variable id="phv00294658.v2.p1.c1" var_name="AFUcomp39b_D" calculated_type="integer" reported_type=""><description>I. Functional Status. HOW MUCH LOWER IS THE WEIGHT THAN A YEAR AGO? Q39B IN AFUD, F; Q32B IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2323</male><female>3045</female></sex></subject_profile><stats><stat n="8831" nulls="303608" mean="17.85" sd="12.1" median="15" min="0" max="180"/><example count="1236">15</example><example count="1083">20</example><example count="1055">10</example><example count="849">12</example><example count="820">11</example><example count="453">30</example><example count="396">25</example><example count="386">0</example><example count="223">13</example><example count="222">14</example></stats></total></variable><variable id="phv00294658.v2.p1.c2" var_name="AFUcomp39b_D" calculated_type="integer" reported_type=""><description>I. Functional Status. HOW MUCH LOWER IS THE WEIGHT THAN A YEAR AGO? Q39B IN AFUD, F; Q32B IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="11" nulls="376" mean="14" sd="5.797" median="11" min="6" max="25"/><enum count="3">11</enum><enum count="2">20</enum><enum count="2">10</enum><enum count="1">12</enum><enum count="1">25</enum><enum count="1">6</enum><enum count="1">18</enum></stats></total></variable><variable id="phv00294659.v2.p1" var_name="AFUcomp32_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO DO HEAVY HOUSE WORK Q32 IN AFUD, F; Q23 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6223</male><female>7564</female></sex></subject_profile><stats><stat n="152165" nulls="160661"/><enum count="122806">Y</enum><enum count="29359">N</enum></stats></total></variable><variable id="phv00294659.v2.p1.c1" var_name="AFUcomp32_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO DO HEAVY HOUSE WORK Q32 IN AFUD, F; Q23 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6216</male><female>7556</female></sex></subject_profile><stats><stat n="151975" nulls="160464"/><enum count="122635">Y</enum><enum count="29340">N</enum></stats></total></variable><variable id="phv00294659.v2.p1.c2" var_name="AFUcomp32_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO DO HEAVY HOUSE WORK Q32 IN AFUD, F; Q23 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="190" nulls="197"/><enum count="171">Y</enum><enum count="19">N</enum></stats></total></variable><variable id="phv00294660.v2.p1" var_name="AFUcomp33_D" calculated_type="string" reported_type=""><description>I. Functional Status. WALK UP AND DOWN STAIRS Q33 IN AFUD, F; Q24 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6223</male><female>7563</female></sex></subject_profile><stats><stat n="152178" nulls="160648"/><enum count="140283">Y</enum><enum count="11895">N</enum></stats></total></variable><variable id="phv00294660.v2.p1.c1" var_name="AFUcomp33_D" calculated_type="string" reported_type=""><description>I. Functional Status. WALK UP AND DOWN STAIRS Q33 IN AFUD, F; Q24 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6216</male><female>7555</female></sex></subject_profile><stats><stat n="151988" nulls="160451"/><enum count="140097">Y</enum><enum count="11891">N</enum></stats></total></variable><variable id="phv00294660.v2.p1.c2" var_name="AFUcomp33_D" calculated_type="string" reported_type=""><description>I. Functional Status. WALK UP AND DOWN STAIRS Q33 IN AFUD, F; Q24 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="190" nulls="197"/><enum count="186">Y</enum><enum count="4">N</enum></stats></total></variable><variable id="phv00294661.v2.p1" var_name="AFUcomp34_D" calculated_type="string" reported_type=""><description>I. Functional Status. WALK HALF A MILE W/O HELP Q34 IN AFUD, F; Q25 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6223</male><female>7563</female></sex></subject_profile><stats><stat n="152002" nulls="160824"/><enum count="130361">Y</enum><enum count="21641">N</enum></stats></total></variable><variable id="phv00294661.v2.p1.c1" var_name="AFUcomp34_D" calculated_type="string" reported_type=""><description>I. Functional Status. WALK HALF A MILE W/O HELP Q34 IN AFUD, F; Q25 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6216</male><female>7555</female></sex></subject_profile><stats><stat n="151812" nulls="160627"/><enum count="130182">Y</enum><enum count="21630">N</enum></stats></total></variable><variable id="phv00294661.v2.p1.c2" var_name="AFUcomp34_D" calculated_type="string" reported_type=""><description>I. Functional Status. WALK HALF A MILE W/O HELP Q34 IN AFUD, F; Q25 IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="190" nulls="197"/><enum count="179">Y</enum><enum count="11">N</enum></stats></total></variable><variable id="phv00294662.v2.p1" var_name="AFUcomp35a_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO GO TO WORK Q35A IN AFUD, F; Q26A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6223</male><female>7564</female></sex></subject_profile><stats><stat n="152194" nulls="160632"/><enum count="88490">A</enum><enum count="59875">Y</enum><enum count="3829">N</enum></stats></total></variable><variable id="phv00294662.v2.p1.c1" var_name="AFUcomp35a_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO GO TO WORK Q35A IN AFUD, F; Q26A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6216</male><female>7556</female></sex></subject_profile><stats><stat n="152004" nulls="160435"/><enum count="88380">A</enum><enum count="59799">Y</enum><enum count="3825">N</enum></stats></total></variable><variable id="phv00294662.v2.p1.c2" var_name="AFUcomp35a_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO GO TO WORK Q35A IN AFUD, F; Q26A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="190" nulls="197"/><enum count="110">A</enum><enum count="76">Y</enum><enum count="4">N</enum></stats></total></variable><variable id="phv00294663.v2.p1" var_name="AFUcomp35b_D" calculated_type="string" reported_type=""><description>I. Functional Status. HEART PROBLEM REASON CANNOT WORK Q35B IN AFUD, F; Q26B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>943</male><female>1384</female></sex></subject_profile><stats><stat n="3826" nulls="309000"/><enum count="2896">N</enum><enum count="881">Y</enum><enum count="49">U</enum></stats></total></variable><variable id="phv00294663.v2.p1.c1" var_name="AFUcomp35b_D" calculated_type="string" reported_type=""><description>I. Functional Status. HEART PROBLEM REASON CANNOT WORK Q35B IN AFUD, F; Q26B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>942</male><female>1383</female></sex></subject_profile><stats><stat n="3822" nulls="308617"/><enum count="2892">N</enum><enum count="881">Y</enum><enum count="49">U</enum></stats></total></variable><variable id="phv00294663.v2.p1.c2" var_name="AFUcomp35b_D" calculated_type="string" reported_type=""><description>I. Functional Status. HEART PROBLEM REASON CANNOT WORK Q35B IN AFUD, F; Q26B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="4" nulls="383"/><enum count="4">N</enum></stats></total></variable><variable id="phv00294664.v2.p1" var_name="AFUcomp36a_D" calculated_type="string" reported_type=""><description>I. Functional Status. MISSED WORK FOR HEALTH REASONS Q36A IN AFUD, F; Q27A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>4504</male><female>4893</female></sex></subject_profile><stats><stat n="59835" nulls="252991"/><enum count="54874">N</enum><enum count="4961">Y</enum></stats></total></variable><variable id="phv00294664.v2.p1.c1" var_name="AFUcomp36a_D" calculated_type="string" reported_type=""><description>I. Functional Status. MISSED WORK FOR HEALTH REASONS Q36A IN AFUD, F; Q27A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>4498</male><female>4886</female></sex></subject_profile><stats><stat n="59759" nulls="252680"/><enum count="54806">N</enum><enum count="4953">Y</enum></stats></total></variable><variable id="phv00294664.v2.p1.c2" var_name="AFUcomp36a_D" calculated_type="string" reported_type=""><description>I. Functional Status. MISSED WORK FOR HEALTH REASONS Q36A IN AFUD, F; Q27A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6</male><female>7</female></sex></subject_profile><stats><stat n="76" nulls="311"/><enum count="68">N</enum><enum count="8">Y</enum></stats></total></variable><variable id="phv00294665.v2.p1" var_name="AFUcomp37a_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO DO USUAL ACTIVITIES Q37A IN AFUD AND, F; Q28A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6223</male><female>7564</female></sex></subject_profile><stats><stat n="152176" nulls="160650"/><enum count="140735">Y</enum><enum count="11441">N</enum></stats></total></variable><variable id="phv00294665.v2.p1.c1" var_name="AFUcomp37a_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO DO USUAL ACTIVITIES Q37A IN AFUD AND, F; Q28A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6216</male><female>7556</female></sex></subject_profile><stats><stat n="151986" nulls="160453"/><enum count="140550">Y</enum><enum count="11436">N</enum></stats></total></variable><variable id="phv00294665.v2.p1.c2" var_name="AFUcomp37a_D" calculated_type="string" reported_type=""><description>I. Functional Status. ABLE TO DO USUAL ACTIVITIES Q37A IN AFUD AND, F; Q28A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="190" nulls="197"/><enum count="185">Y</enum><enum count="5">N</enum></stats></total></variable><variable id="phv00294666.v2.p1" var_name="AFUcomp37b_D" calculated_type="string" reported_type=""><description>I. Functional Status. HEALTH PR. WHY NOT DOING USL ACT. Q37B IN AFUD, F; Q28B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2059</male><female>2679</female></sex></subject_profile><stats><stat n="11363" nulls="301463"/><enum count="9482">N</enum><enum count="1617">Y</enum><enum count="264">U</enum></stats></total></variable><variable id="phv00294666.v2.p1.c1" var_name="AFUcomp37b_D" calculated_type="string" reported_type=""><description>I. Functional Status. HEALTH PR. WHY NOT DOING USL ACT. Q37B IN AFUD, F; Q28B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2056</male><female>2678</female></sex></subject_profile><stats><stat n="11358" nulls="301081"/><enum count="9477">N</enum><enum count="1617">Y</enum><enum count="264">U</enum></stats></total></variable><variable id="phv00294666.v2.p1.c2" var_name="AFUcomp37b_D" calculated_type="string" reported_type=""><description>I. Functional Status. HEALTH PR. WHY NOT DOING USL ACT. Q37B IN AFUD, F; Q28B IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>3</male><female>1</female></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="5">N</enum></stats></total></variable><variable id="phv00294667.v2.p1" var_name="AFUcomp38a_D" calculated_type="string" reported_type=""><description>I. Functional Status. HAVE YOU CUT DOWN ON ACTIVITIES Q38A IN AFUD, F; Q29A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6128</male><female>7460</female></sex></subject_profile><stats><stat n="140776" nulls="172050"/><enum count="132027">N</enum><enum count="8749">Y</enum></stats></total></variable><variable id="phv00294667.v2.p1.c1" var_name="AFUcomp38a_D" calculated_type="string" reported_type=""><description>I. Functional Status. HAVE YOU CUT DOWN ON ACTIVITIES Q38A IN AFUD, F; Q29A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6121</male><female>7452</female></sex></subject_profile><stats><stat n="140591" nulls="171848"/><enum count="131858">N</enum><enum count="8733">Y</enum></stats></total></variable><variable id="phv00294667.v2.p1.c2" var_name="AFUcomp38a_D" calculated_type="string" reported_type=""><description>I. Functional Status. HAVE YOU CUT DOWN ON ACTIVITIES Q38A IN AFUD, F; Q29A IN AFUG-K [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="185" nulls="202"/><enum count="169">N</enum><enum count="16">Y</enum></stats></total></variable><variable id="phv00294668.v2.p1" var_name="AFUcomp39a_D" calculated_type="string" reported_type=""><description>I. Functional Status. WEIGHT LOSS MORE THAN 10LBS OVER THE PAST YEAR Q39A IN AFUD, F; Q32A IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6221</male><female>7564</female></sex></subject_profile><stats><stat n="77355" nulls="235471"/><enum count="67540">N</enum><enum count="9188">Y</enum><enum count="627">U</enum></stats></total></variable><variable id="phv00294668.v2.p1.c1" var_name="AFUcomp39a_D" calculated_type="string" reported_type=""><description>I. Functional Status. WEIGHT LOSS MORE THAN 10LBS OVER THE PAST YEAR Q39A IN AFUD, F; Q32A IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6214</male><female>7556</female></sex></subject_profile><stats><stat n="77264" nulls="235175"/><enum count="67460">N</enum><enum count="9177">Y</enum><enum count="627">U</enum></stats></total></variable><variable id="phv00294668.v2.p1.c2" var_name="AFUcomp39a_D" calculated_type="string" reported_type=""><description>I. Functional Status. WEIGHT LOSS MORE THAN 10LBS OVER THE PAST YEAR Q39A IN AFUD, F; Q32A IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="91" nulls="296"/><enum count="80">N</enum><enum count="11">Y</enum></stats></total></variable><variable id="phv00294669.v2.p1" var_name="AFUcomp39c_D" calculated_type="string" reported_type=""><description>I. Functional Status. TRYING TO LOSE THIS WEIGHT? Q39C IN AFUD, F; Q32C IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2473</male><female>3244</female></sex></subject_profile><stats><stat n="9694" nulls="303132"/><enum count="5694">Y</enum><enum count="3692">N</enum><enum count="308">U</enum></stats></total></variable><variable id="phv00294669.v2.p1.c1" var_name="AFUcomp39c_D" calculated_type="string" reported_type=""><description>I. Functional Status. TRYING TO LOSE THIS WEIGHT? Q39C IN AFUD, F; Q32C IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2471</male><female>3242</female></sex></subject_profile><stats><stat n="9683" nulls="302756"/><enum count="5687">Y</enum><enum count="3688">N</enum><enum count="308">U</enum></stats></total></variable><variable id="phv00294669.v2.p1.c2" var_name="AFUcomp39c_D" calculated_type="string" reported_type=""><description>I. Functional Status. TRYING TO LOSE THIS WEIGHT? Q39C IN AFUD, F; Q32C IN AFUE [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="11" nulls="376"/><enum count="7">Y</enum><enum count="4">N</enum></stats></total></variable><variable id="phv00294670.v2.p1" var_name="AFUcomp40a_D" calculated_type="string" reported_type=""><description>I. Functional Status. CURRENT MARITAL STATUS AFU40A IN AFUD, F;  Q31 IN AFUG-K; Q51 IN AFUL-M; Q70 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6224</male><female>7565</female></sex></subject_profile><stats><stat n="207236" nulls="105590"/><enum count="144569">M</enum><enum count="36726">W</enum><enum count="17371">D</enum><enum count="4815">N</enum><enum count="3755">S</enum></stats></total></variable><variable id="phv00294670.v2.p1.c1" var_name="AFUcomp40a_D" calculated_type="string" reported_type=""><description>I. Functional Status. CURRENT MARITAL STATUS AFU40A IN AFUD, F;  Q31 IN AFUG-K; Q51 IN AFUL-M; Q70 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6217</male><female>7557</female></sex></subject_profile><stats><stat n="206953" nulls="105486"/><enum count="144326">M</enum><enum count="36705">W</enum><enum count="17352">D</enum><enum count="4815">N</enum><enum count="3755">S</enum></stats></total></variable><variable id="phv00294670.v2.p1.c2" var_name="AFUcomp40a_D" calculated_type="string" reported_type=""><description>I. Functional Status. CURRENT MARITAL STATUS AFU40A IN AFUD, F;  Q31 IN AFUG-K; Q51 IN AFUL-M; Q70 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="283" nulls="104"/><enum count="243">M</enum><enum count="21">W</enum><enum count="19">D</enum></stats></total></variable><variable id="phv00294671.v2.p1" var_name="AFUcomp40b_D" calculated_type="string" reported_type=""><description>I. Functional Status. WHEN BECAME WIDOWED/DIVORCED/SEPARATED? Q40B IN AFUD, F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1002</male><female>2699</female></sex></subject_profile><stats><stat n="13941" nulls="298885"/><enum count="12760">D</enum><enum count="509">C</enum><enum count="341">B</enum><enum count="244">E</enum><enum count="87">A</enum></stats></total></variable><variable id="phv00294671.v2.p1.c1" var_name="AFUcomp40b_D" calculated_type="string" reported_type=""><description>I. Functional Status. WHEN BECAME WIDOWED/DIVORCED/SEPARATED? Q40B IN AFUD, F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1001</male><female>2699</female></sex></subject_profile><stats><stat n="13936" nulls="298503"/><enum count="12755">D</enum><enum count="509">C</enum><enum count="341">B</enum><enum count="244">E</enum><enum count="87">A</enum></stats></total></variable><variable id="phv00294671.v2.p1.c2" var_name="AFUcomp40b_D" calculated_type="string" reported_type=""><description>I. Functional Status. WHEN BECAME WIDOWED/DIVORCED/SEPARATED? Q40B IN AFUD, F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="5">D</enum></stats></total></variable><variable id="phv00294672.v2.p1" var_name="AFUcomp40c_D" calculated_type="string" reported_type=""><description>I. Functional Status. SOMEONE YOU CLOSE TO DIED IN THE PAST YEAR? Q40C IN AFUD, F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6214</male><female>7559</female></sex></subject_profile><stats><stat n="63161" nulls="249665"/><enum count="44274">N</enum><enum count="18783">Y</enum><enum count="104">U</enum></stats></total></variable><variable id="phv00294672.v2.p1.c1" var_name="AFUcomp40c_D" calculated_type="string" reported_type=""><description>I. Functional Status. SOMEONE YOU CLOSE TO DIED IN THE PAST YEAR? Q40C IN AFUD, F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>6207</male><female>7551</female></sex></subject_profile><stats><stat n="63086" nulls="249353"/><enum count="44215">N</enum><enum count="18767">Y</enum><enum count="104">U</enum></stats></total></variable><variable id="phv00294672.v2.p1.c2" var_name="AFUcomp40c_D" calculated_type="string" reported_type=""><description>I. Functional Status. SOMEONE YOU CLOSE TO DIED IN THE PAST YEAR? Q40C IN AFUD, F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="75" nulls="312"/><enum count="59">N</enum><enum count="16">Y</enum></stats></total></variable><variable id="phv00294673.v2.p1" var_name="AFUcomp40d_D" calculated_type="string" reported_type=""><description>I. Functional Status. WHEN DID SOMEONE YOU CLOSE TO DIE? AFU40D IN AFUD,F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>4261</male><female>5616</female></sex></subject_profile><stats><stat n="18744" nulls="294082"/><enum count="8681">B</enum><enum count="6372">C</enum><enum count="3592">A</enum><enum count="99">D</enum></stats></total></variable><variable id="phv00294673.v2.p1.c1" var_name="AFUcomp40d_D" calculated_type="string" reported_type=""><description>I. Functional Status. WHEN DID SOMEONE YOU CLOSE TO DIE? AFU40D IN AFUD,F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>4259</male><female>5609</female></sex></subject_profile><stats><stat n="18728" nulls="293711"/><enum count="8674">B</enum><enum count="6368">C</enum><enum count="3587">A</enum><enum count="99">D</enum></stats></total></variable><variable id="phv00294673.v2.p1.c2" var_name="AFUcomp40d_D" calculated_type="string" reported_type=""><description>I. Functional Status. WHEN DID SOMEONE YOU CLOSE TO DIE? AFU40D IN AFUD,F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2</male><female>7</female></sex></subject_profile><stats><stat n="16" nulls="371"/><enum count="7">B</enum><enum count="5">A</enum><enum count="4">C</enum></stats></total></variable><variable id="phv00294674.v2.p1" var_name="AFUcomp40e_D" calculated_type="string" reported_type=""><description>I. Functional Status. RELATIONSHIP TO YOU? AFU40E IN AFUD,F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>4261</male><female>5621</female></sex></subject_profile><stats><stat n="18761" nulls="294065"/><enum count="7894">R</enum><enum count="4800">D</enum><enum count="1640">B</enum><enum count="1554">M</enum><enum count="1152">S</enum><enum count="918">F</enum><enum count="353">C</enum><enum count="344">O</enum><enum count="106">P</enum></stats></total></variable><variable id="phv00294674.v2.p1.c1" var_name="AFUcomp40e_D" calculated_type="string" reported_type=""><description>I. Functional Status. RELATIONSHIP TO YOU? AFU40E IN AFUD,F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>4259</male><female>5614</female></sex></subject_profile><stats><stat n="18745" nulls="293694"/><enum count="7883">R</enum><enum count="4797">D</enum><enum count="1639">B</enum><enum count="1554">M</enum><enum count="1152">S</enum><enum count="918">F</enum><enum count="352">C</enum><enum count="344">O</enum><enum count="106">P</enum></stats></total></variable><variable id="phv00294674.v2.p1.c2" var_name="AFUcomp40e_D" calculated_type="string" reported_type=""><description>I. Functional Status. RELATIONSHIP TO YOU? AFU40E IN AFUD,F [Annual Follow-up Questionnaire Form, Version D]</description><total><subject_profile><sex><male>2</male><female>7</female></sex></subject_profile><stats><stat n="16" nulls="371"/><enum count="11">R</enum><enum count="3">D</enum><enum count="1">B</enum><enum count="1">C</enum></stats></total></variable><variable id="phv00294675.v2.p1" var_name="AFUcomp7a_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - HEART ATTACK Q11A IN AFUL, Q7A IN AFUG-K; Q11A IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5535</male><female>6968</female></sex></subject_profile><stats><stat n="102039" nulls="210787"/><enum count="93305">N</enum><enum count="8474">Y</enum><enum count="260">U</enum></stats></total></variable><variable id="phv00294675.v2.p1.c1" var_name="AFUcomp7a_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - HEART ATTACK Q11A IN AFUL, Q7A IN AFUG-K; Q11A IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5528</male><female>6960</female></sex></subject_profile><stats><stat n="101906" nulls="210533"/><enum count="93180">N</enum><enum count="8466">Y</enum><enum count="260">U</enum></stats></total></variable><variable id="phv00294675.v2.p1.c2" var_name="AFUcomp7a_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - HEART ATTACK Q11A IN AFUL, Q7A IN AFUG-K; Q11A IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="133" nulls="254"/><enum count="125">N</enum><enum count="8">Y</enum></stats></total></variable><variable id="phv00294676.v2.p1" var_name="AFUcomp7e_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - BLOOD CLOT IN LEG Q7E IN AFUG-K; Q16 IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5535</male><female>6969</female></sex></subject_profile><stats><stat n="102049" nulls="210777"/><enum count="98238">N</enum><enum count="3627">Y</enum><enum count="184">U</enum></stats></total></variable><variable id="phv00294676.v2.p1.c1" var_name="AFUcomp7e_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - BLOOD CLOT IN LEG Q7E IN AFUG-K; Q16 IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5528</male><female>6961</female></sex></subject_profile><stats><stat n="101916" nulls="210523"/><enum count="98109">N</enum><enum count="3623">Y</enum><enum count="184">U</enum></stats></total></variable><variable id="phv00294676.v2.p1.c2" var_name="AFUcomp7e_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - BLOOD CLOT IN LEG Q7E IN AFUG-K; Q16 IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="133" nulls="254"/><enum count="129">N</enum><enum count="4">Y</enum></stats></total></variable><variable id="phv00294677.v2.p1" var_name="AFUcomp7f_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - BLOOD CLOT IN LUNGS Q7F IN AFUG-K; Q17A IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5539</male><female>6976</female></sex></subject_profile><stats><stat n="129305" nulls="183521"/><enum count="127811">N</enum><enum count="1393">Y</enum><enum count="101">U</enum></stats></total></variable><variable id="phv00294677.v2.p1.c1" var_name="AFUcomp7f_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - BLOOD CLOT IN LUNGS Q7F IN AFUG-K; Q17A IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5532</male><female>6968</female></sex></subject_profile><stats><stat n="129125" nulls="183314"/><enum count="127631">N</enum><enum count="1393">Y</enum><enum count="101">U</enum></stats></total></variable><variable id="phv00294677.v2.p1.c2" var_name="AFUcomp7f_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - BLOOD CLOT IN LUNGS Q7F IN AFUG-K; Q17A IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="180" nulls="207"/><enum count="180">N</enum></stats></total></variable><variable id="phv00294678.v2.p1" var_name="AFUcomp7i_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - CANCER Q7I IN AFUG-K; Q21A IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5535</male><female>6969</female></sex></subject_profile><stats><stat n="102045" nulls="210781"/><enum count="86792">N</enum><enum count="15136">Y</enum><enum count="117">U</enum></stats></total></variable><variable id="phv00294678.v2.p1.c1" var_name="AFUcomp7i_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - CANCER Q7I IN AFUG-K; Q21A IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5528</male><female>6961</female></sex></subject_profile><stats><stat n="101912" nulls="210527"/><enum count="86685">N</enum><enum count="15110">Y</enum><enum count="117">U</enum></stats></total></variable><variable id="phv00294678.v2.p1.c2" var_name="AFUcomp7i_G" calculated_type="string" reported_type=""><description>B. Death Information. DOCTOR - CANCER Q7I IN AFUG-K; Q21A IN AFUL [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="133" nulls="254"/><enum count="107">N</enum><enum count="26">Y</enum></stats></total></variable><variable id="phv00294679.v2.p1" var_name="AFUcomp7l_G" calculated_type="string" reported_type=""><description>B. Death Information. HAD ANOTHER CANCER Q7L IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1661</male><female>1672</female></sex></subject_profile><stats><stat n="12379" nulls="300447"/><enum count="9930">N</enum><enum count="2429">Y</enum><enum count="20">U</enum></stats></total></variable><variable id="phv00294679.v2.p1.c1" var_name="AFUcomp7l_G" calculated_type="string" reported_type=""><description>B. Death Information. HAD ANOTHER CANCER Q7L IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1659</male><female>1670</female></sex></subject_profile><stats><stat n="12358" nulls="300081"/><enum count="9921">N</enum><enum count="2417">Y</enum><enum count="20">U</enum></stats></total></variable><variable id="phv00294679.v2.p1.c2" var_name="AFUcomp7l_G" calculated_type="string" reported_type=""><description>B. Death Information. HAD ANOTHER CANCER Q7L IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="21" nulls="366"/><enum count="12">Y</enum><enum count="9">N</enum></stats></total></variable><variable id="phv00294680.v2.p1" var_name="AFUcomp7m_G" calculated_type="string" reported_type=""><description>B. Death Information. WHERE OTHER CANCER LOCATED Q7M IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>548</male><female>437</female></sex></subject_profile><stats><stat n="2421" nulls="310405" mean_count="4.683" sd="18.85" median_count="1" min_count="1" max_count="299" distinct_vals="517"/><example count="299">SKIN</example><example count="178">PROSTATE</example><example count="162">COLON</example><example count="131">BREAST</example><example count="92">BLADDER</example><example count="53">UTERUS</example><example count="45">SKIN OF FACE</example><example count="43">KIDNEY</example><example count="42">SKIN FACE</example><example count="41">LUNG</example></stats></total></variable><variable id="phv00294680.v2.p1.c1" var_name="AFUcomp7m_G" calculated_type="string" reported_type=""><description>B. Death Information. WHERE OTHER CANCER LOCATED Q7M IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>547</male><female>436</female></sex></subject_profile><stats><stat n="2409" nulls="310030" mean_count="4.66" sd="18.8" median_count="1" min_count="1" max_count="299" distinct_vals="517"/><example count="299">SKIN</example><example count="175">PROSTATE</example><example count="162">COLON</example><example count="131">BREAST</example><example count="92">BLADDER</example><example count="53">UTERUS</example><example count="45">SKIN OF FACE</example><example count="43">KIDNEY</example><example count="42">SKIN FACE</example><example count="41">LUNG</example></stats></total></variable><variable id="phv00294680.v2.p1.c2" var_name="AFUcomp7m_G" calculated_type="string" reported_type=""><description>B. Death Information. WHERE OTHER CANCER LOCATED Q7M IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>1</female></sex></subject_profile><stats><stat n="12" nulls="375"/><enum count="3">PROSTATE</enum><enum count="2">SKIN FOREHEAD</enum><enum count="2">BREAST RT</enum><enum count="1">BREAST-RIGHT</enum><enum count="1">SKIN ON NOSE</enum><enum count="1">SKIN/FOREHEAD</enum><enum count="1">SKIN NOSE</enum><enum count="1">BREAST RIGHT</enum></stats></total></variable><variable id="phv00294681.v2.p1" var_name="AFUcomp11a_G" calculated_type="string" reported_type=""><description>D. Stroke/TIA. OVERNIGHT STAY IN NURSING HOME  Q11A IN AFUG-K; Q27A IN AFUL-M; Q60 IN AFU V1-V3; Q28 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5565</male><female>6998</female></sex></subject_profile><stats><stat n="159297" nulls="153529"/><enum count="155737">N</enum><enum count="3557">Y</enum><enum count="3">U</enum></stats></total></variable><variable id="phv00294681.v2.p1.c1" var_name="AFUcomp11a_G" calculated_type="string" reported_type=""><description>D. Stroke/TIA. OVERNIGHT STAY IN NURSING HOME  Q11A IN AFUG-K; Q27A IN AFUL-M; Q60 IN AFU V1-V3; Q28 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5558</male><female>6990</female></sex></subject_profile><stats><stat n="159062" nulls="153377"/><enum count="155505">N</enum><enum count="3554">Y</enum><enum count="3">U</enum></stats></total></variable><variable id="phv00294681.v2.p1.c2" var_name="AFUcomp11a_G" calculated_type="string" reported_type=""><description>D. Stroke/TIA. OVERNIGHT STAY IN NURSING HOME  Q11A IN AFUG-K; Q27A IN AFUL-M; Q60 IN AFU V1-V3; Q28 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="235" nulls="152"/><enum count="232">N</enum><enum count="3">Y</enum></stats></total></variable><variable id="phv00294682.v2.p1" var_name="AFUcomp11b_G" calculated_type="string" reported_type=""><description>D. Stroke/TIA. CURRENTLY IN NURSING HOME Q11B IN AFUG-K; Q27B IN AFUL-M; Q61 IN AFU V1-V3; Q29 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3563</male><female>5105</female></sex></subject_profile><stats><stat n="29156" nulls="283670"/><enum count="27686">N</enum><enum count="1470">Y</enum></stats></total></variable><variable id="phv00294682.v2.p1.c1" var_name="AFUcomp11b_G" calculated_type="string" reported_type=""><description>D. Stroke/TIA. CURRENTLY IN NURSING HOME Q11B IN AFUG-K; Q27B IN AFUL-M; Q61 IN AFU V1-V3; Q29 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3556</male><female>5098</female></sex></subject_profile><stats><stat n="29099" nulls="283340"/><enum count="27631">N</enum><enum count="1468">Y</enum></stats></total></variable><variable id="phv00294682.v2.p1.c2" var_name="AFUcomp11b_G" calculated_type="string" reported_type=""><description>D. Stroke/TIA. CURRENTLY IN NURSING HOME Q11B IN AFUG-K; Q27B IN AFUL-M; Q61 IN AFU V1-V3; Q29 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="57" nulls="330"/><enum count="55">N</enum><enum count="2">Y</enum></stats></total></variable><variable id="phv00294683.v2.p1" var_name="AFUcomp12a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. HEART SURGERY SINCE LAST CONTACT Q12A IN AFUG-K; Q41A IN AFUL-M; Q62 IN AFU V1-V3; Q30 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5395</male><female>6874</female></sex></subject_profile><stats><stat n="143752" nulls="169074"/><enum count="141531">N</enum><enum count="2220">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294683.v2.p1.c1" var_name="AFUcomp12a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. HEART SURGERY SINCE LAST CONTACT Q12A IN AFUG-K; Q41A IN AFUL-M; Q62 IN AFU V1-V3; Q30 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5388</male><female>6866</female></sex></subject_profile><stats><stat n="143532" nulls="168907"/><enum count="141315">N</enum><enum count="2216">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294683.v2.p1.c2" var_name="AFUcomp12a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. HEART SURGERY SINCE LAST CONTACT Q12A IN AFUG-K; Q41A IN AFUL-M; Q62 IN AFU V1-V3; Q30 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="220" nulls="167"/><enum count="216">N</enum><enum count="4">Y</enum></stats></total></variable><variable id="phv00294684.v2.p1" var_name="AFUcomp12b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. HEART SURGERY SINCE LAST VISIT Q12B IN AFUG-K; Q41B IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5451</male><female>6872</female></sex></subject_profile><stats><stat n="12926" nulls="299900"/><enum count="12524">N</enum><enum count="402">Y</enum></stats></total></variable><variable id="phv00294684.v2.p1.c1" var_name="AFUcomp12b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. HEART SURGERY SINCE LAST VISIT Q12B IN AFUG-K; Q41B IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5444</male><female>6864</female></sex></subject_profile><stats><stat n="12911" nulls="299528"/><enum count="12510">N</enum><enum count="401">Y</enum></stats></total></variable><variable id="phv00294684.v2.p1.c2" var_name="AFUcomp12b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. HEART SURGERY SINCE LAST VISIT Q12B IN AFUG-K; Q41B IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="15" nulls="372"/><enum count="14">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294685.v2.p1" var_name="AFUcomp13a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. CORONARY BYPASS Q13A IN AFUG-K; Q42A IN AFUL-M; Q63 IN AFU V1-V3; Q31A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1209</male><female>767</female></sex></subject_profile><stats><stat n="2603" nulls="310223"/><enum count="1841">N</enum><enum count="761">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294685.v2.p1.c1" var_name="AFUcomp13a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. CORONARY BYPASS Q13A IN AFUG-K; Q42A IN AFUL-M; Q63 IN AFU V1-V3; Q31A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1205</male><female>767</female></sex></subject_profile><stats><stat n="2598" nulls="309841"/><enum count="1839">N</enum><enum count="758">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294685.v2.p1.c2" var_name="AFUcomp13a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. CORONARY BYPASS Q13A IN AFUG-K; Q42A IN AFUL-M; Q63 IN AFU V1-V3; Q31A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="3">Y</enum><enum count="2">N</enum></stats></total></variable><variable id="phv00294686.v2.p1" var_name="AFUcomp13b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER HEART PROCEDURE Q13B IN AFUG-K; Q42B IN AFUL-M; Q63B IN AFU V1-V3; Q31B IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1209</male><female>767</female></sex></subject_profile><stats><stat n="2602" nulls="310224"/><enum count="1482">Y</enum><enum count="1119">N</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294686.v2.p1.c1" var_name="AFUcomp13b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER HEART PROCEDURE Q13B IN AFUG-K; Q42B IN AFUL-M; Q63B IN AFU V1-V3; Q31B IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1205</male><female>767</female></sex></subject_profile><stats><stat n="2597" nulls="309842"/><enum count="1478">Y</enum><enum count="1118">N</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294686.v2.p1.c2" var_name="AFUcomp13b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER HEART PROCEDURE Q13B IN AFUG-K; Q42B IN AFUL-M; Q63B IN AFU V1-V3; Q31B IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="4">Y</enum><enum count="1">N</enum></stats></total></variable><variable id="phv00294687.v2.p1" var_name="AFUcomp13c_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. CAROTID ENDARTERECTOMYQ13C IN AFUG-K;  Q42C IN AFUL-M; Q63C IN AFU V1-V3; Q31C IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1206</male><female>765</female></sex></subject_profile><stats><stat n="2598" nulls="310228"/><enum count="2239">N</enum><enum count="358">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294687.v2.p1.c1" var_name="AFUcomp13c_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. CAROTID ENDARTERECTOMYQ13C IN AFUG-K;  Q42C IN AFUL-M; Q63C IN AFU V1-V3; Q31C IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1202</male><female>765</female></sex></subject_profile><stats><stat n="2593" nulls="309846"/><enum count="2235">N</enum><enum count="357">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294687.v2.p1.c2" var_name="AFUcomp13c_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. CAROTID ENDARTERECTOMYQ13C IN AFUG-K;  Q42C IN AFUL-M; Q63C IN AFU V1-V3; Q31C IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="4">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294688.v2.p1" var_name="AFUcomp13d_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. SITE OF CAROTID ENDARTERECTOMY Q13D IN AFUG-K; Q42D IN AFUL-M; Q63D IN AFU V1-V3; Q31D IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>175</male><female>132</female></sex></subject_profile><stats><stat n="348" nulls="312478"/><enum count="174">R</enum><enum count="155">L</enum><enum count="19">B</enum></stats></total></variable><variable id="phv00294688.v2.p1.c1" var_name="AFUcomp13d_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. SITE OF CAROTID ENDARTERECTOMY Q13D IN AFUG-K; Q42D IN AFUL-M; Q63D IN AFU V1-V3; Q31D IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>175</male><female>132</female></sex></subject_profile><stats><stat n="348" nulls="312091"/><enum count="174">R</enum><enum count="155">L</enum><enum count="19">B</enum></stats></total></variable><variable id="phv00294688.v2.p1.c2" var_name="AFUcomp13d_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. SITE OF CAROTID ENDARTERECTOMY Q13D IN AFUG-K; Q42D IN AFUL-M; Q63D IN AFU V1-V3; Q31D IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294689.v2.p1" var_name="AFUcomp13e_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER ARTERIAL REVASCULARIZATION Q13E IN AFUG-K; Q42E IN AFUL-M; Q63E IN AFU V1-V3; Q31E IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1203</male><female>769</female></sex></subject_profile><stats><stat n="2596" nulls="310230"/><enum count="2464">N</enum><enum count="131">Y</enum><enum count="1">R</enum></stats></total></variable><variable id="phv00294689.v2.p1.c1" var_name="AFUcomp13e_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER ARTERIAL REVASCULARIZATION Q13E IN AFUG-K; Q42E IN AFUL-M; Q63E IN AFU V1-V3; Q31E IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1199</male><female>769</female></sex></subject_profile><stats><stat n="2591" nulls="309848"/><enum count="2459">N</enum><enum count="131">Y</enum><enum count="1">R</enum></stats></total></variable><variable id="phv00294689.v2.p1.c2" var_name="AFUcomp13e_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER ARTERIAL REVASCULARIZATION Q13E IN AFUG-K; Q42E IN AFUL-M; Q63E IN AFU V1-V3; Q31E IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="5">N</enum></stats></total></variable><variable id="phv00294690.v2.p1" var_name="AFUcomp13f_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER SURGERY ON HEART, ARTERIES Q13F IN AFUG-K;  Q42F IN AFUL-M; Q63F IN AFU V1-V3; Q31F IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1203</male><female>768</female></sex></subject_profile><stats><stat n="2594" nulls="310232"/><enum count="2409">N</enum><enum count="184">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294690.v2.p1.c1" var_name="AFUcomp13f_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER SURGERY ON HEART, ARTERIES Q13F IN AFUG-K;  Q42F IN AFUL-M; Q63F IN AFU V1-V3; Q31F IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1199</male><female>768</female></sex></subject_profile><stats><stat n="2589" nulls="309850"/><enum count="2405">N</enum><enum count="183">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294690.v2.p1.c2" var_name="AFUcomp13f_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. OTHER SURGERY ON HEART, ARTERIES Q13F IN AFUG-K;  Q42F IN AFUL-M; Q63F IN AFU V1-V3; Q31F IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="4">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294691.v2.p1" var_name="AFUcomp14a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY SINCE LAST CONTACT Q14A IN AFUG-K; Q44A IN AFUL-M; Q64 IN AFU V1-V3; Q32 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5395</male><female>6874</female></sex></subject_profile><stats><stat n="143704" nulls="169122"/><enum count="142198">N</enum><enum count="1505">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294691.v2.p1.c1" var_name="AFUcomp14a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY SINCE LAST CONTACT Q14A IN AFUG-K; Q44A IN AFUL-M; Q64 IN AFU V1-V3; Q32 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5388</male><female>6866</female></sex></subject_profile><stats><stat n="143484" nulls="168955"/><enum count="141981">N</enum><enum count="1502">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294691.v2.p1.c2" var_name="AFUcomp14a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY SINCE LAST CONTACT Q14A IN AFUG-K; Q44A IN AFUL-M; Q64 IN AFU V1-V3; Q32 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="220" nulls="167"/><enum count="217">N</enum><enum count="3">Y</enum></stats></total></variable><variable id="phv00294692.v2.p1" var_name="AFUcomp14b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY SINCE LAST VISIT Q14B IN AFUG-K; Q44B IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5449</male><female>6868</female></sex></subject_profile><stats><stat n="12919" nulls="299907"/><enum count="12707">N</enum><enum count="212">Y</enum></stats></total></variable><variable id="phv00294692.v2.p1.c1" var_name="AFUcomp14b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY SINCE LAST VISIT Q14B IN AFUG-K; Q44B IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5442</male><female>6860</female></sex></subject_profile><stats><stat n="12904" nulls="299535"/><enum count="12692">N</enum><enum count="212">Y</enum></stats></total></variable><variable id="phv00294692.v2.p1.c2" var_name="AFUcomp14b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY SINCE LAST VISIT Q14B IN AFUG-K; Q44B IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="15" nulls="372"/><enum count="15">N</enum></stats></total></variable><variable id="phv00294693.v2.p1" var_name="AFUcomp15a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF CORONARY ARTERIES Q15A IN AFUG-K; Q45A IN AFUL-M; Q64A IN AFU V1-V3; Q32A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>788</male><female>469</female></sex></subject_profile><stats><stat n="1706" nulls="311120"/><enum count="1349">Y</enum><enum count="356">N</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294693.v2.p1.c1" var_name="AFUcomp15a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF CORONARY ARTERIES Q15A IN AFUG-K; Q45A IN AFUL-M; Q64A IN AFU V1-V3; Q32A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>785</male><female>469</female></sex></subject_profile><stats><stat n="1703" nulls="310736"/><enum count="1347">Y</enum><enum count="355">N</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294693.v2.p1.c2" var_name="AFUcomp15a_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF CORONARY ARTERIES Q15A IN AFUG-K; Q45A IN AFUL-M; Q64A IN AFU V1-V3; Q32A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3</male></sex></subject_profile><stats><stat n="3" nulls="384"/><enum count="2">Y</enum><enum count="1">N</enum></stats></total></variable><variable id="phv00294694.v2.p1" var_name="AFUcomp15b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF NECK ARTERIES Q15B IN AFUG-K; Q45B IN AFUL-M; Q64B IN AFU V1-V3; Q32B IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>790</male><female>469</female></sex></subject_profile><stats><stat n="1709" nulls="311117"/><enum count="1621">N</enum><enum count="87">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294694.v2.p1.c1" var_name="AFUcomp15b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF NECK ARTERIES Q15B IN AFUG-K; Q45B IN AFUL-M; Q64B IN AFU V1-V3; Q32B IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>787</male><female>469</female></sex></subject_profile><stats><stat n="1706" nulls="310733"/><enum count="1618">N</enum><enum count="87">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294694.v2.p1.c2" var_name="AFUcomp15b_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF NECK ARTERIES Q15B IN AFUG-K; Q45B IN AFUL-M; Q64B IN AFU V1-V3; Q32B IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3</male></sex></subject_profile><stats><stat n="3" nulls="384"/><enum count="3">N</enum></stats></total></variable><variable id="phv00294695.v2.p1" var_name="AFUcomp15c_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF LOWER EXTRM ARTERIES Q15C IN AFUG-K; Q45C IN AFUL-M; Q64C IN AFU V1-V3; Q32C IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>789</male><female>469</female></sex></subject_profile><stats><stat n="1709" nulls="311117"/><enum count="1407">N</enum><enum count="301">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294695.v2.p1.c1" var_name="AFUcomp15c_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF LOWER EXTRM ARTERIES Q15C IN AFUG-K; Q45C IN AFUL-M; Q64C IN AFU V1-V3; Q32C IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>786</male><female>469</female></sex></subject_profile><stats><stat n="1706" nulls="310733"/><enum count="1404">N</enum><enum count="301">Y</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294695.v2.p1.c2" var_name="AFUcomp15c_G" calculated_type="string" reported_type=""><description>F. Invasive Procedures. ANGIOPLASTY OF LOWER EXTRM ARTERIES Q15C IN AFUG-K; Q45C IN AFUL-M; Q64C IN AFU V1-V3; Q32C IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3</male></sex></subject_profile><stats><stat n="3" nulls="384"/><enum count="3">N</enum></stats></total></variable><variable id="phv00294696.v2.p1" var_name="AFUcomp16a_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR HIGH BP Q16A IN AFUG-K; Q46A IN AFUL-M; Q65A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5546</male><female>6983</female></sex></subject_profile><stats><stat n="144005" nulls="168821"/><enum count="82411">Y</enum><enum count="61024">N</enum><enum count="570">U</enum></stats></total></variable><variable id="phv00294696.v2.p1.c1" var_name="AFUcomp16a_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR HIGH BP Q16A IN AFUG-K; Q46A IN AFUL-M; Q65A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5539</male><female>6975</female></sex></subject_profile><stats><stat n="143797" nulls="168642"/><enum count="82342">Y</enum><enum count="60885">N</enum><enum count="570">U</enum></stats></total></variable><variable id="phv00294696.v2.p1.c2" var_name="AFUcomp16a_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR HIGH BP Q16A IN AFUG-K; Q46A IN AFUL-M; Q65A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="208" nulls="179"/><enum count="139">N</enum><enum count="69">Y</enum></stats></total></variable><variable id="phv00294697.v2.p1" var_name="AFUcomp16b_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR HIGH BLOOD CHOL Q16B IN AFUG-K; Q46B IN AFUL-M; Q65B IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5546</male><female>6983</female></sex></subject_profile><stats><stat n="143964" nulls="168862"/><enum count="85616">N</enum><enum count="57674">Y</enum><enum count="674">U</enum></stats></total></variable><variable id="phv00294697.v2.p1.c1" var_name="AFUcomp16b_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR HIGH BLOOD CHOL Q16B IN AFUG-K; Q46B IN AFUL-M; Q65B IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5539</male><female>6975</female></sex></subject_profile><stats><stat n="143756" nulls="168683"/><enum count="85465">N</enum><enum count="57617">Y</enum><enum count="674">U</enum></stats></total></variable><variable id="phv00294697.v2.p1.c2" var_name="AFUcomp16b_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR HIGH BLOOD CHOL Q16B IN AFUG-K; Q46B IN AFUL-M; Q65B IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="208" nulls="179"/><enum count="151">N</enum><enum count="57">Y</enum></stats></total></variable><variable id="phv00294698.v2.p1" var_name="AFUcomp16c_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR DIABETES OR BLOOD SUGAR Q16C IN AFUG-K; Q46C IN AFUL-M; Q65C IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5546</male><female>6983</female></sex></subject_profile><stats><stat n="144054" nulls="168772"/><enum count="118312">N</enum><enum count="25541">Y</enum><enum count="201">U</enum></stats></total></variable><variable id="phv00294698.v2.p1.c1" var_name="AFUcomp16c_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR DIABETES OR BLOOD SUGAR Q16C IN AFUG-K; Q46C IN AFUL-M; Q65C IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5539</male><female>6975</female></sex></subject_profile><stats><stat n="143846" nulls="168593"/><enum count="118106">N</enum><enum count="25539">Y</enum><enum count="201">U</enum></stats></total></variable><variable id="phv00294698.v2.p1.c2" var_name="AFUcomp16c_G" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR DIABETES OR BLOOD SUGAR Q16C IN AFUG-K; Q46C IN AFUL-M; Q65C IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="208" nulls="179"/><enum count="206">N</enum><enum count="2">Y</enum></stats></total></variable><variable id="phv00294699.v2.p1" var_name="AFUcomp17_G" calculated_type="string" reported_type=""><description>G. Interview. TAKING ASPIRIN Q17 IN AFUG-K; Q49 IN AFUL-M; Q66 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5546</male><female>6983</female></sex></subject_profile><stats><stat n="144019" nulls="168807"/><enum count="75083">Y</enum><enum count="68582">N</enum><enum count="354">U</enum></stats></total></variable><variable id="phv00294699.v2.p1.c1" var_name="AFUcomp17_G" calculated_type="string" reported_type=""><description>G. Interview. TAKING ASPIRIN Q17 IN AFUG-K; Q49 IN AFUL-M; Q66 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5539</male><female>6975</female></sex></subject_profile><stats><stat n="143811" nulls="168628"/><enum count="74990">Y</enum><enum count="68467">N</enum><enum count="354">U</enum></stats></total></variable><variable id="phv00294699.v2.p1.c2" var_name="AFUcomp17_G" calculated_type="string" reported_type=""><description>G. Interview. TAKING ASPIRIN Q17 IN AFUG-K; Q49 IN AFUL-M; Q66 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="208" nulls="179"/><enum count="115">N</enum><enum count="93">Y</enum></stats></total></variable><variable id="phv00294700.v2.p1" var_name="AFUcomp18_G" calculated_type="string" reported_type=""><description>G. Interview. GENDER OF PARTICIPANT Q18 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5532</male><female>6969</female></sex></subject_profile><stats><stat n="88994" nulls="223832"/><enum count="50359">F</enum><enum count="38635">M</enum></stats></total></variable><variable id="phv00294700.v2.p1.c1" var_name="AFUcomp18_G" calculated_type="string" reported_type=""><description>G. Interview. GENDER OF PARTICIPANT Q18 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5525</male><female>6961</female></sex></subject_profile><stats><stat n="88879" nulls="223560"/><enum count="50298">F</enum><enum count="38581">M</enum></stats></total></variable><variable id="phv00294700.v2.p1.c2" var_name="AFUcomp18_G" calculated_type="string" reported_type=""><description>G. Interview. GENDER OF PARTICIPANT Q18 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="115" nulls="272"/><enum count="61">F</enum><enum count="54">M</enum></stats></total></variable><variable id="phv00294701.v2.p1" var_name="AFUcomp19a_G" calculated_type="string" reported_type=""><description>G. Interview. FEMALE HORMONE SINCE LAST CONTACT Q19A IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>35</male><female>6853</female></sex></subject_profile><stats><stat n="43251" nulls="269575"/><enum count="32069">N</enum><enum count="11182">Y</enum></stats></total></variable><variable id="phv00294701.v2.p1.c1" var_name="AFUcomp19a_G" calculated_type="string" reported_type=""><description>G. Interview. FEMALE HORMONE SINCE LAST CONTACT Q19A IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>35</male><female>6845</female></sex></subject_profile><stats><stat n="43198" nulls="269241"/><enum count="32032">N</enum><enum count="11166">Y</enum></stats></total></variable><variable id="phv00294701.v2.p1.c2" var_name="AFUcomp19a_G" calculated_type="string" reported_type=""><description>G. Interview. FEMALE HORMONE SINCE LAST CONTACT Q19A IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>8</female></sex></subject_profile><stats><stat n="53" nulls="334"/><enum count="37">N</enum><enum count="16">Y</enum></stats></total></variable><variable id="phv00294702.v2.p1" var_name="AFUcomp19b_G" calculated_type="string" reported_type=""><description>G. Interview. FEMALE HORMONE SINCE LAST VISIT Q19B IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>8</male><female>6860</female></sex></subject_profile><stats><stat n="7069" nulls="305757"/><enum count="4320">N</enum><enum count="2749">Y</enum></stats></total></variable><variable id="phv00294702.v2.p1.c1" var_name="AFUcomp19b_G" calculated_type="string" reported_type=""><description>G. Interview. FEMALE HORMONE SINCE LAST VISIT Q19B IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>8</male><female>6852</female></sex></subject_profile><stats><stat n="7061" nulls="305378"/><enum count="4315">N</enum><enum count="2746">Y</enum></stats></total></variable><variable id="phv00294702.v2.p1.c2" var_name="AFUcomp19b_G" calculated_type="string" reported_type=""><description>G. Interview. FEMALE HORMONE SINCE LAST VISIT Q19B IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>8</female></sex></subject_profile><stats><stat n="8" nulls="379"/><enum count="5">N</enum><enum count="3">Y</enum></stats></total></variable><variable id="phv00294703.v2.p1" var_name="AFUcomp19c_G" calculated_type="string" reported_type=""><description>G. Interview. NAME OF FEMALE HORMONES Q19C IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3</male><female>3282</female></sex></subject_profile><stats><stat n="13886" nulls="298940" mean_count="34.29" sd="293.6" median_count="1" min_count="1" max_count="5221" distinct_vals="405"/><example count="5221">PREMARIN</example><example count="1943">PREMPRO</example><example count="1845">PREMARIN (CONJUGATED</example><example count="415">ESTRADIOL</example><example count="404">ESTRACE</example><example count="312">EVISTA</example><example count="279">PREMPRO (CONJUGATED</example><example count="243">ESTRACE (ESTRADIOL)</example><example count="216">EVISTA  (RALOXIFENE)</example><example count="211">ESTRADERM</example></stats></total></variable><variable id="phv00294703.v2.p1.c1" var_name="AFUcomp19c_G" calculated_type="string" reported_type=""><description>G. Interview. NAME OF FEMALE HORMONES Q19C IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>3</male><female>3279</female></sex></subject_profile><stats><stat n="13867" nulls="298572" mean_count="34.24" sd="293.1" median_count="1" min_count="1" max_count="5213" distinct_vals="405"/><example count="5213">PREMARIN</example><example count="1939">PREMPRO</example><example count="1839">PREMARIN (CONJUGATED</example><example count="415">ESTRADIOL</example><example count="404">ESTRACE</example><example count="312">EVISTA</example><example count="278">PREMPRO (CONJUGATED</example><example count="243">ESTRACE (ESTRADIOL)</example><example count="216">EVISTA  (RALOXIFENE)</example><example count="211">ESTRADERM</example></stats></total></variable><variable id="phv00294703.v2.p1.c2" var_name="AFUcomp19c_G" calculated_type="string" reported_type=""><description>G. Interview. NAME OF FEMALE HORMONES Q19C IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>3</female></sex></subject_profile><stats><stat n="19" nulls="368"/><enum count="8">PREMARIN</enum><enum count="6">PREMARIN (CONJUGATED</enum><enum count="4">PREMPRO</enum><enum count="1">PREMPRO (CONJUGATED</enum></stats></total></variable><variable id="phv00294704.v2.p1" var_name="AFUcomp19d_G" calculated_type="string" reported_type=""><description>G. Interview. NAME OF FEMALE HORMONES Q19D IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>1513</female></sex></subject_profile><stats><stat n="3184" nulls="309642" mean_count="60.08" sd="255.5" median_count="7" min_count="1" max_count="1845" distinct_vals="53"/><example count="1845">ESTROGEN)</example><example count="279">ESTROGEN &amp; PROGESTER</example><example count="216">60 MG</example><example count="153">TRANSDERMAL)</example><example count="98">S MEDICATION)</example><example count="77">/NORETHINDRONE)</example><example count="67">RTHO-EST</example><example count="63">&amp; PROGESTERIN</example><example count="54">E ACETATE/ETHINYL ES</example><example count="45">D ESTROGEN/METHYLTES</example></stats></total></variable><variable id="phv00294704.v2.p1.c1" var_name="AFUcomp19d_G" calculated_type="string" reported_type=""><description>G. Interview. NAME OF FEMALE HORMONES Q19D IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>1510</female></sex></subject_profile><stats><stat n="3177" nulls="309262" mean_count="59.94" sd="254.7" median_count="7" min_count="1" max_count="1839" distinct_vals="53"/><example count="1839">ESTROGEN)</example><example count="278">ESTROGEN &amp; PROGESTER</example><example count="216">60 MG</example><example count="153">TRANSDERMAL)</example><example count="98">S MEDICATION)</example><example count="77">/NORETHINDRONE)</example><example count="67">RTHO-EST</example><example count="63">&amp; PROGESTERIN</example><example count="54">E ACETATE/ETHINYL ES</example><example count="45">D ESTROGEN/METHYLTES</example></stats></total></variable><variable id="phv00294704.v2.p1.c2" var_name="AFUcomp19d_G" calculated_type="string" reported_type=""><description>G. Interview. NAME OF FEMALE HORMONES Q19D IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>3</female></sex></subject_profile><stats><stat n="7" nulls="380"/><enum count="6">ESTROGEN)</enum><enum count="1">ESTROGEN &amp; PROGESTER</enum></stats></total></variable><variable id="phv00294705.v2.p1" var_name="AFUcomp20_G" calculated_type="integer" reported_type=""><description>G. Interview. FEMALE HORMONE CODE 1 Q20 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>2</male><female>3171</female></sex></subject_profile><stats><stat n="13154" nulls="299672" mean="1.1E+05" sd="5579" median="1.1E+05" min="1.1E+05" max="1.2E+05"/><example count="7077">108351</example><example count="2298">121823</example><example count="1967">108282</example><example count="545">122323</example><example count="387">108379</example><example count="276">111112</example><example count="158">108265</example><example count="87">108276</example><example count="63">112565</example><example count="52">112601</example></stats></total></variable><variable id="phv00294705.v2.p1.c1" var_name="AFUcomp20_G" calculated_type="integer" reported_type=""><description>G. Interview. FEMALE HORMONE CODE 1 Q20 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>2</male><female>3168</female></sex></subject_profile><stats><stat n="13135" nulls="299304" mean="1.1E+05" sd="5578" median="1.1E+05" min="1.1E+05" max="1.2E+05"/><example count="7063">108351</example><example count="2293">121823</example><example count="1967">108282</example><example count="545">122323</example><example count="387">108379</example><example count="276">111112</example><example count="158">108265</example><example count="87">108276</example><example count="63">112565</example><example count="52">112601</example></stats></total></variable><variable id="phv00294705.v2.p1.c2" var_name="AFUcomp20_G" calculated_type="integer" reported_type=""><description>G. Interview. FEMALE HORMONE CODE 1 Q20 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>3</female></sex></subject_profile><stats><stat n="19" nulls="368" mean="1.1E+05" sd="6095" median="1.1E+05" min="1.1E+05" max="1.2E+05"/><enum count="14">108351</enum><enum count="5">121823</enum></stats></total></variable><variable id="phv00294706.v2.p1" var_name="AFUcomp21_G" calculated_type="string" reported_type=""><description>G. Interview. USE OF SECOND FEMALE HORMONE Q21 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male><female>3286</female></sex></subject_profile><stats><stat n="13885" nulls="298941"/><enum count="12159">N</enum><enum count="1726">Y</enum></stats></total></variable><variable id="phv00294706.v2.p1.c1" var_name="AFUcomp21_G" calculated_type="string" reported_type=""><description>G. Interview. USE OF SECOND FEMALE HORMONE Q21 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>4</male><female>3283</female></sex></subject_profile><stats><stat n="13866" nulls="298573"/><enum count="12141">N</enum><enum count="1725">Y</enum></stats></total></variable><variable id="phv00294706.v2.p1.c2" var_name="AFUcomp21_G" calculated_type="string" reported_type=""><description>G. Interview. USE OF SECOND FEMALE HORMONE Q21 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>3</female></sex></subject_profile><stats><stat n="19" nulls="368"/><enum count="18">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294707.v2.p1" var_name="AFUcomp21a_G" calculated_type="string" reported_type=""><description>G. Interview. NAME 2 OF FEMALE HORMONE Q21A IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>710</female></sex></subject_profile><stats><stat n="1711" nulls="311115" mean_count="11.56" sd="49.97" median_count="1" min_count="1" max_count="543" distinct_vals="148"/><example count="543">PROVERA</example><example count="206">MEDROXYPROGESTERONE</example><example count="144">PREMARIN</example><example count="84">PROGESTERONE</example><example count="76">PROVERA (MEDROXYPROG</example><example count="55">PREMPRO</example><example count="55">ESTRADIOL</example><example count="49">CYCRIN</example><example count="43">PROMETRIUM</example><example count="36">ESTRACE</example></stats></total></variable><variable id="phv00294707.v2.p1.c1" var_name="AFUcomp21a_G" calculated_type="string" reported_type=""><description>G. Interview. NAME 2 OF FEMALE HORMONE Q21A IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>709</female></sex></subject_profile><stats><stat n="1710" nulls="310729" mean_count="11.55" sd="49.97" median_count="1" min_count="1" max_count="543" distinct_vals="148"/><example count="543">PROVERA</example><example count="206">MEDROXYPROGESTERONE</example><example count="144">PREMARIN</example><example count="84">PROGESTERONE</example><example count="76">PROVERA (MEDROXYPROG</example><example count="55">PREMPRO</example><example count="55">ESTRADIOL</example><example count="49">CYCRIN</example><example count="43">PROMETRIUM</example><example count="36">ESTRACE</example></stats></total></variable><variable id="phv00294707.v2.p1.c2" var_name="AFUcomp21a_G" calculated_type="string" reported_type=""><description>G. Interview. NAME 2 OF FEMALE HORMONE Q21A IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><female>1</female></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">ESTROVEN (NATURAL SU</enum></stats></total></variable><variable id="phv00294708.v2.p1" var_name="AFUcomp22_G" calculated_type="integer" reported_type=""><description>G. Interview. FEMALE HORMONE CODE 2 Q22 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>680</female></sex></subject_profile><stats><stat n="1594" nulls="311231" mean="1.1E+05" sd="3436" median="1.1E+05" min="1.1E+05" max="1.2E+05"/><example count="949">111112</example><example count="179">108282</example><example count="170">108351</example><example count="99">121823</example><example count="84">115780</example><example count="29">108379</example><example count="27">108265</example><example count="19">112601</example><example count="19">122323</example><example count="6">108276</example></stats></total></variable><variable id="phv00294708.v2.p1.c1" var_name="AFUcomp22_G" calculated_type="integer" reported_type=""><description>G. Interview. FEMALE HORMONE CODE 2 Q22 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>1</male><female>680</female></sex></subject_profile><stats><stat n="1594" nulls="310844" mean="1.1E+05" sd="3436" median="1.1E+05" min="1.1E+05" max="1.2E+05"/><example count="949">111112</example><example count="179">108282</example><example count="170">108351</example><example count="99">121823</example><example count="84">115780</example><example count="29">108379</example><example count="27">108265</example><example count="19">112601</example><example count="19">122323</example><example count="6">108276</example></stats></total></variable><variable id="phv00294708.v2.p1.c2" var_name="AFUcomp22_G" calculated_type="integer" reported_type=""><description>G. Interview. FEMALE HORMONE CODE 2 Q22 IN AFUG-K [Annual Follow-up Questionnaire Form, Version G]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294709.v2.p1" var_name="AFUcomp30_G" calculated_type="string" reported_type=""><description>I. Other Items. SMOKE CIGARETTES Q30 IN AFUG-K; Q50 IN AFUL-M; Q69 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5546</male><female>6983</female></sex></subject_profile><stats><stat n="144093" nulls="168733"/><enum count="130365">N</enum><enum count="13728">Y</enum></stats></total></variable><variable id="phv00294709.v2.p1.c1" var_name="AFUcomp30_G" calculated_type="string" reported_type=""><description>I. Other Items. SMOKE CIGARETTES Q30 IN AFUG-K; Q50 IN AFUL-M; Q69 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5539</male><female>6975</female></sex></subject_profile><stats><stat n="143885" nulls="168554"/><enum count="130189">N</enum><enum count="13696">Y</enum></stats></total></variable><variable id="phv00294709.v2.p1.c2" var_name="AFUcomp30_G" calculated_type="string" reported_type=""><description>I. Other Items. SMOKE CIGARETTES Q30 IN AFUG-K; Q50 IN AFUL-M; Q69 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="208" nulls="179"/><enum count="176">N</enum><enum count="32">Y</enum></stats></total></variable><variable id="phv00294710.v2.p1" var_name="AFUcomp32_G" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYMENT STATUS Q32 IN AFUG [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>525</male><female>706</female></sex></subject_profile><stats><stat n="1232" nulls="311594"/><enum count="545">F</enum><enum count="352">B</enum><enum count="140">A</enum><enum count="123">G</enum><enum count="29">E</enum><enum count="25">D</enum><enum count="18">C</enum></stats></total></variable><variable id="phv00294710.v2.p1.c1" var_name="AFUcomp32_G" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYMENT STATUS Q32 IN AFUG [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>525</male><female>706</female></sex></subject_profile><stats><stat n="1232" nulls="311207"/><enum count="545">F</enum><enum count="352">B</enum><enum count="140">A</enum><enum count="123">G</enum><enum count="29">E</enum><enum count="25">D</enum><enum count="18">C</enum></stats></total></variable><variable id="phv00294710.v2.p1.c2" var_name="AFUcomp32_G" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYMENT STATUS Q32 IN AFUG [Annual Follow-up Questionnaire Form, Version G]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294711.v2.p1" var_name="AFUcomp34_G" calculated_type="string" reported_type=""><description>J. Administrative Information. LIVE WITHIN STUDY BOUNDARIES Q34 IN AFUG-K;  Q53 IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5829</male><female>7270</female></sex></subject_profile><stats><stat n="142592" nulls="170234"/><enum count="114354">Y</enum><enum count="22881">N</enum><enum count="5357">U</enum></stats></total></variable><variable id="phv00294711.v2.p1.c1" var_name="AFUcomp34_G" calculated_type="string" reported_type=""><description>J. Administrative Information. LIVE WITHIN STUDY BOUNDARIES Q34 IN AFUG-K;  Q53 IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5822</male><female>7262</female></sex></subject_profile><stats><stat n="142411" nulls="170028"/><enum count="114189">Y</enum><enum count="22865">N</enum><enum count="5357">U</enum></stats></total></variable><variable id="phv00294711.v2.p1.c2" var_name="AFUcomp34_G" calculated_type="string" reported_type=""><description>J. Administrative Information. LIVE WITHIN STUDY BOUNDARIES Q34 IN AFUG-K;  Q53 IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="181" nulls="206"/><enum count="165">Y</enum><enum count="16">N</enum></stats></total></variable><variable id="phv00294712.v2.p1" var_name="AFUcomp35_G" calculated_type="string" reported_type=""><description>J. Administrative Information. ABLE TO GET RECORDS Q35 IN AFUG-K; Q54 IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5829</male><female>7270</female></sex></subject_profile><stats><stat n="142580" nulls="170246"/><enum count="133101">Y</enum><enum count="9475">N</enum><enum count="4">U</enum></stats></total></variable><variable id="phv00294712.v2.p1.c1" var_name="AFUcomp35_G" calculated_type="string" reported_type=""><description>J. Administrative Information. ABLE TO GET RECORDS Q35 IN AFUG-K; Q54 IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>5822</male><female>7262</female></sex></subject_profile><stats><stat n="142399" nulls="170040"/><enum count="132925">Y</enum><enum count="9470">N</enum><enum count="4">U</enum></stats></total></variable><variable id="phv00294712.v2.p1.c2" var_name="AFUcomp35_G" calculated_type="string" reported_type=""><description>J. Administrative Information. ABLE TO GET RECORDS Q35 IN AFUG-K; Q54 IN AFUL-M [Annual Follow-up Questionnaire Form, Version G]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="181" nulls="206"/><enum count="176">Y</enum><enum count="5">N</enum></stats></total></variable><variable id="phv00294713.v2.p1" var_name="AFUcomp36_H" calculated_type="integer" reported_type=""><description>J. Administrative Information. RESULT CODE Q36 IN AFUG-K; Q55 IN AFUL-M [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>5829</male><female>7270</female></sex></subject_profile><stats><stat n="115233" nulls="170337" mean="5.072" sd="12.21" median="3" min="1" max="98"/><example count="101921">3</example><example count="26511">3A</example><example count="4412">9</example><example count="3327">8</example><example count="2866">7</example><example count="1925">98</example><example count="745">3B</example><example count="629">5</example><example count="71">4</example><example count="34">6</example></stats></total></variable><variable id="phv00294713.v2.p1.c1" var_name="AFUcomp36_H" calculated_type="integer" reported_type=""><description>J. Administrative Information. RESULT CODE Q36 IN AFUG-K; Q55 IN AFUL-M [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>5822</male><female>7262</female></sex></subject_profile><stats><stat n="115099" nulls="170131" mean="5.075" sd="12.21" median="3" min="1" max="98"/><example count="101788">3</example><example count="26464">3A</example><example count="4412">9</example><example count="3327">8</example><example count="2866">7</example><example count="1925">98</example><example count="745">3B</example><example count="628">5</example><example count="71">4</example><example count="34">6</example></stats></total></variable><variable id="phv00294713.v2.p1.c2" var_name="AFUcomp36_H" calculated_type="integer" reported_type=""><description>J. Administrative Information. RESULT CODE Q36 IN AFUG-K; Q55 IN AFUL-M [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="134" nulls="206" mean="3.015" sd="0.1728" median="3" min="3" max="5"/><enum count="133">3</enum><enum count="47">3A</enum><enum count="1">5</enum></stats></total></variable><variable id="phv00294714.v2.p1" var_name="AFUcomp32a_H" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYMENT STATUS Q32A IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>5515</male><female>6960</female></sex></subject_profile><stats><stat n="76271" nulls="236555"/><enum count="53572">D</enum><enum count="16728">B</enum><enum count="5164">A</enum><enum count="807">C</enum></stats></total></variable><variable id="phv00294714.v2.p1.c1" var_name="AFUcomp32a_H" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYMENT STATUS Q32A IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>5508</male><female>6952</female></sex></subject_profile><stats><stat n="76171" nulls="236268"/><enum count="53510">D</enum><enum count="16705">B</enum><enum count="5149">A</enum><enum count="807">C</enum></stats></total></variable><variable id="phv00294714.v2.p1.c2" var_name="AFUcomp32a_H" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYMENT STATUS Q32A IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="100" nulls="287"/><enum count="62">D</enum><enum count="23">B</enum><enum count="15">A</enum></stats></total></variable><variable id="phv00294715.v2.p1" var_name="AFUcomp32b_H" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYED STATUS Q32B IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>2256</male><female>2605</female></sex></subject_profile><stats><stat n="16721" nulls="296105"/><enum count="16356">A</enum><enum count="365">B</enum></stats></total></variable><variable id="phv00294715.v2.p1.c1" var_name="AFUcomp32b_H" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYED STATUS Q32B IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>2253</male><female>2602</female></sex></subject_profile><stats><stat n="16698" nulls="295741"/><enum count="16333">A</enum><enum count="365">B</enum></stats></total></variable><variable id="phv00294715.v2.p1.c2" var_name="AFUcomp32b_H" calculated_type="string" reported_type=""><description>I. Other Items. EMPLOYED STATUS Q32B IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>3</male><female>3</female></sex></subject_profile><stats><stat n="23" nulls="364"/><enum count="23">A</enum></stats></total></variable><variable id="phv00294716.v2.p1" var_name="AFUcomp32c_H" calculated_type="string" reported_type=""><description>I. Other Items. UNEMPLOYED STATUS Q32C IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>229</male><female>386</female></sex></subject_profile><stats><stat n="809" nulls="312017"/><enum count="581">B</enum><enum count="228">A</enum></stats></total></variable><variable id="phv00294716.v2.p1.c1" var_name="AFUcomp32c_H" calculated_type="string" reported_type=""><description>I. Other Items. UNEMPLOYED STATUS Q32C IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>229</male><female>386</female></sex></subject_profile><stats><stat n="809" nulls="311630"/><enum count="581">B</enum><enum count="228">A</enum></stats></total></variable><variable id="phv00294716.v2.p1.c2" var_name="AFUcomp32c_H" calculated_type="string" reported_type=""><description>I. Other Items. UNEMPLOYED STATUS Q32C IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294717.v2.p1" var_name="AFUcomp32d_H" calculated_type="string" reported_type=""><description>I. Other Items. RETIRED STATUS Q32D IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>4988</male><female>6197</female></sex></subject_profile><stats><stat n="53568" nulls="259258"/><enum count="45805">A</enum><enum count="7763">B</enum></stats></total></variable><variable id="phv00294717.v2.p1.c1" var_name="AFUcomp32d_H" calculated_type="string" reported_type=""><description>I. Other Items. RETIRED STATUS Q32D IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>4981</male><female>6191</female></sex></subject_profile><stats><stat n="53506" nulls="258933"/><enum count="45748">A</enum><enum count="7758">B</enum></stats></total></variable><variable id="phv00294717.v2.p1.c2" var_name="AFUcomp32d_H" calculated_type="string" reported_type=""><description>I. Other Items. RETIRED STATUS Q32D IN AFUH-K [Annual Follow-up Questionnaire Form, Version H]</description><total><subject_profile><sex><male>7</male><female>6</female></sex></subject_profile><stats><stat n="62" nulls="325"/><enum count="57">A</enum><enum count="5">B</enum></stats></total></variable><variable id="phv00294718.v2.p1" var_name="AFUcomp8b_K" calculated_type="string" reported_type=""><description>D. Stroke/TIA. HOSPITALIZED FOR STROKE, TIA Q8B IN AFUK; Q22B IN AFUL-M; Q49 IN AFU V1-V3; Q17 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version K]</description><total><subject_profile><sex><male>420</male><female>549</female></sex></subject_profile><stats><stat n="1298" nulls="311528"/><enum count="675">Y</enum><enum count="623">N</enum></stats></total></variable><variable id="phv00294718.v2.p1.c1" var_name="AFUcomp8b_K" calculated_type="string" reported_type=""><description>D. Stroke/TIA. HOSPITALIZED FOR STROKE, TIA Q8B IN AFUK; Q22B IN AFUL-M; Q49 IN AFU V1-V3; Q17 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version K]</description><total><subject_profile><sex><male>420</male><female>549</female></sex></subject_profile><stats><stat n="1298" nulls="311141"/><enum count="675">Y</enum><enum count="623">N</enum></stats></total></variable><variable id="phv00294718.v2.p1.c2" var_name="AFUcomp8b_K" calculated_type="string" reported_type=""><description>D. Stroke/TIA. HOSPITALIZED FOR STROKE, TIA Q8B IN AFUK; Q22B IN AFUL-M; Q49 IN AFU V1-V3; Q17 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version K]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294719.v2.p1" var_name="AFUcomp7b_L" calculated_type="string" reported_type=""><description>C. General Health. REPORTED HF DIAGNOSIS WITHOUT DOCUMENTED HF HOSPITALIZATION?  Q7B IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4169</male><female>5705</female></sex></subject_profile><stats><stat n="10278" nulls="302548"/><enum count="9376">N</enum><enum count="902">Y</enum></stats></total></variable><variable id="phv00294719.v2.p1.c1" var_name="AFUcomp7b_L" calculated_type="string" reported_type=""><description>C. General Health. REPORTED HF DIAGNOSIS WITHOUT DOCUMENTED HF HOSPITALIZATION?  Q7B IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4162</male><female>5697</female></sex></subject_profile><stats><stat n="10263" nulls="302176"/><enum count="9362">N</enum><enum count="901">Y</enum></stats></total></variable><variable id="phv00294719.v2.p1.c2" var_name="AFUcomp7b_L" calculated_type="string" reported_type=""><description>C. General Health. REPORTED HF DIAGNOSIS WITHOUT DOCUMENTED HF HOSPITALIZATION?  Q7B IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="15" nulls="372"/><enum count="14">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294720.v2.p1" var_name="AFUcomp8d_L" calculated_type="string" reported_type=""><description>C. General Health. WITHIN 3 YRS OF TODAY'S DATE (LAST SAW DOCTOR FOR HF)? Q8D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>269</male><female>255</female></sex></subject_profile><stats><stat n="528" nulls="312298"/><enum count="400">Y</enum><enum count="123">N</enum><enum count="5">U</enum></stats></total></variable><variable id="phv00294720.v2.p1.c1" var_name="AFUcomp8d_L" calculated_type="string" reported_type=""><description>C. General Health. WITHIN 3 YRS OF TODAY'S DATE (LAST SAW DOCTOR FOR HF)? Q8D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>268</male><female>255</female></sex></subject_profile><stats><stat n="527" nulls="311912"/><enum count="399">Y</enum><enum count="123">N</enum><enum count="5">U</enum></stats></total></variable><variable id="phv00294720.v2.p1.c2" var_name="AFUcomp8d_L" calculated_type="string" reported_type=""><description>C. General Health. WITHIN 3 YRS OF TODAY'S DATE (LAST SAW DOCTOR FOR HF)? Q8D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">Y</enum></stats></total></variable><variable id="phv00294721.v2.p1" var_name="AFUcomp8f_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE? (LAST SAW DOCTOR FOR HF) Q8F IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>270</male><female>256</female></sex></subject_profile><stats><stat n="530" nulls="312296"/><enum count="292">N</enum><enum count="216">Y</enum><enum count="22">U</enum></stats></total></variable><variable id="phv00294721.v2.p1.c1" var_name="AFUcomp8f_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE? (LAST SAW DOCTOR FOR HF) Q8F IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>269</male><female>256</female></sex></subject_profile><stats><stat n="529" nulls="311910"/><enum count="291">N</enum><enum count="216">Y</enum><enum count="22">U</enum></stats></total></variable><variable id="phv00294721.v2.p1.c2" var_name="AFUcomp8f_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE? (LAST SAW DOCTOR FOR HF) Q8F IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294722.v2.p1" var_name="AFUcomp8g_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE AT ANOTHER TIME? Q8G IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>270</male><female>256</female></sex></subject_profile><stats><stat n="530" nulls="312296"/><enum count="394">N</enum><enum count="119">Y</enum><enum count="17">U</enum></stats></total></variable><variable id="phv00294722.v2.p1.c1" var_name="AFUcomp8g_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE AT ANOTHER TIME? Q8G IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>269</male><female>256</female></sex></subject_profile><stats><stat n="529" nulls="311910"/><enum count="393">N</enum><enum count="119">Y</enum><enum count="17">U</enum></stats></total></variable><variable id="phv00294722.v2.p1.c2" var_name="AFUcomp8g_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE AT ANOTHER TIME? Q8G IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294723.v2.p1" var_name="AFUcomp9d_L" calculated_type="string" reported_type=""><description>C. General Health. WAS THIS WITHIN 3 YRS OF TODAY'S DATE (DOCTOR-HF SINCE LAST CONTACT)? Q9D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>168</male><female>230</female></sex></subject_profile><stats><stat n="487" nulls="312339"/><enum count="470">Y</enum><enum count="11">N</enum><enum count="6">U</enum></stats></total></variable><variable id="phv00294723.v2.p1.c1" var_name="AFUcomp9d_L" calculated_type="string" reported_type=""><description>C. General Health. WAS THIS WITHIN 3 YRS OF TODAY'S DATE (DOCTOR-HF SINCE LAST CONTACT)? Q9D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>168</male><female>230</female></sex></subject_profile><stats><stat n="487" nulls="311952"/><enum count="470">Y</enum><enum count="11">N</enum><enum count="6">U</enum></stats></total></variable><variable id="phv00294723.v2.p1.c2" var_name="AFUcomp9d_L" calculated_type="string" reported_type=""><description>C. General Health. WAS THIS WITHIN 3 YRS OF TODAY'S DATE (DOCTOR-HF SINCE LAST CONTACT)? Q9D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294724.v2.p1" var_name="AFUcomp9e_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE AT THAT TIME? (DOCTOR-HF SINCE LAST CONTACT) Q9E IN AFUL-M; Q33 IN V1; Q8 IN SAF V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>209</male><female>301</female></sex></subject_profile><stats><stat n="617" nulls="312209"/><enum count="364">Y</enum><enum count="247">N</enum><enum count="6">U</enum></stats></total></variable><variable id="phv00294724.v2.p1.c1" var_name="AFUcomp9e_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE AT THAT TIME? (DOCTOR-HF SINCE LAST CONTACT) Q9E IN AFUL-M; Q33 IN V1; Q8 IN SAF V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>208</male><female>301</female></sex></subject_profile><stats><stat n="616" nulls="311823"/><enum count="364">Y</enum><enum count="246">N</enum><enum count="6">U</enum></stats></total></variable><variable id="phv00294724.v2.p1.c2" var_name="AFUcomp9e_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR HEART FAILURE AT THAT TIME? (DOCTOR-HF SINCE LAST CONTACT) Q9E IN AFUL-M; Q33 IN V1; Q8 IN SAF V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294725.v2.p1" var_name="AFUcomp10d_L" calculated_type="string" reported_type=""><description>C. General Health. WITHIN 3 YRS OF TODAY'S DATE (DOCTOR-HEART IS WEAK)? Q10D IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>252</male><female>226</female></sex></subject_profile><stats><stat n="525" nulls="312301"/><enum count="374">Y</enum><enum count="133">N</enum><enum count="18">U</enum></stats></total></variable><variable id="phv00294725.v2.p1.c1" var_name="AFUcomp10d_L" calculated_type="string" reported_type=""><description>C. General Health. WITHIN 3 YRS OF TODAY'S DATE (DOCTOR-HEART IS WEAK)? Q10D IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>252</male><female>226</female></sex></subject_profile><stats><stat n="525" nulls="311914"/><enum count="374">Y</enum><enum count="133">N</enum><enum count="18">U</enum></stats></total></variable><variable id="phv00294725.v2.p1.c2" var_name="AFUcomp10d_L" calculated_type="string" reported_type=""><description>C. General Health. WITHIN 3 YRS OF TODAY'S DATE (DOCTOR-HEART IS WEAK)? Q10D IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294726.v2.p1" var_name="AFUcomp10e_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR WEAK HEART MUSCLE? Q10E IN AFUL-M; Q33 IN AFU V1; Q8 IN SAF V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>448</male><female>402</female></sex></subject_profile><stats><stat n="1061" nulls="311765"/><enum count="615">N</enum><enum count="432">Y</enum><enum count="14">U</enum></stats></total></variable><variable id="phv00294726.v2.p1.c1" var_name="AFUcomp10e_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR WEAK HEART MUSCLE? Q10E IN AFUL-M; Q33 IN AFU V1; Q8 IN SAF V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>447</male><female>402</female></sex></subject_profile><stats><stat n="1060" nulls="311379"/><enum count="615">N</enum><enum count="431">Y</enum><enum count="14">U</enum></stats></total></variable><variable id="phv00294726.v2.p1.c2" var_name="AFUcomp10e_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR WEAK HEART MUSCLE? Q10E IN AFUL-M; Q33 IN AFU V1; Q8 IN SAF V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">Y</enum></stats></total></variable><variable id="phv00294727.v2.p1" var_name="AFUcomp11b_L" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-ANGINA Q11B IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4187</male><female>5719</female></sex></subject_profile><stats><stat n="13040" nulls="299786"/><enum count="12170">N</enum><enum count="809">Y</enum><enum count="61">U</enum></stats></total></variable><variable id="phv00294727.v2.p1.c1" var_name="AFUcomp11b_L" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-ANGINA Q11B IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4180</male><female>5711</female></sex></subject_profile><stats><stat n="13022" nulls="299417"/><enum count="12153">N</enum><enum count="808">Y</enum><enum count="61">U</enum></stats></total></variable><variable id="phv00294727.v2.p1.c2" var_name="AFUcomp11b_L" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-ANGINA Q11B IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="18" nulls="369"/><enum count="17">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294728.v2.p1" var_name="AFUcomp11c_L" calculated_type="string" reported_type=""><description>C. General Health. FIRST TOLD ANGINA SINCE LAST CONTACT? Q11C IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>383</male><female>316</female></sex></subject_profile><stats><stat n="806" nulls="312020"/><enum count="693">N</enum><enum count="105">Y</enum><enum count="8">U</enum></stats></total></variable><variable id="phv00294728.v2.p1.c1" var_name="AFUcomp11c_L" calculated_type="string" reported_type=""><description>C. General Health. FIRST TOLD ANGINA SINCE LAST CONTACT? Q11C IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>382</male><female>316</female></sex></subject_profile><stats><stat n="805" nulls="311634"/><enum count="692">N</enum><enum count="105">Y</enum><enum count="8">U</enum></stats></total></variable><variable id="phv00294728.v2.p1.c2" var_name="AFUcomp11c_L" calculated_type="string" reported_type=""><description>C. General Health. FIRST TOLD ANGINA SINCE LAST CONTACT? Q11C IN AFUL [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1</male></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294729.v2.p1" var_name="AFUcomp13a_L" calculated_type="string" reported_type=""><description>C. General Health. SWELLING IN YOUR FEET OR ANKLES AT THE END OF THE DAY? Q13A IN AFUL-M; Q27 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4270</male><female>5835</female></sex></subject_profile><stats><stat n="54084" nulls="258742"/><enum count="44034">N</enum><enum count="10008">Y</enum><enum count="42">U</enum></stats></total></variable><variable id="phv00294729.v2.p1.c1" var_name="AFUcomp13a_L" calculated_type="string" reported_type=""><description>C. General Health. SWELLING IN YOUR FEET OR ANKLES AT THE END OF THE DAY? Q13A IN AFUL-M; Q27 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4263</male><female>5827</female></sex></subject_profile><stats><stat n="53991" nulls="258448"/><enum count="43959">N</enum><enum count="9990">Y</enum><enum count="42">U</enum></stats></total></variable><variable id="phv00294729.v2.p1.c2" var_name="AFUcomp13a_L" calculated_type="string" reported_type=""><description>C. General Health. SWELLING IN YOUR FEET OR ANKLES AT THE END OF THE DAY? Q13A IN AFUL-M; Q27 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="93" nulls="294"/><enum count="75">N</enum><enum count="18">Y</enum></stats></total></variable><variable id="phv00294730.v2.p1" var_name="AFUcomp13b_L" calculated_type="string" reported_type=""><description>C. General Health. SWELLING IN YOUR FEET OR ANKLES GONE IN THE MORNING? Q13B IN AFUL-M; Q27A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1325</male><female>2583</female></sex></subject_profile><stats><stat n="10004" nulls="302822"/><enum count="7568">Y</enum><enum count="2369">N</enum><enum count="67">U</enum></stats></total></variable><variable id="phv00294730.v2.p1.c1" var_name="AFUcomp13b_L" calculated_type="string" reported_type=""><description>C. General Health. SWELLING IN YOUR FEET OR ANKLES GONE IN THE MORNING? Q13B IN AFUL-M; Q27A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1323</male><female>2579</female></sex></subject_profile><stats><stat n="9986" nulls="302453"/><enum count="7555">Y</enum><enum count="2365">N</enum><enum count="66">U</enum></stats></total></variable><variable id="phv00294730.v2.p1.c2" var_name="AFUcomp13b_L" calculated_type="string" reported_type=""><description>C. General Health. SWELLING IN YOUR FEET OR ANKLES GONE IN THE MORNING? Q13B IN AFUL-M; Q27A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>4</female></sex></subject_profile><stats><stat n="18" nulls="369"/><enum count="13">Y</enum><enum count="4">N</enum><enum count="1">U</enum></stats></total></variable><variable id="phv00294731.v2.p1" var_name="AFUcomp16d_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR BLOOD CLOT IN A LEG? Q16D IN AFUL-M; Q43 IN AFU V1-V3; Q14B IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>231</male><female>364</female></sex></subject_profile><stats><stat n="729" nulls="312097"/><enum count="424">Y</enum><enum count="297">N</enum><enum count="8">U</enum></stats></total></variable><variable id="phv00294731.v2.p1.c1" var_name="AFUcomp16d_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR BLOOD CLOT IN A LEG? Q16D IN AFUL-M; Q43 IN AFU V1-V3; Q14B IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>231</male><female>363</female></sex></subject_profile><stats><stat n="728" nulls="311711"/><enum count="424">Y</enum><enum count="296">N</enum><enum count="8">U</enum></stats></total></variable><variable id="phv00294731.v2.p1.c2" var_name="AFUcomp16d_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR BLOOD CLOT IN A LEG? Q16D IN AFUL-M; Q43 IN AFU V1-V3; Q14B IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><female>1</female></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294732.v2.p1" var_name="AFUcomp17b_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR A BLOOD CLOT IN LUNGS Q17B IN AFUL-M; Q46 IN AFU V1-V3; Q15B IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>99</male><female>180</female></sex></subject_profile><stats><stat n="554" nulls="312272"/><enum count="325">Y</enum><enum count="224">N</enum><enum count="5">U</enum></stats></total></variable><variable id="phv00294732.v2.p1.c1" var_name="AFUcomp17b_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR A BLOOD CLOT IN LUNGS Q17B IN AFUL-M; Q46 IN AFU V1-V3; Q15B IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>99</male><female>180</female></sex></subject_profile><stats><stat n="554" nulls="311885"/><enum count="325">Y</enum><enum count="224">N</enum><enum count="5">U</enum></stats></total></variable><variable id="phv00294732.v2.p1.c2" var_name="AFUcomp17b_L" calculated_type="string" reported_type=""><description>C. General Health. HOSPITALIZED FOR A BLOOD CLOT IN LUNGS Q17B IN AFUL-M; Q46 IN AFU V1-V3; Q15B IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294733.v2.p1" var_name="AFUcomp19a_L" calculated_type="string" reported_type=""><description>C. General Health. DIFFICULTY BREATHING AT NIGHT Q19A IN AFUL-M; Q21A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4222</male><female>5774</female></sex></subject_profile><stats><stat n="51594" nulls="261232"/><enum count="49599">N</enum><enum count="1939">Y</enum><enum count="56">U</enum></stats></total></variable><variable id="phv00294733.v2.p1.c1" var_name="AFUcomp19a_L" calculated_type="string" reported_type=""><description>C. General Health. DIFFICULTY BREATHING AT NIGHT Q19A IN AFUL-M; Q21A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4215</male><female>5766</female></sex></subject_profile><stats><stat n="51502" nulls="260937"/><enum count="49509">N</enum><enum count="1937">Y</enum><enum count="56">U</enum></stats></total></variable><variable id="phv00294733.v2.p1.c2" var_name="AFUcomp19a_L" calculated_type="string" reported_type=""><description>C. General Health. DIFFICULTY BREATHING AT NIGHT Q19A IN AFUL-M; Q21A IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="92" nulls="295"/><enum count="90">N</enum><enum count="2">Y</enum></stats></total></variable><variable id="phv00294734.v2.p1" var_name="AFUcomp19b_L" calculated_type="string" reported_type=""><description>C. General Health. SHORTNESS OF BREATH WHEN HURRYING ON THE LEVEL Q19B IN AFUL-M; Q21B IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4222</male><female>5774</female></sex></subject_profile><stats><stat n="51581" nulls="261245"/><enum count="40919">N</enum><enum count="10109">Y</enum><enum count="453">D</enum><enum count="100">U</enum></stats></total></variable><variable id="phv00294734.v2.p1.c1" var_name="AFUcomp19b_L" calculated_type="string" reported_type=""><description>C. General Health. SHORTNESS OF BREATH WHEN HURRYING ON THE LEVEL Q19B IN AFUL-M; Q21B IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4215</male><female>5766</female></sex></subject_profile><stats><stat n="51489" nulls="260950"/><enum count="40837">N</enum><enum count="10099">Y</enum><enum count="453">D</enum><enum count="100">U</enum></stats></total></variable><variable id="phv00294734.v2.p1.c2" var_name="AFUcomp19b_L" calculated_type="string" reported_type=""><description>C. General Health. SHORTNESS OF BREATH WHEN HURRYING ON THE LEVEL Q19B IN AFUL-M; Q21B IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="92" nulls="295"/><enum count="82">N</enum><enum count="10">Y</enum></stats></total></variable><variable id="phv00294735.v2.p1" var_name="AFUcomp19c_L" calculated_type="string" reported_type=""><description>C. General Health. SHORTNESS OF BREATH WHEN WALKING AT ORDINARY PACE Q19C IN AFUL-M; Q21C IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1635</male><female>2526</female></sex></subject_profile><stats><stat n="10174" nulls="302652"/><enum count="6795">N</enum><enum count="3363">Y</enum><enum count="16">U</enum></stats></total></variable><variable id="phv00294735.v2.p1.c1" var_name="AFUcomp19c_L" calculated_type="string" reported_type=""><description>C. General Health. SHORTNESS OF BREATH WHEN WALKING AT ORDINARY PACE Q19C IN AFUL-M; Q21C IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1632</male><female>2524</female></sex></subject_profile><stats><stat n="10164" nulls="302275"/><enum count="6786">N</enum><enum count="3362">Y</enum><enum count="16">U</enum></stats></total></variable><variable id="phv00294735.v2.p1.c2" var_name="AFUcomp19c_L" calculated_type="string" reported_type=""><description>C. General Health. SHORTNESS OF BREATH WHEN WALKING AT ORDINARY PACE Q19C IN AFUL-M; Q21C IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3</male><female>2</female></sex></subject_profile><stats><stat n="10" nulls="377"/><enum count="9">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294736.v2.p1" var_name="AFUcomp19d_L" calculated_type="string" reported_type=""><description>C. General Health. STOP FOR BREATH WHEN WALKING AT YOUR OWN PACE Q19D IN AFUL-M; Q21D IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>686</male><female>1156</female></sex></subject_profile><stats><stat n="3443" nulls="309383"/><enum count="2520">Y</enum><enum count="919">N</enum><enum count="4">U</enum></stats></total></variable><variable id="phv00294736.v2.p1.c1" var_name="AFUcomp19d_L" calculated_type="string" reported_type=""><description>C. General Health. STOP FOR BREATH WHEN WALKING AT YOUR OWN PACE Q19D IN AFUL-M; Q21D IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>686</male><female>1155</female></sex></subject_profile><stats><stat n="3442" nulls="308997"/><enum count="2520">Y</enum><enum count="918">N</enum><enum count="4">U</enum></stats></total></variable><variable id="phv00294736.v2.p1.c2" var_name="AFUcomp19d_L" calculated_type="string" reported_type=""><description>C. General Health. STOP FOR BREATH WHEN WALKING AT YOUR OWN PACE Q19D IN AFUL-M; Q21D IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><female>1</female></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">N</enum></stats></total></variable><variable id="phv00294737.v2.p1" var_name="AFUcomp19e_L" calculated_type="string" reported_type=""><description>C. General Health. STOP FOR BREATH AFTER WALKING 100 YARDS ON THE LEVEL Q19E IN AFUL-M; Q21E IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>538</male><female>896</female></sex></subject_profile><stats><stat n="2575" nulls="310251"/><enum count="2050">Y</enum><enum count="514">N</enum><enum count="11">U</enum></stats></total></variable><variable id="phv00294737.v2.p1.c1" var_name="AFUcomp19e_L" calculated_type="string" reported_type=""><description>C. General Health. STOP FOR BREATH AFTER WALKING 100 YARDS ON THE LEVEL Q19E IN AFUL-M; Q21E IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>538</male><female>896</female></sex></subject_profile><stats><stat n="2575" nulls="309864"/><enum count="2050">Y</enum><enum count="514">N</enum><enum count="11">U</enum></stats></total></variable><variable id="phv00294737.v2.p1.c2" var_name="AFUcomp19e_L" calculated_type="string" reported_type=""><description>C. General Health. STOP FOR BREATH AFTER WALKING 100 YARDS ON THE LEVEL Q19E IN AFUL-M; Q21E IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294738.v2.p1" var_name="AFUcomp19f_L" calculated_type="string" reported_type=""><description>C. General Health. DIFFICULTY BREATHING WHEN NOT ACTIVE Q19F IN AFUL-M; Q22 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4076</male><female>5606</female></sex></subject_profile><stats><stat n="43443" nulls="269383"/><enum count="42672">N</enum><enum count="756">Y</enum><enum count="15">U</enum></stats></total></variable><variable id="phv00294738.v2.p1.c1" var_name="AFUcomp19f_L" calculated_type="string" reported_type=""><description>C. General Health. DIFFICULTY BREATHING WHEN NOT ACTIVE Q19F IN AFUL-M; Q22 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4069</male><female>5598</female></sex></subject_profile><stats><stat n="43361" nulls="269078"/><enum count="42590">N</enum><enum count="756">Y</enum><enum count="15">U</enum></stats></total></variable><variable id="phv00294738.v2.p1.c2" var_name="AFUcomp19f_L" calculated_type="string" reported_type=""><description>C. General Health. DIFFICULTY BREATHING WHEN NOT ACTIVE Q19F IN AFUL-M; Q22 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="82" nulls="305"/><enum count="82">N</enum></stats></total></variable><variable id="phv00294739.v2.p1" var_name="AFUcomp19g_L" calculated_type="string" reported_type=""><description>C. General Health. USUALLY COUGH OR WHEEZING Q19G IN AFUL-M; Q23 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4221</male><female>5774</female></sex></subject_profile><stats><stat n="51598" nulls="261228"/><enum count="44972">N</enum><enum count="6611">Y</enum><enum count="15">U</enum></stats></total></variable><variable id="phv00294739.v2.p1.c1" var_name="AFUcomp19g_L" calculated_type="string" reported_type=""><description>C. General Health. USUALLY COUGH OR WHEEZING Q19G IN AFUL-M; Q23 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4214</male><female>5766</female></sex></subject_profile><stats><stat n="51506" nulls="260933"/><enum count="44892">N</enum><enum count="6599">Y</enum><enum count="15">U</enum></stats></total></variable><variable id="phv00294739.v2.p1.c2" var_name="AFUcomp19g_L" calculated_type="string" reported_type=""><description>C. General Health. USUALLY COUGH OR WHEEZING Q19G IN AFUL-M; Q23 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="92" nulls="295"/><enum count="80">N</enum><enum count="12">Y</enum></stats></total></variable><variable id="phv00294740.v2.p1" var_name="AFUcomp20b_L" calculated_type="string" reported_type=""><description>C. General Health. PAIN IN LEGS CAUSED BY BLOCKAGE OF ARTERIES Q20B IN AFUL-M; Q26 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4268</male><female>5836</female></sex></subject_profile><stats><stat n="54061" nulls="258765"/><enum count="53027">N</enum><enum count="753">Y</enum><enum count="281">U</enum></stats></total></variable><variable id="phv00294740.v2.p1.c1" var_name="AFUcomp20b_L" calculated_type="string" reported_type=""><description>C. General Health. PAIN IN LEGS CAUSED BY BLOCKAGE OF ARTERIES Q20B IN AFUL-M; Q26 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4261</male><female>5828</female></sex></subject_profile><stats><stat n="53968" nulls="258471"/><enum count="52938">N</enum><enum count="753">Y</enum><enum count="277">U</enum></stats></total></variable><variable id="phv00294740.v2.p1.c2" var_name="AFUcomp20b_L" calculated_type="string" reported_type=""><description>C. General Health. PAIN IN LEGS CAUSED BY BLOCKAGE OF ARTERIES Q20B IN AFUL-M; Q26 IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="93" nulls="294"/><enum count="89">N</enum><enum count="4">U</enum></stats></total></variable><variable id="phv00294741.v2.p1" var_name="AFUcomp25a_L" calculated_type="string" reported_type=""><description>E. Administration. OUTPATIENT TREATMENT SINCE LAST CONTACT Q25A IN AFUL-M; Q14 OR Q57 IN AFU V1-V3; Q25 IN SAF V1-V3; Q11 IN DEC V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4530</male><female>6114</female></sex></subject_profile><stats><stat n="71149" nulls="241677"/><enum count="57907">N</enum><enum count="12654">Y</enum><enum count="588">U</enum></stats></total></variable><variable id="phv00294741.v2.p1.c1" var_name="AFUcomp25a_L" calculated_type="string" reported_type=""><description>E. Administration. OUTPATIENT TREATMENT SINCE LAST CONTACT Q25A IN AFUL-M; Q14 OR Q57 IN AFU V1-V3; Q25 IN SAF V1-V3; Q11 IN DEC V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4523</male><female>6106</female></sex></subject_profile><stats><stat n="71029" nulls="241410"/><enum count="57799">N</enum><enum count="12642">Y</enum><enum count="588">U</enum></stats></total></variable><variable id="phv00294741.v2.p1.c2" var_name="AFUcomp25a_L" calculated_type="string" reported_type=""><description>E. Administration. OUTPATIENT TREATMENT SINCE LAST CONTACT Q25A IN AFUL-M; Q14 OR Q57 IN AFU V1-V3; Q25 IN SAF V1-V3; Q11 IN DEC V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="120" nulls="267"/><enum count="108">N</enum><enum count="12">Y</enum></stats></total></variable><variable id="phv00294742.v2.p1" var_name="AFUcomp25b_L" calculated_type="string" reported_type=""><description>E. Administration. OUTPATIENT TREATMENT FOR HEART OR BREATHING PROBLEM Q25B IN AFUL-M; Q15 OR Q58 IN AFU V1-V3; Q26 IN SAF V1-V3; Q12 IN DEC V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2724</male><female>3790</female></sex></subject_profile><stats><stat n="12621" nulls="300205"/><enum count="11054">N</enum><enum count="1534">Y</enum><enum count="33">U</enum></stats></total></variable><variable id="phv00294742.v2.p1.c1" var_name="AFUcomp25b_L" calculated_type="string" reported_type=""><description>E. Administration. OUTPATIENT TREATMENT FOR HEART OR BREATHING PROBLEM Q25B IN AFUL-M; Q15 OR Q58 IN AFU V1-V3; Q26 IN SAF V1-V3; Q12 IN DEC V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2721</male><female>3786</female></sex></subject_profile><stats><stat n="12609" nulls="299830"/><enum count="11044">N</enum><enum count="1532">Y</enum><enum count="33">U</enum></stats></total></variable><variable id="phv00294742.v2.p1.c2" var_name="AFUcomp25b_L" calculated_type="string" reported_type=""><description>E. Administration. OUTPATIENT TREATMENT FOR HEART OR BREATHING PROBLEM Q25B IN AFUL-M; Q15 OR Q58 IN AFU V1-V3; Q26 IN SAF V1-V3; Q12 IN DEC V1 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3</male><female>4</female></sex></subject_profile><stats><stat n="12" nulls="375"/><enum count="10">N</enum><enum count="2">Y</enum></stats></total></variable><variable id="phv00294743.v2.p1" var_name="AFUcomp_hosp_reason12" calculated_type="string" reported_type=""><description>HOSPITALIZATION REASON Q42A-F IN AFUD,F; Q34A-F IN AFUE; Q37A-F IN AFUG-K; Q28A, 29A-39A IN AFUL-M; Q11A-13A OR Q52A-Q56A IN AFU V1-V3; Q20A-24A IN SAF V1-V3; Q8A-10A IN DEC V1</description><total><stats><stat n="0" nulls="312826"/></stats></total></variable><variable id="phv00294743.v2.p1.c1" var_name="AFUcomp_hosp_reason12" calculated_type="string" reported_type=""><description>HOSPITALIZATION REASON Q42A-F IN AFUD,F; Q34A-F IN AFUE; Q37A-F IN AFUG-K; Q28A, 29A-39A IN AFUL-M; Q11A-13A OR Q52A-Q56A IN AFU V1-V3; Q20A-24A IN SAF V1-V3; Q8A-10A IN DEC V1</description><total><stats><stat n="0" nulls="312439"/></stats></total></variable><variable id="phv00294743.v2.p1.c2" var_name="AFUcomp_hosp_reason12" calculated_type="string" reported_type=""><description>HOSPITALIZATION REASON Q42A-F IN AFUD,F; Q34A-F IN AFUE; Q37A-F IN AFUG-K; Q28A, 29A-39A IN AFUL-M; Q11A-13A OR Q52A-Q56A IN AFU V1-V3; Q20A-24A IN SAF V1-V3; Q8A-10A IN DEC V1</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294744.v2.p1" var_name="AFUcomp46d_L" calculated_type="string" reported_type=""><description>H. Interview. MEDS FOR HEART FAILURE Q46D IN AFUL-M; Q65D IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4291</male><female>5860</female></sex></subject_profile><stats><stat n="54993" nulls="257833"/><enum count="52446">N</enum><enum count="2092">Y</enum><enum count="455">U</enum></stats></total></variable><variable id="phv00294744.v2.p1.c1" var_name="AFUcomp46d_L" calculated_type="string" reported_type=""><description>H. Interview. MEDS FOR HEART FAILURE Q46D IN AFUL-M; Q65D IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4284</male><female>5852</female></sex></subject_profile><stats><stat n="54900" nulls="257539"/><enum count="52353">N</enum><enum count="2092">Y</enum><enum count="455">U</enum></stats></total></variable><variable id="phv00294744.v2.p1.c2" var_name="AFUcomp46d_L" calculated_type="string" reported_type=""><description>H. Interview. MEDS FOR HEART FAILURE Q46D IN AFUL-M; Q65D IN AFU V1-V3 [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="93" nulls="294"/><enum count="93">N</enum></stats></total></variable><variable id="phv00294745.v2.p1" var_name="AFUcomp47_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATIONS TO REPORT Q47 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4252</male><female>5815</female></sex></subject_profile><stats><stat n="40116" nulls="272710"/><enum count="35578">Y</enum><enum count="3622">N</enum><enum count="554">R</enum><enum count="362">U</enum></stats></total></variable><variable id="phv00294745.v2.p1.c1" var_name="AFUcomp47_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATIONS TO REPORT Q47 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4245</male><female>5807</female></sex></subject_profile><stats><stat n="40051" nulls="272388"/><enum count="35522">Y</enum><enum count="3613">N</enum><enum count="554">R</enum><enum count="362">U</enum></stats></total></variable><variable id="phv00294745.v2.p1.c2" var_name="AFUcomp47_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATIONS TO REPORT Q47 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="65" nulls="322"/><enum count="56">Y</enum><enum count="9">N</enum></stats></total></variable><variable id="phv00294746.v2.p1" var_name="AFUcomp48a_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48A IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4011</male><female>5569</female></sex></subject_profile><stats><stat n="35659" nulls="277167" mean_count="17.4" sd="89.72" median_count="2" min_count="1" max_count="1980" distinct_vals="2049"/><example count="1980">LIPITOR</example><example count="1583">LISINOPRIL</example><example count="1466">ASPIRIN</example><example count="1380">ATENOLOL</example><example count="934">SIMVASTATIN</example><example count="879">HYDROCHLOROTHIAZIDE</example><example count="765">METFORMIN HCL</example><example count="595">SYNTHROID</example><example count="525">DIOVAN</example><example count="507">TOPROL XL</example></stats></total></variable><variable id="phv00294746.v2.p1.c1" var_name="AFUcomp48a_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48A IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4004</male><female>5562</female></sex></subject_profile><stats><stat n="35603" nulls="276836" mean_count="17.43" sd="89.76" median_count="2" min_count="1" max_count="1980" distinct_vals="2043"/><example count="1980">LIPITOR</example><example count="1580">LISINOPRIL</example><example count="1465">ASPIRIN</example><example count="1380">ATENOLOL</example><example count="933">SIMVASTATIN</example><example count="878">HYDROCHLOROTHIAZIDE</example><example count="765">METFORMIN HCL</example><example count="592">SYNTHROID</example><example count="523">DIOVAN</example><example count="506">TOPROL XL</example></stats></total></variable><variable id="phv00294746.v2.p1.c2" var_name="AFUcomp48a_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48A IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="56" nulls="331"/><example count="4">VERAPAMIL HCL</example><example count="3">SYNTHROID</example><example count="3">LISINOPRIL</example><example count="3">PREMARIN</example><example count="3">PROPECIA</example><example count="2">CRESTOR</example><example count="2">LEVOTHYROXINE SODIUM</example><example count="2">AMLODIPINE BESYLATE</example><example count="2">WARFARIN SODIUM</example><example count="2">PRILOSEC</example></stats></total></variable><variable id="phv00294747.v2.p1" var_name="AFUcomp48a1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48A1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4011</male><female>5568</female></sex></subject_profile><stats><stat n="35654" nulls="277172" mean="4.5E+05" sd="170000" median="3.8E+05" min="11000" max="1.0E+06"/><example count="4581">394000</example><example count="2952">641000</example><example count="2856">332000</example><example count="2299">361000</example><example count="1773">340000</example><example count="1338">361500</example><example count="1314">281000</example><example count="1061">492700</example><example count="1057">376000</example><example count="1004">272500</example></stats></total></variable><variable id="phv00294747.v2.p1.c1" var_name="AFUcomp48a1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48A1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>4004</male><female>5561</female></sex></subject_profile><stats><stat n="35598" nulls="276841" mean="4.5E+05" sd="170000" median="3.8E+05" min="11000" max="1.0E+06"/><example count="4577">394000</example><example count="2949">641000</example><example count="2854">332000</example><example count="2294">361000</example><example count="1766">340000</example><example count="1336">361500</example><example count="1308">281000</example><example count="1059">492700</example><example count="1056">376000</example><example count="1004">272500</example></stats></total></variable><variable id="phv00294747.v2.p1.c2" var_name="AFUcomp48a1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48A1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="56" nulls="331" mean="4.6E+05" sd="210000" median="3.7E+05" min="31000" max="9.7E+05"/><example count="7">340000</example><example count="6">281000</example><example count="5">361000</example><example count="4">394000</example><example count="3">568510</example><example count="3">907360</example><example count="3">240000</example><example count="3">641000</example><example count="2">832000</example><example count="2">492700</example></stats></total></variable><variable id="phv00294748.v2.p1" var_name="AFUcomp48b_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48B IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3823</male><female>5339</female></sex></subject_profile><stats><stat n="32766" nulls="280060" mean_count="15.66" sd="71.35" median_count="2" min_count="1" max_count="1593" distinct_vals="2092"/><example count="1593">LISINOPRIL</example><example count="1218">LIPITOR</example><example count="1052">HYDROCHLOROTHIAZIDE</example><example count="911">ATENOLOL</example><example count="860">SIMVASTATIN</example><example count="748">ASPIRIN</example><example count="560">AMLODIPINE BESYLATE</example><example count="546">METFORMIN HCL</example><example count="475">LEVOTHYROXINE SODIUM</example><example count="447">TOPROL XL</example></stats></total></variable><variable id="phv00294748.v2.p1.c1" var_name="AFUcomp48b_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48B IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3816</male><female>5332</female></sex></subject_profile><stats><stat n="32716" nulls="279723" mean_count="15.65" sd="71.25" median_count="2" min_count="1" max_count="1590" distinct_vals="2091"/><example count="1590">LISINOPRIL</example><example count="1214">LIPITOR</example><example count="1049">HYDROCHLOROTHIAZIDE</example><example count="911">ATENOLOL</example><example count="860">SIMVASTATIN</example><example count="747">ASPIRIN</example><example count="560">AMLODIPINE BESYLATE</example><example count="546">METFORMIN HCL</example><example count="475">LEVOTHYROXINE SODIUM</example><example count="446">TOPROL XL</example></stats></total></variable><variable id="phv00294748.v2.p1.c2" var_name="AFUcomp48b_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48B IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="50" nulls="337"/><example count="4">LIPITOR</example><example count="3">LISINOPRIL</example><example count="3">METOPROLOL SUCCINATE ER</example><example count="3">HYDROCHLOROTHIAZIDE</example><example count="3">BISOPROLOL &amp; HYDROCHLOROTHIAZIDE TAB 10 6.25 MG</example><example count="2">PLAVIX</example><example count="2">PREMARIN</example><example count="2">PROTONIX</example><example count="2">FEXOFENADINE HCL</example><example count="1">PANTOPRAZOLE SODIUM EC TAB 20 MG (BASE EQUIV)</example></stats></total></variable><variable id="phv00294749.v2.p1" var_name="AFUcomp48b1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48B1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3823</male><female>5339</female></sex></subject_profile><stats><stat n="32763" nulls="280062" mean="4.5E+05" sd="180000" median="3.8E+05" min="11000" max="1.0E+06"/><example count="3381">394000</example><example count="2343">361000</example><example count="2335">332000</example><example count="1749">340000</example><example count="1643">641000</example><example count="1287">376000</example><example count="1167">281000</example><example count="1091">492700</example><example count="986">361500</example><example count="722">272500</example></stats></total></variable><variable id="phv00294749.v2.p1.c1" var_name="AFUcomp48b1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48B1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3816</male><female>5332</female></sex></subject_profile><stats><stat n="32713" nulls="279725" mean="4.5E+05" sd="180000" median="3.8E+05" min="11000" max="1.0E+06"/><example count="3375">394000</example><example count="2340">361000</example><example count="2330">332000</example><example count="1748">340000</example><example count="1639">641000</example><example count="1283">376000</example><example count="1167">281000</example><example count="1087">492700</example><example count="986">361500</example><example count="722">272500</example></stats></total></variable><variable id="phv00294749.v2.p1.c2" var_name="AFUcomp48b1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48B1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="50" nulls="337" mean="4.6E+05" sd="170000" median="3.9E+05" min="1.6E+05" max="9.1E+05"/><example count="6">394000</example><example count="5">332000</example><example count="4">376000</example><example count="4">492700</example><example count="4">641000</example><example count="4">415500</example><example count="3">361000</example><example count="3">369920</example><example count="2">240000</example><example count="2">851580</example></stats></total></variable><variable id="phv00294750.v2.p1" var_name="AFUcomp48c_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48C IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3532</male><female>4993</female></sex></subject_profile><stats><stat n="28689" nulls="284137" mean_count="13.91" sd="58.06" median_count="2" min_count="1" max_count="1160" distinct_vals="2063"/><example count="1160">LISINOPRIL</example><example count="920">LIPITOR</example><example count="857">HYDROCHLOROTHIAZIDE</example><example count="842">ASPIRIN</example><example count="719">SIMVASTATIN</example><example count="570">ATENOLOL</example><example count="444">AMLODIPINE BESYLATE</example><example count="420">FUROSEMIDE</example><example count="407">METFORMIN HCL</example><example count="378">OMEPRAZOLE</example></stats></total></variable><variable id="phv00294750.v2.p1.c1" var_name="AFUcomp48c_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48C IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3526</male><female>4988</female></sex></subject_profile><stats><stat n="28644" nulls="283795" mean_count="13.9" sd="58" median_count="2" min_count="1" max_count="1156" distinct_vals="2060"/><example count="1156">LISINOPRIL</example><example count="919">LIPITOR</example><example count="855">HYDROCHLOROTHIAZIDE</example><example count="842">ASPIRIN</example><example count="719">SIMVASTATIN</example><example count="570">ATENOLOL</example><example count="442">AMLODIPINE BESYLATE</example><example count="419">FUROSEMIDE</example><example count="407">METFORMIN HCL</example><example count="378">OMEPRAZOLE</example></stats></total></variable><variable id="phv00294750.v2.p1.c2" var_name="AFUcomp48c_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48C IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>6</male><female>5</female></sex></subject_profile><stats><stat n="45" nulls="342"/><example count="4">LISINOPRIL</example><example count="2">CRESTOR</example><example count="2">LEVOTHYROXINE SODIUM</example><example count="2">AMLODIPINE BESYLATE</example><example count="2">HYDROCHLOROTHIAZIDE</example><example count="2">CARAFATE</example><example count="2">FLOMAX</example><example count="1">SYNTHROID</example><example count="1">XALATAN</example><example count="1">LIPITOR</example></stats></total></variable><variable id="phv00294751.v2.p1" var_name="AFUcomp48c1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48C1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3532</male><female>4993</female></sex></subject_profile><stats><stat n="28682" nulls="284142" mean="4.8E+05" sd="190000" median="3.9E+05" min="11000" max="1.0E+06"/><example count="2703">394000</example><example count="1823">641000</example><example count="1721">361000</example><example count="1637">332000</example><example count="1316">340000</example><example count="1092">492700</example><example count="1034">376000</example><example count="911">281000</example><example count="738">361500</example><example count="593">372000</example></stats></total></variable><variable id="phv00294751.v2.p1.c1" var_name="AFUcomp48c1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48C1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3526</male><female>4988</female></sex></subject_profile><stats><stat n="28637" nulls="283800" mean="4.8E+05" sd="190000" median="3.9E+05" min="11000" max="1.0E+06"/><example count="2698">394000</example><example count="1821">641000</example><example count="1717">361000</example><example count="1635">332000</example><example count="1314">340000</example><example count="1091">492700</example><example count="1030">376000</example><example count="908">281000</example><example count="738">361500</example><example count="592">372000</example></stats></total></variable><variable id="phv00294751.v2.p1.c2" var_name="AFUcomp48c1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48C1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>6</male><female>5</female></sex></subject_profile><stats><stat n="45" nulls="342" mean="4.6E+05" sd="180000" median="3.8E+05" min="2.1E+05" max="9.0E+05"/><example count="5">394000</example><example count="4">361000</example><example count="4">376000</example><example count="3">493000</example><example count="3">281000</example><example count="2">568520</example><example count="2">332000</example><example count="2">369920</example><example count="2">641000</example><example count="2">340000</example></stats></total></variable><variable id="phv00294752.v2.p1" var_name="AFUcomp48d_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3139</male><female>4532</female></sex></subject_profile><stats><stat n="24124" nulls="288702" mean_count="12.06" sd="45.58" median_count="2" min_count="1" max_count="851" distinct_vals="2000"/><example count="851">ASPIRIN</example><example count="706">LISINOPRIL</example><example count="638">LIPITOR</example><example count="615">HYDROCHLOROTHIAZIDE</example><example count="539">SIMVASTATIN</example><example count="385">ATENOLOL</example><example count="383">FUROSEMIDE</example><example count="358">OMEPRAZOLE</example><example count="332">AMLODIPINE BESYLATE</example><example count="301">METFORMIN HCL</example></stats></total></variable><variable id="phv00294752.v2.p1.c1" var_name="AFUcomp48d_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3133</male><female>4528</female></sex></subject_profile><stats><stat n="24084" nulls="288355" mean_count="12.07" sd="45.59" median_count="2" min_count="1" max_count="851" distinct_vals="1996"/><example count="851">ASPIRIN</example><example count="706">LISINOPRIL</example><example count="638">LIPITOR</example><example count="615">HYDROCHLOROTHIAZIDE</example><example count="539">SIMVASTATIN</example><example count="385">ATENOLOL</example><example count="383">FUROSEMIDE</example><example count="358">OMEPRAZOLE</example><example count="332">AMLODIPINE BESYLATE</example><example count="299">METFORMIN HCL</example></stats></total></variable><variable id="phv00294752.v2.p1.c2" var_name="AFUcomp48d_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48D IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>6</male><female>4</female></sex></subject_profile><stats><stat n="40" nulls="347"/><example count="3">WARFARIN SODIUM</example><example count="2">SYNTHROID</example><example count="2">AVODART</example><example count="2">ASPIRIN LOW DOSE</example><example count="2">BUTISOL SODIUM</example><example count="2">METFORMIN HCL</example><example count="2">DOXYCYCLINE HYCLATE</example><example count="2">FEXOFENADINE HCL</example><example count="1">FLUTICASONE FUROATE NASAL SUSP 27.5 MCG/SPRAY</example><example count="1">XALATAN</example></stats></total></variable><variable id="phv00294753.v2.p1" var_name="AFUcomp48d1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48D1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3138</male><female>4530</female></sex></subject_profile><stats><stat n="24118" nulls="288706" mean="5.0E+05" sd="200000" median="3.9E+05" min="11000" max="1.0E+06"/><example count="2006">394000</example><example count="1871">641000</example><example count="1195">332000</example><example count="1082">361000</example><example count="1008">492700</example><example count="982">340000</example><example count="747">376000</example><example count="644">281000</example><example count="577">372000</example><example count="519">361500</example></stats></total></variable><variable id="phv00294753.v2.p1.c1" var_name="AFUcomp48d1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48D1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3132</male><female>4526</female></sex></subject_profile><stats><stat n="24078" nulls="288359" mean="5.0E+05" sd="200000" median="3.9E+05" min="11000" max="1.0E+06"/><example count="2005">394000</example><example count="1868">641000</example><example count="1194">332000</example><example count="1081">361000</example><example count="1006">492700</example><example count="982">340000</example><example count="747">376000</example><example count="642">281000</example><example count="577">372000</example><example count="518">361500</example></stats></total></variable><variable id="phv00294753.v2.p1.c2" var_name="AFUcomp48d1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48D1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>6</male><female>4</female></sex></subject_profile><stats><stat n="40" nulls="347" mean="5.2E+05" sd="220000" median="5.3E+05" min="40000" max="8.6E+05"/><example count="3">832000</example><example count="3">641000</example><example count="2">422000</example><example count="2">568510</example><example count="2">601000</example><example count="2">721000</example><example count="2">862500</example><example count="2">492700</example><example count="2">40000</example><example count="2">281000</example></stats></total></variable><variable id="phv00294754.v2.p1" var_name="AFUcomp48e_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48E IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2681</male><female>3958</female></sex></subject_profile><stats><stat n="19378" nulls="293448" mean_count="10.12" sd="36.09" median_count="2" min_count="1" max_count="750" distinct_vals="1914"/><example count="750">ASPIRIN</example><example count="468">LISINOPRIL</example><example count="462">LIPITOR</example><example count="407">SIMVASTATIN</example><example count="393">HYDROCHLOROTHIAZIDE</example><example count="326">FUROSEMIDE</example><example count="267">FISH OIL</example><example count="260">OMEPRAZOLE</example><example count="239">AMLODIPINE BESYLATE</example><example count="239">METFORMIN HCL</example></stats></total></variable><variable id="phv00294754.v2.p1.c1" var_name="AFUcomp48e_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48E IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2675</male><female>3954</female></sex></subject_profile><stats><stat n="19344" nulls="293095" mean_count="10.12" sd="36.04" median_count="2" min_count="1" max_count="748" distinct_vals="1912"/><example count="748">ASPIRIN</example><example count="468">LISINOPRIL</example><example count="462">LIPITOR</example><example count="407">SIMVASTATIN</example><example count="393">HYDROCHLOROTHIAZIDE</example><example count="326">FUROSEMIDE</example><example count="264">FISH OIL</example><example count="260">OMEPRAZOLE</example><example count="238">AMLODIPINE BESYLATE</example><example count="238">METFORMIN HCL</example></stats></total></variable><variable id="phv00294754.v2.p1.c2" var_name="AFUcomp48e_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48E IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>6</male><female>4</female></sex></subject_profile><stats><stat n="34" nulls="353"/><example count="3">FISH OIL</example><example count="2">XALATAN</example><example count="2">BUTISOL SODIUM</example><example count="2">ASPIRIN</example><example count="2">ATENOLOL</example><example count="2">FLOMAX</example><example count="1">FLUTICASONE FUROATE NASAL SUSP 27.5 MCG/SPRAY</example><example count="1">AVODART</example><example count="1">ASPIRIN LOW DOSE</example><example count="1">FLAX SEED OIL</example></stats></total></variable><variable id="phv00294755.v2.p1" var_name="AFUcomp48e1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48E1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2681</male><female>3958</female></sex></subject_profile><stats><stat n="19376" nulls="293450" mean="5.2E+05" sd="200000" median="4.6E+05" min="12000" max="1.0E+06"/><example count="1670">641000</example><example count="1496">394000</example><example count="784">492700</example><example count="782">332000</example><example count="707">361000</example><example count="605">340000</example><example count="482">376000</example><example count="452">372000</example><example count="434">281000</example><example count="365">361500</example></stats></total></variable><variable id="phv00294755.v2.p1.c1" var_name="AFUcomp48e1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48E1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2675</male><female>3954</female></sex></subject_profile><stats><stat n="19342" nulls="293097" mean="5.2E+05" sd="200000" median="4.6E+05" min="12000" max="1.0E+06"/><example count="1666">641000</example><example count="1496">394000</example><example count="783">492700</example><example count="780">332000</example><example count="707">361000</example><example count="604">340000</example><example count="481">376000</example><example count="452">372000</example><example count="434">281000</example><example count="365">361500</example></stats></total></variable><variable id="phv00294755.v2.p1.c2" var_name="AFUcomp48e1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48E1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>6</male><female>4</female></sex></subject_profile><stats><stat n="34" nulls="353" mean="6.2E+05" sd="200000" median="6.0E+05" min="3.3E+05" max="9.7E+05"/><example count="4">641000</example><example count="3">805000</example><example count="2">422000</example><example count="2">863300</example><example count="2">601000</example><example count="2">568520</example><example count="2">540000</example><example count="2">332000</example><example count="2">415500</example><example count="1">772020</example></stats></total></variable><variable id="phv00294756.v2.p1" var_name="AFUcomp48f_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48F IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2237</male><female>3345</female></sex></subject_profile><stats><stat n="15199" nulls="297627" mean_count="8.539" sd="27.94" median_count="2" min_count="1" max_count="649" distinct_vals="1780"/><example count="649">ASPIRIN</example><example count="283">LISINOPRIL</example><example count="257">LIPITOR</example><example count="252">FISH OIL</example><example count="251">SIMVASTATIN</example><example count="238">FUROSEMIDE</example><example count="224">HYDROCHLOROTHIAZIDE</example><example count="207">OMEPRAZOLE</example><example count="195">VITAMIN D</example><example count="178">CALCIUM</example></stats></total></variable><variable id="phv00294756.v2.p1.c1" var_name="AFUcomp48f_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48F IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2232</male><female>3341</female></sex></subject_profile><stats><stat n="15176" nulls="297263" mean_count="8.545" sd="27.92" median_count="2" min_count="1" max_count="648" distinct_vals="1776"/><example count="648">ASPIRIN</example><example count="283">LISINOPRIL</example><example count="257">LIPITOR</example><example count="251">SIMVASTATIN</example><example count="251">FISH OIL</example><example count="238">FUROSEMIDE</example><example count="222">HYDROCHLOROTHIAZIDE</example><example count="207">OMEPRAZOLE</example><example count="194">VITAMIN D</example><example count="178">CALCIUM</example></stats></total></variable><variable id="phv00294756.v2.p1.c2" var_name="AFUcomp48f_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48F IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>5</male><female>4</female></sex></subject_profile><stats><stat n="23" nulls="364"/><example count="2">VITAMIN B 12</example><example count="2">HYDROCHLOROTHIAZIDE</example><example count="2">FLOMAX</example><example count="1">ALPRAZOLAM</example><example count="1">NORPACE</example><example count="1">AMLODIPINE BESYLATE</example><example count="1">VITAMIN D</example><example count="1">NIACIN FLUSH FREE</example><example count="1">ASPIRIN</example><example count="1">OS CAL</example></stats></total></variable><variable id="phv00294757.v2.p1" var_name="AFUcomp48f1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48F1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2237</male><female>3345</female></sex></subject_profile><stats><stat n="15197" nulls="297628" mean="5.4E+05" sd="200000" median="4.9E+05" min="12000" max="1.0E+06"/><example count="1344">641000</example><example count="894">394000</example><example count="616">492700</example><example count="513">332000</example><example count="443">361000</example><example count="387">340000</example><example count="356">372000</example><example count="293">791099</example><example count="287">783100</example><example count="280">376000</example></stats></total></variable><variable id="phv00294757.v2.p1.c1" var_name="AFUcomp48f1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48F1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2232</male><female>3341</female></sex></subject_profile><stats><stat n="15174" nulls="297264" mean="5.4E+05" sd="200000" median="4.9E+05" min="12000" max="1.0E+06"/><example count="1341">641000</example><example count="894">394000</example><example count="616">492700</example><example count="513">332000</example><example count="443">361000</example><example count="386">340000</example><example count="356">372000</example><example count="293">791099</example><example count="287">783100</example><example count="278">376000</example></stats></total></variable><variable id="phv00294757.v2.p1.c2" var_name="AFUcomp48f1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48F1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>5</male><female>4</female></sex></subject_profile><stats><stat n="23" nulls="364" mean="5.9E+05" sd="210000" median="5.7E+05" min="2.1E+05" max="9.5E+05"/><example count="3">641000</example><example count="2">568520</example><example count="2">376000</example><example count="2">821000</example><example count="2">415500</example><example count="1">422000</example><example count="1">772020</example><example count="1">951836</example><example count="1">771030</example><example count="1">862500</example></stats></total></variable><variable id="phv00294758.v2.p1" var_name="AFUcomp48g_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48G IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1821</male><female>2781</female></sex></subject_profile><stats><stat n="11647" nulls="301179" mean_count="7.529" sd="21.63" median_count="2" min_count="1" max_count="438" distinct_vals="1547"/><example count="438">ASPIRIN</example><example count="208">FISH OIL</example><example count="187">LISINOPRIL</example><example count="187">CENTRUM SILVER</example><example count="185">VITAMIN D</example><example count="183">FUROSEMIDE</example><example count="177">LIPITOR</example><example count="167">SIMVASTATIN</example><example count="152">CALCIUM</example><example count="133">OMEPRAZOLE</example></stats></total></variable><variable id="phv00294758.v2.p1.c1" var_name="AFUcomp48g_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48G IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1816</male><female>2778</female></sex></subject_profile><stats><stat n="11627" nulls="300812" mean_count="7.53" sd="21.63" median_count="2" min_count="1" max_count="437" distinct_vals="1544"/><example count="437">ASPIRIN</example><example count="208">FISH OIL</example><example count="187">LISINOPRIL</example><example count="187">CENTRUM SILVER</example><example count="185">VITAMIN D</example><example count="183">FUROSEMIDE</example><example count="177">LIPITOR</example><example count="167">SIMVASTATIN</example><example count="152">CALCIUM</example><example count="133">OMEPRAZOLE</example></stats></total></variable><variable id="phv00294758.v2.p1.c2" var_name="AFUcomp48g_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48G IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>5</male><female>3</female></sex></subject_profile><stats><stat n="20" nulls="367"/><example count="2">NIACIN</example><example count="1">STALEVO 100</example><example count="1">SUDAFED</example><example count="1">OS CAL 500 + D</example><example count="1">VITAMIN B 12</example><example count="1">VITAMIN C</example><example count="1">QUINAPRIL HCL</example><example count="1">PLAVIX</example><example count="1">ONE DAILY MENS</example><example count="1">NIACIN FLUSH FREE</example></stats></total></variable><variable id="phv00294759.v2.p1" var_name="AFUcomp48g1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48G1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1821</male><female>2781</female></sex></subject_profile><stats><stat n="11645" nulls="301181" mean="5.6E+05" sd="210000" median="5.7E+05" min="11000" max="1.0E+06"/><example count="960">641000</example><example count="633">394000</example><example count="427">492700</example><example count="349">332000</example><example count="303">783100</example><example count="285">361000</example><example count="263">372000</example><example count="247">340000</example><example count="237">791099</example><example count="221">782000</example></stats></total></variable><variable id="phv00294759.v2.p1.c1" var_name="AFUcomp48g1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48G1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1816</male><female>2778</female></sex></subject_profile><stats><stat n="11625" nulls="300814" mean="5.6E+05" sd="210000" median="5.7E+05" min="11000" max="1.0E+06"/><example count="959">641000</example><example count="633">394000</example><example count="427">492700</example><example count="349">332000</example><example count="302">783100</example><example count="284">361000</example><example count="263">372000</example><example count="247">340000</example><example count="236">791099</example><example count="219">782000</example></stats></total></variable><variable id="phv00294759.v2.p1.c2" var_name="AFUcomp48g1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48G1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>5</male><female>3</female></sex></subject_profile><stats><stat n="20" nulls="367" mean="6.1E+05" sd="220000" median="6.9E+05" min="2.1E+05" max="9.5E+05"/><example count="2">782000</example><example count="1">783100</example><example count="1">361000</example><example count="1">791099</example><example count="1">491010</example><example count="1">394500</example><example count="1">950945</example><example count="1">333000</example><example count="1">771030</example><example count="1">821000</example></stats></total></variable><variable id="phv00294760.v2.p1" var_name="AFUcomp48h_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48H IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1449</male><female>2211</female></sex></subject_profile><stats><stat n="8648" nulls="304178" mean_count="6.103" sd="16.91" median_count="1" min_count="1" max_count="341" distinct_vals="1417"/><example count="341">ASPIRIN</example><example count="193">FISH OIL</example><example count="162">VITAMIN D</example><example count="143">CENTRUM SILVER</example><example count="132">FUROSEMIDE</example><example count="124">LISINOPRIL</example><example count="120">CALCIUM</example><example count="109">SIMVASTATIN</example><example count="102">LIPITOR</example><example count="97">CALCIUM + D</example></stats></total></variable><variable id="phv00294760.v2.p1.c1" var_name="AFUcomp48h_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48H IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1446</male><female>2209</female></sex></subject_profile><stats><stat n="8637" nulls="303802" mean_count="6.095" sd="16.87" median_count="1" min_count="1" max_count="340" distinct_vals="1417"/><example count="340">ASPIRIN</example><example count="191">FISH OIL</example><example count="161">VITAMIN D</example><example count="143">CENTRUM SILVER</example><example count="132">FUROSEMIDE</example><example count="124">LISINOPRIL</example><example count="120">CALCIUM</example><example count="109">SIMVASTATIN</example><example count="102">LIPITOR</example><example count="96">CALCIUM + D</example></stats></total></variable><variable id="phv00294760.v2.p1.c2" var_name="AFUcomp48h_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48H IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3</male><female>2</female></sex></subject_profile><stats><stat n="11" nulls="376"/><enum count="2">FISH OIL</enum><enum count="1">ADVIL</enum><enum count="1">VITAMIN D3</enum><enum count="1">QUINAPRIL HCL</enum><enum count="1">CALCIUM + D</enum><enum count="1">VITAMIN D</enum><enum count="1">ASPIRIN BUFFERED (CA CARB MG CARB MG OX) TAB 32...</enum><enum count="1">ASPIRIN</enum><enum count="1">LACTULOSE</enum><enum count="1">MULTI VIT</enum></stats></total></variable><variable id="phv00294761.v2.p1" var_name="AFUcomp48h1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48H1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1448</male><female>2211</female></sex></subject_profile><stats><stat n="8644" nulls="304180" mean="5.7E+05" sd="210000" median="5.8E+05" min="11000" max="1.0E+06"/><example count="703">641000</example><example count="388">394000</example><example count="303">492700</example><example count="240">783100</example><example count="218">332000</example><example count="206">805000</example><example count="192">372000</example><example count="188">361000</example><example count="185">782000</example><example count="183">772020</example></stats></total></variable><variable id="phv00294761.v2.p1.c1" var_name="AFUcomp48h1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48H1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1445</male><female>2209</female></sex></subject_profile><stats><stat n="8633" nulls="303804" mean="5.7E+05" sd="210000" median="5.8E+05" min="11000" max="1.0E+06"/><example count="702">641000</example><example count="388">394000</example><example count="303">492700</example><example count="240">783100</example><example count="218">332000</example><example count="204">805000</example><example count="192">372000</example><example count="187">361000</example><example count="184">782000</example><example count="181">772020</example></stats></total></variable><variable id="phv00294761.v2.p1.c2" var_name="AFUcomp48h1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48H1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>3</male><female>2</female></sex></subject_profile><stats><stat n="11" nulls="376" mean="6.8E+05" sd="150000" median="7.7E+05" min="3.6E+05" max="8.0E+05"/><enum count="2">772020</enum><enum count="2">805000</enum><enum count="1">361000</enum><enum count="1">791099</enum><enum count="1">641099</enum><enum count="1">466000</enum><enum count="1">641000</enum><enum count="1">661000</enum><enum count="1">782000</enum></stats></total></variable><variable id="phv00294762.v2.p1" var_name="AFUcomp48i_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48I IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1127</male><female>1687</female></sex></subject_profile><stats><stat n="6279" nulls="306547" mean_count="5.285" sd="13.02" median_count="1" min_count="1" max_count="240" distinct_vals="1188"/><example count="240">ASPIRIN</example><example count="129">VITAMIN D</example><example count="119">FISH OIL</example><example count="106">CENTRUM SILVER</example><example count="89">CALCIUM</example><example count="83">LISINOPRIL</example><example count="82">FUROSEMIDE</example><example count="80">LIPITOR</example><example count="75">SIMVASTATIN</example><example count="74">CALCIUM + D</example></stats></total></variable><variable id="phv00294762.v2.p1.c1" var_name="AFUcomp48i_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48I IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1125</male><female>1685</female></sex></subject_profile><stats><stat n="6269" nulls="306170" mean_count="5.286" sd="13.02" median_count="1" min_count="1" max_count="240" distinct_vals="1186"/><example count="240">ASPIRIN</example><example count="129">VITAMIN D</example><example count="119">FISH OIL</example><example count="106">CENTRUM SILVER</example><example count="88">CALCIUM</example><example count="83">LISINOPRIL</example><example count="82">FUROSEMIDE</example><example count="80">LIPITOR</example><example count="75">SIMVASTATIN</example><example count="74">CALCIUM + D</example></stats></total></variable><variable id="phv00294762.v2.p1.c2" var_name="AFUcomp48i_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48I IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="10" nulls="377"/><enum count="2">VITAMIN C</enum><enum count="1">SLO NIACIN</enum><enum count="1">MULTI DAY</enum><enum count="1">SINEMET</enum><enum count="1">CALCIUM</enum><enum count="1">ONE DAILY MENS</enum><enum count="1">FLAXSEED OIL</enum><enum count="1">NIASPAN</enum><enum count="1">LORATADINE</enum></stats></total></variable><variable id="phv00294763.v2.p1" var_name="AFUcomp48i1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48I1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1127</male><female>1687</female></sex></subject_profile><stats><stat n="6277" nulls="306549" mean="5.8E+05" sd="210000" median="5.8E+05" min="11000" max="1.0E+06"/><example count="511">641000</example><example count="264">394000</example><example count="193">492700</example><example count="188">783100</example><example count="160">772020</example><example count="155">782000</example><example count="142">791099</example><example count="138">271040</example><example count="127">372000</example><example count="126">332000</example></stats></total></variable><variable id="phv00294763.v2.p1.c1" var_name="AFUcomp48i1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48I1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>1125</male><female>1685</female></sex></subject_profile><stats><stat n="6267" nulls="306172" mean="5.8E+05" sd="210000" median="5.8E+05" min="11000" max="1.0E+06"/><example count="511">641000</example><example count="264">394000</example><example count="193">492700</example><example count="187">783100</example><example count="160">772020</example><example count="154">782000</example><example count="142">791099</example><example count="138">271040</example><example count="127">372000</example><example count="126">332000</example></stats></total></variable><variable id="phv00294763.v2.p1.c2" var_name="AFUcomp48i1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48I1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="10" nulls="377" mean="7.2E+05" sd="170000" median="7.7E+05" min="3.9E+05" max="9.5E+05"/><enum count="2">771080</enum><enum count="1">783100</enum><enum count="1">394500</enum><enum count="1">951836</enum><enum count="1">771030</enum><enum count="1">732099</enum><enum count="1">791000</enum><enum count="1">782000</enum><enum count="1">415500</enum></stats></total></variable><variable id="phv00294764.v2.p1" var_name="AFUcomp48j_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48J IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>860</male><female>1285</female></sex></subject_profile><stats><stat n="4552" nulls="308274" mean_count="4.441" sd="9.83" median_count="1" min_count="1" max_count="159" distinct_vals="1025"/><example count="159">ASPIRIN</example><example count="110">FISH OIL</example><example count="84">VITAMIN D</example><example count="83">CENTRUM SILVER</example><example count="74">CALCIUM</example><example count="59">CALCIUM + D</example><example count="53">OMEPRAZOLE</example><example count="50">METFORMIN HCL</example><example count="49">FUROSEMIDE</example><example count="46">LIPITOR</example></stats></total></variable><variable id="phv00294764.v2.p1.c1" var_name="AFUcomp48j_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48J IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>858</male><female>1283</female></sex></subject_profile><stats><stat n="4544" nulls="307895" mean_count="4.433" sd="9.79" median_count="1" min_count="1" max_count="159" distinct_vals="1025"/><example count="159">ASPIRIN</example><example count="107">FISH OIL</example><example count="84">VITAMIN D</example><example count="83">CENTRUM SILVER</example><example count="74">CALCIUM</example><example count="59">CALCIUM + D</example><example count="52">OMEPRAZOLE</example><example count="50">METFORMIN HCL</example><example count="49">FUROSEMIDE</example><example count="46">LIPITOR</example></stats></total></variable><variable id="phv00294764.v2.p1.c2" var_name="AFUcomp48j_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48J IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="8" nulls="379"/><enum count="3">FISH OIL</enum><enum count="1">PRIMIDONE</enum><enum count="1">OS CAL 500 + D</enum><enum count="1">OMEPRAZOLE</enum><enum count="1">PRILOSEC</enum><enum count="1">METHOTREXATE</enum></stats></total></variable><variable id="phv00294765.v2.p1" var_name="AFUcomp48j1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48J1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>860</male><female>1284</female></sex></subject_profile><stats><stat n="4549" nulls="308276" mean="5.9E+05" sd="210000" median="6.0E+05" min="12000" max="1.0E+06"/><example count="330">641000</example><example count="157">492700</example><example count="147">394000</example><example count="133">783100</example><example count="118">791099</example><example count="111">805000</example><example count="103">271040</example><example count="101">782000</example><example count="98">772020</example><example count="85">791000</example></stats></total></variable><variable id="phv00294765.v2.p1.c1" var_name="AFUcomp48j1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48J1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>858</male><female>1282</female></sex></subject_profile><stats><stat n="4541" nulls="307897" mean="5.9E+05" sd="210000" median="6.0E+05" min="12000" max="1.0E+06"/><example count="330">641000</example><example count="155">492700</example><example count="147">394000</example><example count="133">783100</example><example count="117">791099</example><example count="108">805000</example><example count="103">271040</example><example count="101">782000</example><example count="98">772020</example><example count="85">791000</example></stats></total></variable><variable id="phv00294765.v2.p1.c2" var_name="AFUcomp48j1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48J1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>2</female></sex></subject_profile><stats><stat n="8" nulls="379" mean="6.4E+05" sd="220000" median="7.6E+05" min="2.1E+05" max="8.0E+05"/><enum count="3">805000</enum><enum count="2">492700</enum><enum count="1">791099</enum><enum count="1">213000</enum><enum count="1">726000</enum></stats></total></variable><variable id="phv00294766.v2.p1" var_name="AFUcomp48k_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48K IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>642</male><female>984</female></sex></subject_profile><stats><stat n="3280" nulls="309546" mean_count="3.546" sd="7.005" median_count="1" min_count="1" max_count="99" distinct_vals="925"/><example count="99">ASPIRIN</example><example count="87">FISH OIL</example><example count="65">CENTRUM SILVER</example><example count="60">VITAMIN D</example><example count="46">CALCIUM</example><example count="38">IRON</example><example count="35">CALCIUM + D</example><example count="31">OMEPRAZOLE</example><example count="29">FUROSEMIDE</example><example count="28">LISINOPRIL</example></stats></total></variable><variable id="phv00294766.v2.p1.c1" var_name="AFUcomp48k_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48K IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>640</male><female>983</female></sex></subject_profile><stats><stat n="3275" nulls="309164" mean_count="3.544" sd="6.992" median_count="1" min_count="1" max_count="98" distinct_vals="924"/><example count="98">ASPIRIN</example><example count="87">FISH OIL</example><example count="65">CENTRUM SILVER</example><example count="60">VITAMIN D</example><example count="46">CALCIUM</example><example count="38">IRON</example><example count="35">CALCIUM + D</example><example count="31">OMEPRAZOLE</example><example count="29">FUROSEMIDE</example><example count="28">LISINOPRIL</example></stats></total></variable><variable id="phv00294766.v2.p1.c2" var_name="AFUcomp48k_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48K IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>1</female></sex></subject_profile><stats><stat n="5" nulls="382"/><enum count="1">STALEVO 100</enum><enum count="1">COQ10</enum><enum count="1">DOXYCYCLINE HYCLATE CAP 100 MG</enum><enum count="1">ASPIRIN</enum><enum count="1">PRILOSEC</enum></stats></total></variable><variable id="phv00294767.v2.p1" var_name="AFUcomp48k1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48K1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>642</male><female>984</female></sex></subject_profile><stats><stat n="3280" nulls="309546" mean="6.0E+05" sd="210000" median="6.4E+05" min="12000" max="1.0E+06"/><example count="207">641000</example><example count="100">783100</example><example count="100">492700</example><example count="90">394000</example><example count="90">805000</example><example count="81">791099</example><example count="76">772020</example><example count="76">271040</example><example count="65">782000</example><example count="61">442010</example></stats></total></variable><variable id="phv00294767.v2.p1.c1" var_name="AFUcomp48k1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48K1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>640</male><female>983</female></sex></subject_profile><stats><stat n="3275" nulls="309164" mean="6.0E+05" sd="210000" median="6.4E+05" min="12000" max="1.0E+06"/><example count="206">641000</example><example count="100">783100</example><example count="99">492700</example><example count="90">394000</example><example count="90">805000</example><example count="81">791099</example><example count="76">772020</example><example count="76">271040</example><example count="65">782000</example><example count="61">442010</example></stats></total></variable><variable id="phv00294767.v2.p1.c2" var_name="AFUcomp48k1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48K1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>2</male><female>1</female></sex></subject_profile><stats><stat n="5" nulls="382" mean="5.7E+05" sd="340000" median="6.4E+05" min="40000" max="9.5E+05"/><enum count="1">950945</enum><enum count="1">732099</enum><enum count="1">492700</enum><enum count="1">40000</enum><enum count="1">641000</enum></stats></total></variable><variable id="phv00294768.v2.p1" var_name="AFUcomp48l_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48L IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>480</male><female>757</female></sex></subject_profile><stats><stat n="2355" nulls="310471" mean_count="3.103" sd="5.663" median_count="1" min_count="1" max_count="68" distinct_vals="759"/><example count="68">ASPIRIN</example><example count="54">VITAMIN D</example><example count="49">CENTRUM SILVER</example><example count="49">FISH OIL</example><example count="38">CALCIUM + D</example><example count="34">CALCIUM</example><example count="29">MULTIVITAMINS</example><example count="28">LANTUS</example><example count="28">ALBUTEROL</example><example count="26">SIMVASTATIN</example></stats></total></variable><variable id="phv00294768.v2.p1.c1" var_name="AFUcomp48l_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48L IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>480</male><female>756</female></sex></subject_profile><stats><stat n="2354" nulls="310085" mean_count="3.101" sd="5.662" median_count="1" min_count="1" max_count="68" distinct_vals="759"/><example count="68">ASPIRIN</example><example count="54">VITAMIN D</example><example count="49">CENTRUM SILVER</example><example count="49">FISH OIL</example><example count="38">CALCIUM + D</example><example count="34">CALCIUM</example><example count="29">MULTIVITAMINS</example><example count="28">LANTUS</example><example count="28">ALBUTEROL</example><example count="26">SIMVASTATIN</example></stats></total></variable><variable id="phv00294768.v2.p1.c2" var_name="AFUcomp48l_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48L IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><female>1</female></sex></subject_profile><stats><stat n="1" nulls="386"/><enum count="1">LORATADINE</enum></stats></total></variable><variable id="phv00294769.v2.p1" var_name="AFUcomp48l1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48L1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>480</male><female>755</female></sex></subject_profile><stats><stat n="2353" nulls="310471" mean="6.0E+05" sd="210000" median="6.4E+05" min="12000" max="1.0E+06"/><example count="122">641000</example><example count="77">783100</example><example count="67">791099</example><example count="61">772020</example><example count="61">271040</example><example count="60">394000</example><example count="59">782000</example><example count="55">492700</example><example count="54">442010</example><example count="51">805000</example></stats></total></variable><variable id="phv00294769.v2.p1.c1" var_name="AFUcomp48l1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48L1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>480</male><female>754</female></sex></subject_profile><stats><stat n="2352" nulls="310085" mean="6.0E+05" sd="210000" median="6.4E+05" min="12000" max="1.0E+06"/><example count="122">641000</example><example count="77">783100</example><example count="67">791099</example><example count="61">772020</example><example count="61">271040</example><example count="60">394000</example><example count="59">782000</example><example count="55">492700</example><example count="54">442010</example><example count="51">805000</example></stats></total></variable><variable id="phv00294769.v2.p1.c2" var_name="AFUcomp48l1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48L1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><female>1</female></sex></subject_profile><stats><stat n="1" nulls="386" mean="4.2E+05" median="4.2E+05" min="4.2E+05" max="4.2E+05"/><enum count="1">415500</enum></stats></total></variable><variable id="phv00294770.v2.p1" var_name="AFUcomp48m_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48M IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>338</male><female>545</female></sex></subject_profile><stats><stat n="1665" nulls="311161" mean_count="2.685" sd="3.982" median_count="1" min_count="1" max_count="58" distinct_vals="620"/><example count="58">ASPIRIN</example><example count="32">CENTRUM SILVER</example><example count="23">VITAMIN D</example><example count="23">FISH OIL</example><example count="21">CALCIUM</example><example count="20">CALCIUM + D</example><example count="17">ADVAIR DISKUS</example><example count="16">LIPITOR</example><example count="15">VITAMIN C</example><example count="15">LANTUS</example></stats></total></variable><variable id="phv00294770.v2.p1.c1" var_name="AFUcomp48m_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48M IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>338</male><female>545</female></sex></subject_profile><stats><stat n="1665" nulls="310774" mean_count="2.685" sd="3.982" median_count="1" min_count="1" max_count="58" distinct_vals="620"/><example count="58">ASPIRIN</example><example count="32">CENTRUM SILVER</example><example count="23">VITAMIN D</example><example count="23">FISH OIL</example><example count="21">CALCIUM</example><example count="20">CALCIUM + D</example><example count="17">ADVAIR DISKUS</example><example count="16">LIPITOR</example><example count="15">VITAMIN C</example><example count="15">LANTUS</example></stats></total></variable><variable id="phv00294770.v2.p1.c2" var_name="AFUcomp48m_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48M IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294771.v2.p1" var_name="AFUcomp48m1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48M1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>338</male><female>542</female></sex></subject_profile><stats><stat n="1662" nulls="311164" mean="6.0E+05" sd="220000" median="6.2E+05" min="19900" max="1.0E+06"/><example count="101">641000</example><example count="49">394000</example><example count="49">782000</example><example count="47">271040</example><example count="45">783100</example><example count="43">791099</example><example count="36">442010</example><example count="34">492700</example><example count="30">340000</example><example count="26">772020</example></stats></total></variable><variable id="phv00294771.v2.p1.c1" var_name="AFUcomp48m1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48M1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>338</male><female>542</female></sex></subject_profile><stats><stat n="1662" nulls="310777" mean="6.0E+05" sd="220000" median="6.2E+05" min="19900" max="1.0E+06"/><example count="101">641000</example><example count="49">394000</example><example count="49">782000</example><example count="47">271040</example><example count="45">783100</example><example count="43">791099</example><example count="36">442010</example><example count="34">492700</example><example count="30">340000</example><example count="26">772020</example></stats></total></variable><variable id="phv00294771.v2.p1.c2" var_name="AFUcomp48m1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48M1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294772.v2.p1" var_name="AFUcomp48n_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48N IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>245</male><female>395</female></sex></subject_profile><stats><stat n="1193" nulls="311633" mean_count="2.29" sd="3.076" median_count="1" min_count="1" max_count="28" distinct_vals="521"/><example count="28">CENTRUM SILVER</example><example count="26">VITAMIN D</example><example count="26">ASPIRIN</example><example count="20">FISH OIL</example><example count="19">CALCIUM</example><example count="17">CALCIUM + D</example><example count="14">TYLENOL</example><example count="14">MULTIVITAMINS</example><example count="12">PREDNISONE</example><example count="12">LANTUS</example></stats></total></variable><variable id="phv00294772.v2.p1.c1" var_name="AFUcomp48n_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48N IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>245</male><female>395</female></sex></subject_profile><stats><stat n="1193" nulls="311246" mean_count="2.29" sd="3.076" median_count="1" min_count="1" max_count="28" distinct_vals="521"/><example count="28">CENTRUM SILVER</example><example count="26">VITAMIN D</example><example count="26">ASPIRIN</example><example count="20">FISH OIL</example><example count="19">CALCIUM</example><example count="17">CALCIUM + D</example><example count="14">TYLENOL</example><example count="14">MULTIVITAMINS</example><example count="12">PREDNISONE</example><example count="12">LANTUS</example></stats></total></variable><variable id="phv00294772.v2.p1.c2" var_name="AFUcomp48n_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48N IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294773.v2.p1" var_name="AFUcomp48n1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48N1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>245</male><female>394</female></sex></subject_profile><stats><stat n="1192" nulls="311634" mean="5.9E+05" sd="210000" median="6.0E+05" min="19900" max="9.9E+05"/><example count="63">641000</example><example count="38">783100</example><example count="36">271040</example><example count="34">492700</example><example count="30">791099</example><example count="29">772020</example><example count="26">394000</example><example count="25">442010</example><example count="24">642000</example><example count="22">422000</example></stats></total></variable><variable id="phv00294773.v2.p1.c1" var_name="AFUcomp48n1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48N1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>245</male><female>394</female></sex></subject_profile><stats><stat n="1192" nulls="311247" mean="5.9E+05" sd="210000" median="6.0E+05" min="19900" max="9.9E+05"/><example count="63">641000</example><example count="38">783100</example><example count="36">271040</example><example count="34">492700</example><example count="30">791099</example><example count="29">772020</example><example count="26">394000</example><example count="25">442010</example><example count="24">642000</example><example count="22">422000</example></stats></total></variable><variable id="phv00294773.v2.p1.c2" var_name="AFUcomp48n1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48N1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294774.v2.p1" var_name="AFUcomp48o_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48O IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>181</male><female>282</female></sex></subject_profile><stats><stat n="860" nulls="311966" mean_count="1.963" sd="2.323" median_count="1" min_count="1" max_count="25" distinct_vals="438"/><example count="25">VITAMIN D</example><example count="22">ASPIRIN</example><example count="17">FISH OIL</example><example count="13">CENTRUM SILVER</example><example count="11">XALATAN</example><example count="10">PREDNISONE</example><example count="10">ADVAIR DISKUS</example><example count="9">VITAMIN E</example><example count="8">VITAMIN C</example><example count="8">PLAVIX</example></stats></total></variable><variable id="phv00294774.v2.p1.c1" var_name="AFUcomp48o_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48O IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>181</male><female>282</female></sex></subject_profile><stats><stat n="860" nulls="311579" mean_count="1.963" sd="2.323" median_count="1" min_count="1" max_count="25" distinct_vals="438"/><example count="25">VITAMIN D</example><example count="22">ASPIRIN</example><example count="17">FISH OIL</example><example count="13">CENTRUM SILVER</example><example count="11">XALATAN</example><example count="10">PREDNISONE</example><example count="10">ADVAIR DISKUS</example><example count="9">VITAMIN E</example><example count="8">VITAMIN C</example><example count="8">PLAVIX</example></stats></total></variable><variable id="phv00294774.v2.p1.c2" var_name="AFUcomp48o_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48O IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294775.v2.p1" var_name="AFUcomp48o1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48O1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>181</male><female>282</female></sex></subject_profile><stats><stat n="859" nulls="311967" mean="6.0E+05" sd="220000" median="6.4E+05" min="11000" max="1.0E+06"/><example count="35">641000</example><example count="29">772020</example><example count="25">783100</example><example count="23">442010</example><example count="21">492700</example><example count="21">271040</example><example count="18">805000</example><example count="17">394000</example><example count="16">642000</example><example count="15">782000</example></stats></total></variable><variable id="phv00294775.v2.p1.c1" var_name="AFUcomp48o1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48O1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>181</male><female>282</female></sex></subject_profile><stats><stat n="859" nulls="311580" mean="6.0E+05" sd="220000" median="6.4E+05" min="11000" max="1.0E+06"/><example count="35">641000</example><example count="29">772020</example><example count="25">783100</example><example count="23">442010</example><example count="21">492700</example><example count="21">271040</example><example count="18">805000</example><example count="17">394000</example><example count="16">642000</example><example count="15">782000</example></stats></total></variable><variable id="phv00294775.v2.p1.c2" var_name="AFUcomp48o1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48O1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294776.v2.p1" var_name="AFUcomp48p_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48P IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>122</male><female>206</female></sex></subject_profile><stats><stat n="584" nulls="312242" mean_count="1.802" sd="1.633" median_count="1" min_count="1" max_count="13" distinct_vals="324"/><example count="13">CENTRUM SILVER</example><example count="12">VITAMIN C</example><example count="10">VITAMIN D</example><example count="9">ASPIRIN</example><example count="8">FISH OIL</example><example count="8">SPIRIVA HANDIHALER</example><example count="7">GABAPENTIN</example><example count="7">PREDNISONE</example><example count="7">TYLENOL</example><example count="6">CALCIUM + D</example></stats></total></variable><variable id="phv00294776.v2.p1.c1" var_name="AFUcomp48p_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48P IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>122</male><female>206</female></sex></subject_profile><stats><stat n="584" nulls="311855" mean_count="1.802" sd="1.633" median_count="1" min_count="1" max_count="13" distinct_vals="324"/><example count="13">CENTRUM SILVER</example><example count="12">VITAMIN C</example><example count="10">VITAMIN D</example><example count="9">ASPIRIN</example><example count="8">FISH OIL</example><example count="8">SPIRIVA HANDIHALER</example><example count="7">GABAPENTIN</example><example count="7">PREDNISONE</example><example count="7">TYLENOL</example><example count="6">CALCIUM + D</example></stats></total></variable><variable id="phv00294776.v2.p1.c2" var_name="AFUcomp48p_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48P IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294777.v2.p1" var_name="AFUcomp48p1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48P1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>122</male><female>206</female></sex></subject_profile><stats><stat n="584" nulls="312242" mean="5.8E+05" sd="220000" median="5.8E+05" min="19900" max="9.9E+05"/><example count="19">783100</example><example count="19">641000</example><example count="18">394000</example><example count="16">271040</example><example count="15">492700</example><example count="15">642000</example><example count="14">772020</example><example count="14">771080</example><example count="12">863300</example><example count="11">442099</example></stats></total></variable><variable id="phv00294777.v2.p1.c1" var_name="AFUcomp48p1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48P1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>122</male><female>206</female></sex></subject_profile><stats><stat n="584" nulls="311855" mean="5.8E+05" sd="220000" median="5.8E+05" min="19900" max="9.9E+05"/><example count="19">783100</example><example count="19">641000</example><example count="18">394000</example><example count="16">271040</example><example count="15">492700</example><example count="15">642000</example><example count="14">772020</example><example count="14">771080</example><example count="12">863300</example><example count="11">442099</example></stats></total></variable><variable id="phv00294777.v2.p1.c2" var_name="AFUcomp48p1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48P1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294778.v2.p1" var_name="AFUcomp48q_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48Q IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>96</male><female>165</female></sex></subject_profile><stats><stat n="435" nulls="312391" mean_count="1.599" sd="1.497" median_count="1" min_count="1" max_count="14" distinct_vals="272"/><example count="14">ASPIRIN</example><example count="10">FISH OIL</example><example count="8">SIMVASTATIN</example><example count="7">XALATAN</example><example count="7">CENTRUM SILVER</example><example count="7">SPIRIVA HANDIHALER</example><example count="6">VITAMIN D</example><example count="6">METAMUCIL</example><example count="6">FOLIC ACID</example><example count="5">ADVAIR DISKUS</example></stats></total></variable><variable id="phv00294778.v2.p1.c1" var_name="AFUcomp48q_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48Q IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>96</male><female>165</female></sex></subject_profile><stats><stat n="435" nulls="312004" mean_count="1.599" sd="1.497" median_count="1" min_count="1" max_count="14" distinct_vals="272"/><example count="14">ASPIRIN</example><example count="10">FISH OIL</example><example count="8">SIMVASTATIN</example><example count="7">XALATAN</example><example count="7">CENTRUM SILVER</example><example count="7">SPIRIVA HANDIHALER</example><example count="6">VITAMIN D</example><example count="6">METAMUCIL</example><example count="6">FOLIC ACID</example><example count="5">ADVAIR DISKUS</example></stats></total></variable><variable id="phv00294778.v2.p1.c2" var_name="AFUcomp48q_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48Q IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294779.v2.p1" var_name="AFUcomp48q1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48Q1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>96</male><female>165</female></sex></subject_profile><stats><stat n="435" nulls="312391" mean="5.9E+05" sd="210000" median="5.9E+05" min="11000" max="9.7E+05"/><example count="22">641000</example><example count="17">271040</example><example count="15">442010</example><example count="13">394000</example><example count="10">321000</example><example count="10">492700</example><example count="10">805000</example><example count="9">783100</example><example count="9">581600</example><example count="8">772020</example></stats></total></variable><variable id="phv00294779.v2.p1.c1" var_name="AFUcomp48q1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48Q1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>96</male><female>165</female></sex></subject_profile><stats><stat n="435" nulls="312004" mean="5.9E+05" sd="210000" median="5.9E+05" min="11000" max="9.7E+05"/><example count="22">641000</example><example count="17">271040</example><example count="15">442010</example><example count="13">394000</example><example count="10">321000</example><example count="10">492700</example><example count="10">805000</example><example count="9">783100</example><example count="9">581600</example><example count="8">772020</example></stats></total></variable><variable id="phv00294779.v2.p1.c2" var_name="AFUcomp48q1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48Q1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294780.v2.p1" var_name="AFUcomp48r_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48R IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>79</male><female>128</female></sex></subject_profile><stats><stat n="320" nulls="312506" mean_count="1.495" sd="1.125" median_count="1" min_count="1" max_count="8" distinct_vals="214"/><example count="8">FISH OIL</example><example count="7">VITAMIN D</example><example count="6">CALCIUM + D</example><example count="6">ASPIRIN</example><example count="5">OXYCODONE HCL</example><example count="5">XANAX</example><example count="5">SPIRIVA HANDIHALER</example><example count="4">XALATAN</example><example count="4">LIPITOR</example><example count="4">VITAMIN C</example></stats></total></variable><variable id="phv00294780.v2.p1.c1" var_name="AFUcomp48r_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48R IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>79</male><female>128</female></sex></subject_profile><stats><stat n="320" nulls="312119" mean_count="1.495" sd="1.125" median_count="1" min_count="1" max_count="8" distinct_vals="214"/><example count="8">FISH OIL</example><example count="7">VITAMIN D</example><example count="6">CALCIUM + D</example><example count="6">ASPIRIN</example><example count="5">OXYCODONE HCL</example><example count="5">XANAX</example><example count="5">SPIRIVA HANDIHALER</example><example count="4">XALATAN</example><example count="4">LIPITOR</example><example count="4">VITAMIN C</example></stats></total></variable><variable id="phv00294780.v2.p1.c2" var_name="AFUcomp48r_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48R IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294781.v2.p1" var_name="AFUcomp48r1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48R1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>78</male><female>127</female></sex></subject_profile><stats><stat n="318" nulls="312507" mean="6.1E+05" sd="210000" median="6.4E+05" min="50000" max="1.0E+06"/><example count="13">271040</example><example count="12">651000</example><example count="10">641000</example><example count="9">772020</example><example count="9">791099</example><example count="9">823000</example><example count="8">394000</example><example count="8">442010</example><example count="7">642000</example><example count="7">805000</example></stats></total></variable><variable id="phv00294781.v2.p1.c1" var_name="AFUcomp48r1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48R1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>78</male><female>127</female></sex></subject_profile><stats><stat n="318" nulls="312120" mean="6.1E+05" sd="210000" median="6.4E+05" min="50000" max="1.0E+06"/><example count="13">271040</example><example count="12">651000</example><example count="10">641000</example><example count="9">772020</example><example count="9">791099</example><example count="9">823000</example><example count="8">394000</example><example count="8">442010</example><example count="7">642000</example><example count="7">805000</example></stats></total></variable><variable id="phv00294781.v2.p1.c2" var_name="AFUcomp48r1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48R1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294782.v2.p1" var_name="AFUcomp48s_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48S IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>52</male><female>96</female></sex></subject_profile><stats><stat n="225" nulls="312601" mean_count="1.243" sd="0.5836" median_count="1" min_count="1" max_count="5" distinct_vals="181"/><example count="5">MULTIVITAMINS</example><example count="4">CENTRUM SILVER</example><example count="3">VITAMIN B12</example><example count="3">ASPIRIN</example><example count="3">TYLENOL ARTHRITIS PAIN</example><example count="3">FOLIC ACID</example><example count="3">FISH OIL</example><example count="2">ESTROVEN</example><example count="2">SYNTHROID</example><example count="2">TERAZOSIN</example></stats></total></variable><variable id="phv00294782.v2.p1.c1" var_name="AFUcomp48s_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48S IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>52</male><female>96</female></sex></subject_profile><stats><stat n="225" nulls="312214" mean_count="1.243" sd="0.5836" median_count="1" min_count="1" max_count="5" distinct_vals="181"/><example count="5">MULTIVITAMINS</example><example count="4">CENTRUM SILVER</example><example count="3">VITAMIN B12</example><example count="3">ASPIRIN</example><example count="3">TYLENOL ARTHRITIS PAIN</example><example count="3">FOLIC ACID</example><example count="3">FISH OIL</example><example count="2">ESTROVEN</example><example count="2">SYNTHROID</example><example count="2">TERAZOSIN</example></stats></total></variable><variable id="phv00294782.v2.p1.c2" var_name="AFUcomp48s_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48S IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294783.v2.p1" var_name="AFUcomp48s1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48S1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>52</male><female>96</female></sex></subject_profile><stats><stat n="225" nulls="312601" mean="6.1E+05" sd="220000" median="6.4E+05" min="12000" max="1.0E+06"/><example count="9">783100</example><example count="7">782000</example><example count="7">442010</example><example count="6">271040</example><example count="5">821000</example><example count="5">540000</example><example count="5">394000</example><example count="5">642000</example><example count="5">441000</example><example count="5">651000</example></stats></total></variable><variable id="phv00294783.v2.p1.c1" var_name="AFUcomp48s1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48S1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>52</male><female>96</female></sex></subject_profile><stats><stat n="225" nulls="312214" mean="6.1E+05" sd="220000" median="6.4E+05" min="12000" max="1.0E+06"/><example count="9">783100</example><example count="7">782000</example><example count="7">442010</example><example count="6">271040</example><example count="5">821000</example><example count="5">540000</example><example count="5">394000</example><example count="5">642000</example><example count="5">441000</example><example count="5">651000</example></stats></total></variable><variable id="phv00294783.v2.p1.c2" var_name="AFUcomp48s1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48S1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294784.v2.p1" var_name="AFUcomp48t_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48T IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>39</male><female>71</female></sex></subject_profile><stats><stat n="162" nulls="312664" mean_count="1.2" sd="0.5436" median_count="1" min_count="1" max_count="4" distinct_vals="135"/><example count="4">TYLENOL</example><example count="3">XALATAN</example><example count="3">VITAMIN B12</example><example count="3">VITAMIN C</example><example count="3">ADVAIR DISKUS</example><example count="3">CALCIUM + D</example><example count="3">ZOLOFT</example><example count="2">PULMICORT</example><example count="2">XANAX</example><example count="2">ACETAMINOPHEN</example></stats></total></variable><variable id="phv00294784.v2.p1.c1" var_name="AFUcomp48t_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48T IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>39</male><female>71</female></sex></subject_profile><stats><stat n="162" nulls="312277" mean_count="1.2" sd="0.5436" median_count="1" min_count="1" max_count="4" distinct_vals="135"/><example count="4">TYLENOL</example><example count="3">XALATAN</example><example count="3">VITAMIN B12</example><example count="3">VITAMIN C</example><example count="3">ADVAIR DISKUS</example><example count="3">CALCIUM + D</example><example count="3">ZOLOFT</example><example count="2">PULMICORT</example><example count="2">XANAX</example><example count="2">ACETAMINOPHEN</example></stats></total></variable><variable id="phv00294784.v2.p1.c2" var_name="AFUcomp48t_L" calculated_type="string" reported_type=""><description>H. Interview. MEDICATION NAME Q48T IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294785.v2.p1" var_name="AFUcomp48t1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48T1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>39</male><female>71</female></sex></subject_profile><stats><stat n="162" nulls="312664" mean="6.0E+05" sd="220000" median="5.9E+05" min="1.1E+05" max="9.9E+05"/><example count="6">642000</example><example count="5">422000</example><example count="5">641000</example><example count="4">444000</example><example count="4">791099</example><example count="4">321000</example><example count="4">821000</example><example count="4">492700</example><example count="4">442099</example><example count="4">442010</example></stats></total></variable><variable id="phv00294785.v2.p1.c1" var_name="AFUcomp48t1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48T1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><subject_profile><sex><male>39</male><female>71</female></sex></subject_profile><stats><stat n="162" nulls="312277" mean="6.0E+05" sd="220000" median="5.9E+05" min="1.1E+05" max="9.9E+05"/><example count="6">642000</example><example count="5">422000</example><example count="5">641000</example><example count="4">444000</example><example count="4">791099</example><example count="4">321000</example><example count="4">821000</example><example count="4">492700</example><example count="4">442099</example><example count="4">442010</example></stats></total></variable><variable id="phv00294785.v2.p1.c2" var_name="AFUcomp48t1_L" calculated_type="integer" reported_type=""><description>H. Interview. MEDICATION CODE Q48T1 IN AFUL-M [Annual Follow-up Questionnaire Form, Version L]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294786.v2.p1" var_name="AFUcomp11a_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-HEART ATTACK SINCE LAST CONTACT? Q11A IN AFUM; Q36 IN AFU V1-V3; Q10 IN SAF V1-V3</description><total><subject_profile><sex><male>4074</male><female>5655</female></sex></subject_profile><stats><stat n="54685" nulls="258141"/><enum count="54306">N</enum><enum count="357">Y</enum><enum count="22">U</enum></stats></total></variable><variable id="phv00294786.v2.p1.c1" var_name="AFUcomp11a_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-HEART ATTACK SINCE LAST CONTACT? Q11A IN AFUM; Q36 IN AFU V1-V3; Q10 IN SAF V1-V3</description><total><subject_profile><sex><male>4067</male><female>5647</female></sex></subject_profile><stats><stat n="54583" nulls="257856"/><enum count="54204">N</enum><enum count="357">Y</enum><enum count="22">U</enum></stats></total></variable><variable id="phv00294786.v2.p1.c2" var_name="AFUcomp11a_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-HEART ATTACK SINCE LAST CONTACT? Q11A IN AFUM; Q36 IN AFU V1-V3; Q10 IN SAF V1-V3</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="102" nulls="285"/><enum count="102">N</enum></stats></total></variable><variable id="phv00294787.v2.p1" var_name="AFUcomp11c_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-ANGINA SINCE LAST CONTACT? Q11C IN AFUM; Q40 IN AFU V1-V3; Q14 IN SAF V1-V3</description><total><subject_profile><sex><male>4074</male><female>5655</female></sex></subject_profile><stats><stat n="54697" nulls="258129"/><enum count="53684">N</enum><enum count="979">Y</enum><enum count="34">U</enum></stats></total></variable><variable id="phv00294787.v2.p1.c1" var_name="AFUcomp11c_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-ANGINA SINCE LAST CONTACT? Q11C IN AFUM; Q40 IN AFU V1-V3; Q14 IN SAF V1-V3</description><total><subject_profile><sex><male>4067</male><female>5647</female></sex></subject_profile><stats><stat n="54595" nulls="257844"/><enum count="53582">N</enum><enum count="979">Y</enum><enum count="34">U</enum></stats></total></variable><variable id="phv00294787.v2.p1.c2" var_name="AFUcomp11c_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR-ANGINA SINCE LAST CONTACT? Q11C IN AFUM; Q40 IN AFU V1-V3; Q14 IN SAF V1-V3</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="102" nulls="285"/><enum count="102">N</enum></stats></total></variable><variable id="phv00294788.v2.p1" var_name="AFUcomp16_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR - BLOOD CLOT IN LEG SINCE LAST CONTACT? Q16 IN AFUM;Q42 IN AFU V1-V3; Q14A IN SAF V2-V3</description><total><subject_profile><sex><male>4068</male><female>5648</female></sex></subject_profile><stats><stat n="43568" nulls="269258"/><enum count="43281">N</enum><enum count="256">Y</enum><enum count="31">U</enum></stats></total></variable><variable id="phv00294788.v2.p1.c1" var_name="AFUcomp16_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR - BLOOD CLOT IN LEG SINCE LAST CONTACT? Q16 IN AFUM;Q42 IN AFU V1-V3; Q14A IN SAF V2-V3</description><total><subject_profile><sex><male>4061</male><female>5640</female></sex></subject_profile><stats><stat n="43489" nulls="268950"/><enum count="43202">N</enum><enum count="256">Y</enum><enum count="31">U</enum></stats></total></variable><variable id="phv00294788.v2.p1.c2" var_name="AFUcomp16_M" calculated_type="string" reported_type=""><description>C. General Health. DOCTOR - BLOOD CLOT IN LEG SINCE LAST CONTACT? Q16 IN AFUM;Q42 IN AFU V1-V3; Q14A IN SAF V2-V3</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="79" nulls="308"/><enum count="79">N</enum></stats></total></variable><variable id="phv00294789.v2.p1" var_name="AFUcomp21a_M" calculated_type="string" reported_type=""><description>E. Administration. DOCTOR - CANCER SINCE LAST CONTACT Q21A IN AFUM; Q28 IN AFU V1-V3; Q2A IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version M]</description><total><subject_profile><sex><male>4035</male><female>5602</female></sex></subject_profile><stats><stat n="42373" nulls="270453"/><enum count="40783">N</enum><enum count="1567">Y</enum><enum count="23">U</enum></stats></total></variable><variable id="phv00294789.v2.p1.c1" var_name="AFUcomp21a_M" calculated_type="string" reported_type=""><description>E. Administration. DOCTOR - CANCER SINCE LAST CONTACT Q21A IN AFUM; Q28 IN AFU V1-V3; Q2A IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version M]</description><total><subject_profile><sex><male>4028</male><female>5594</female></sex></subject_profile><stats><stat n="42294" nulls="270145"/><enum count="40705">N</enum><enum count="1566">Y</enum><enum count="23">U</enum></stats></total></variable><variable id="phv00294789.v2.p1.c2" var_name="AFUcomp21a_M" calculated_type="string" reported_type=""><description>E. Administration. DOCTOR - CANCER SINCE LAST CONTACT Q21A IN AFUM; Q28 IN AFU V1-V3; Q2A IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version M]</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="79" nulls="308"/><enum count="78">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294790.v2.p1" var_name="AFUcomp2_v1" calculated_type="string" reported_type=""><description>A. Status. IS THE PARTICIPANT DECEASED Q2 IN AFU V1-V3; Q2 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>989</male><female>1123</female></sex></subject_profile><stats><stat n="3556" nulls="309270"/><enum count="2747">N</enum><enum count="809">Y</enum></stats></total></variable><variable id="phv00294790.v2.p1.c1" var_name="AFUcomp2_v1" calculated_type="string" reported_type=""><description>A. Status. IS THE PARTICIPANT DECEASED Q2 IN AFU V1-V3; Q2 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>989</male><female>1123</female></sex></subject_profile><stats><stat n="3556" nulls="308883"/><enum count="2747">N</enum><enum count="809">Y</enum></stats></total></variable><variable id="phv00294790.v2.p1.c2" var_name="AFUcomp2_v1" calculated_type="string" reported_type=""><description>A. Status. IS THE PARTICIPANT DECEASED Q2 IN AFU V1-V3; Q2 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294791.v2.p1" var_name="AFUcomp29_V1" calculated_type="string" reported_type=""><description>D. Cardiovascular Events. MAY I ASK SOME QUESTIONS ABOUT PARTICIPANT'S HEALTH Q29 IN AFU V1-V3; Q3 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>650</male><female>794</female></sex></subject_profile><stats><stat n="2653" nulls="310173"/><enum count="2045">Y</enum><enum count="608">N</enum></stats></total></variable><variable id="phv00294791.v2.p1.c1" var_name="AFUcomp29_V1" calculated_type="string" reported_type=""><description>D. Cardiovascular Events. MAY I ASK SOME QUESTIONS ABOUT PARTICIPANT'S HEALTH Q29 IN AFU V1-V3; Q3 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>650</male><female>794</female></sex></subject_profile><stats><stat n="2653" nulls="309786"/><enum count="2045">Y</enum><enum count="608">N</enum></stats></total></variable><variable id="phv00294791.v2.p1.c2" var_name="AFUcomp29_V1" calculated_type="string" reported_type=""><description>D. Cardiovascular Events. MAY I ASK SOME QUESTIONS ABOUT PARTICIPANT'S HEALTH Q29 IN AFU V1-V3; Q3 IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294792.v2.p1" var_name="AFUcomp29a_V1" calculated_type="string" reported_type=""><description>D. Cardiovascular Events. SOMEONE ELSE WE CAN ASK ABOUT PARTICIPANT'S HEALTH Q29A IN AFU V1-V3; Q3A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>203</male><female>290</female></sex></subject_profile><stats><stat n="590" nulls="312236"/><enum count="587">N</enum><enum count="2">Y</enum><enum count="1">R</enum></stats></total></variable><variable id="phv00294792.v2.p1.c1" var_name="AFUcomp29a_V1" calculated_type="string" reported_type=""><description>D. Cardiovascular Events. SOMEONE ELSE WE CAN ASK ABOUT PARTICIPANT'S HEALTH Q29A IN AFU V1-V3; Q3A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>203</male><female>290</female></sex></subject_profile><stats><stat n="590" nulls="311849"/><enum count="587">N</enum><enum count="2">Y</enum><enum count="1">R</enum></stats></total></variable><variable id="phv00294792.v2.p1.c2" var_name="AFUcomp29a_V1" calculated_type="string" reported_type=""><description>D. Cardiovascular Events. SOMEONE ELSE WE CAN ASK ABOUT PARTICIPANT'S HEALTH Q29A IN AFU V1-V3; Q3A IN SAF V1-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294793.v2.p1" var_name="AFUcomp45_V1" calculated_type="string" reported_type=""><description>Hospitalization for Blood Clot in Leg. BLOOD CLOT IN LUNGS OR A PULMONARY EMBOLUS SINCE LAST CONTACT Q45 IN AFU V1-V3; Q15A IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>3255</male><female>4703</female></sex></subject_profile><stats><stat n="16276" nulls="296550"/><enum count="16220">N</enum><enum count="56">Y</enum></stats></total></variable><variable id="phv00294793.v2.p1.c1" var_name="AFUcomp45_V1" calculated_type="string" reported_type=""><description>Hospitalization for Blood Clot in Leg. BLOOD CLOT IN LUNGS OR A PULMONARY EMBOLUS SINCE LAST CONTACT Q45 IN AFU V1-V3; Q15A IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>3248</male><female>4696</female></sex></subject_profile><stats><stat n="16244" nulls="296195"/><enum count="16188">N</enum><enum count="56">Y</enum></stats></total></variable><variable id="phv00294793.v2.p1.c2" var_name="AFUcomp45_V1" calculated_type="string" reported_type=""><description>Hospitalization for Blood Clot in Leg. BLOOD CLOT IN LUNGS OR A PULMONARY EMBOLUS SINCE LAST CONTACT Q45 IN AFU V1-V3; Q15A IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="32" nulls="355"/><enum count="32">N</enum></stats></total></variable><variable id="phv00294794.v2.p1" var_name="AFUcomp21f_V2" calculated_type="string" reported_type=""><description>C. General Health. WALK SLOWER DUE TO SHORTNESS OF BREATH Q21F IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>25</male><female>56</female></sex></subject_profile><stats><stat n="81" nulls="312745"/><enum count="68">N</enum><enum count="13">Y</enum></stats></total></variable><variable id="phv00294794.v2.p1.c1" var_name="AFUcomp21f_V2" calculated_type="string" reported_type=""><description>C. General Health. WALK SLOWER DUE TO SHORTNESS OF BREATH Q21F IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>25</male><female>56</female></sex></subject_profile><stats><stat n="81" nulls="312358"/><enum count="68">N</enum><enum count="13">Y</enum></stats></total></variable><variable id="phv00294794.v2.p1.c2" var_name="AFUcomp21f_V2" calculated_type="string" reported_type=""><description>C. General Health. WALK SLOWER DUE TO SHORTNESS OF BREATH Q21F IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294795.v2.p1" var_name="AFUcomp28c4_V2" calculated_type="string" reported_type=""><description>C. General Health. CITY OF CLINIC OR INSTITUTION FOR CANCER DOCTOR Q28C4 IN AFU V2-V3; Q2C4 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>14</male><female>15</female></sex></subject_profile><stats><stat n="29" nulls="312797"/><example count="6">Jackson</example><example count="5">WINSTON SALEM</example><example count="4">HAGERSTOWN</example><example count="3">ROBBINSDALE</example><example count="1">OSSEO</example><example count="1">CRYSTAL</example><example count="1">BALTIMORE</example><example count="1">WEST DAVENPORT</example><example count="1">WINCHESTER</example><example count="1">Saint Louis Park</example></stats></total></variable><variable id="phv00294795.v2.p1.c1" var_name="AFUcomp28c4_V2" calculated_type="string" reported_type=""><description>C. General Health. CITY OF CLINIC OR INSTITUTION FOR CANCER DOCTOR Q28C4 IN AFU V2-V3; Q2C4 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>14</male><female>15</female></sex></subject_profile><stats><stat n="29" nulls="312410"/><example count="6">Jackson</example><example count="5">WINSTON SALEM</example><example count="4">HAGERSTOWN</example><example count="3">ROBBINSDALE</example><example count="1">OSSEO</example><example count="1">CRYSTAL</example><example count="1">BALTIMORE</example><example count="1">WEST DAVENPORT</example><example count="1">WINCHESTER</example><example count="1">Saint Louis Park</example></stats></total></variable><variable id="phv00294795.v2.p1.c2" var_name="AFUcomp28c4_V2" calculated_type="string" reported_type=""><description>C. General Health. CITY OF CLINIC OR INSTITUTION FOR CANCER DOCTOR Q28C4 IN AFU V2-V3; Q2C4 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294796.v2.p1" var_name="AFUcomp28c5_V2" calculated_type="string" reported_type=""><description>C. General Health. STATE OF CLINIC OR INSTITUTION FOR CANCER DOCTOR Q28C5 IN AFU V2-V3; Q2C5 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>14</male><female>15</female></sex></subject_profile><stats><stat n="29" nulls="312797"/><enum count="8">MN</enum><enum count="7">MS</enum><enum count="6">NC</enum><enum count="5">MD</enum><enum count="1">VA</enum><enum count="1">OK</enum><enum count="1">FL</enum></stats></total></variable><variable id="phv00294796.v2.p1.c1" var_name="AFUcomp28c5_V2" calculated_type="string" reported_type=""><description>C. General Health. STATE OF CLINIC OR INSTITUTION FOR CANCER DOCTOR Q28C5 IN AFU V2-V3; Q2C5 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>14</male><female>15</female></sex></subject_profile><stats><stat n="29" nulls="312410"/><enum count="8">MN</enum><enum count="7">MS</enum><enum count="6">NC</enum><enum count="5">MD</enum><enum count="1">VA</enum><enum count="1">OK</enum><enum count="1">FL</enum></stats></total></variable><variable id="phv00294796.v2.p1.c2" var_name="AFUcomp28c5_V2" calculated_type="string" reported_type=""><description>C. General Health. STATE OF CLINIC OR INSTITUTION FOR CANCER DOCTOR Q28C5 IN AFU V2-V3; Q2C5 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00376102.v1.p1" var_name="AFUcomp65_V2" calculated_type="string" reported_type=""><description>G. Interview. TOOK ANY PRESCRIPTION MEDICATIONS IN THE PAST 4 WEEKS? Q65 IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>34</male><female>67</female></sex></subject_profile><stats><stat n="101" nulls="312725"/><enum count="97">Y</enum><enum count="4">N</enum></stats></total></variable><variable id="phv00376102.v1.p1.c1" var_name="AFUcomp65_V2" calculated_type="string" reported_type=""><description>G. Interview. TOOK ANY PRESCRIPTION MEDICATIONS IN THE PAST 4 WEEKS? Q65 IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>34</male><female>67</female></sex></subject_profile><stats><stat n="101" nulls="312338"/><enum count="97">Y</enum><enum count="4">N</enum></stats></total></variable><variable id="phv00376102.v1.p1.c2" var_name="AFUcomp65_V2" calculated_type="string" reported_type=""><description>G. Interview. TOOK ANY PRESCRIPTION MEDICATIONS IN THE PAST 4 WEEKS? Q65 IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294797.v2.p1" var_name="AFUcomp65e_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR ASTHMA Q65E IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="87">N</enum><enum count="10">Y</enum></stats></total></variable><variable id="phv00294797.v2.p1.c1" var_name="AFUcomp65e_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR ASTHMA Q65E IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="87">N</enum><enum count="10">Y</enum></stats></total></variable><variable id="phv00294797.v2.p1.c2" var_name="AFUcomp65e_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR ASTHMA Q65E IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294798.v2.p1" var_name="AFUcomp65f_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR CHRONIC BRONCHITIS OR EMPHYSEMA Q65F IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="94">N</enum><enum count="3">Y</enum></stats></total></variable><variable id="phv00294798.v2.p1.c1" var_name="AFUcomp65f_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR CHRONIC BRONCHITIS OR EMPHYSEMA Q65F IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="94">N</enum><enum count="3">Y</enum></stats></total></variable><variable id="phv00294798.v2.p1.c2" var_name="AFUcomp65f_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR CHRONIC BRONCHITIS OR EMPHYSEMA Q65F IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294799.v2.p1" var_name="AFUcomp65g_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR CHEST PAIN OR ANGINA Q65G IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="93">N</enum><enum count="4">Y</enum></stats></total></variable><variable id="phv00294799.v2.p1.c1" var_name="AFUcomp65g_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR CHEST PAIN OR ANGINA Q65G IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="93">N</enum><enum count="4">Y</enum></stats></total></variable><variable id="phv00294799.v2.p1.c2" var_name="AFUcomp65g_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR CHEST PAIN OR ANGINA Q65G IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294800.v2.p1" var_name="AFUcomp65h_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR ABNORMAL HEART RHYTHM Q65H IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="91">N</enum><enum count="6">Y</enum></stats></total></variable><variable id="phv00294800.v2.p1.c1" var_name="AFUcomp65h_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR ABNORMAL HEART RHYTHM Q65H IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="91">N</enum><enum count="6">Y</enum></stats></total></variable><variable id="phv00294800.v2.p1.c2" var_name="AFUcomp65h_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR ABNORMAL HEART RHYTHM Q65H IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294801.v2.p1" var_name="AFUcomp65i_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR BLOOD THINNING Q65I IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="76">N</enum><enum count="21">Y</enum></stats></total></variable><variable id="phv00294801.v2.p1.c1" var_name="AFUcomp65i_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR BLOOD THINNING Q65I IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="76">N</enum><enum count="21">Y</enum></stats></total></variable><variable id="phv00294801.v2.p1.c2" var_name="AFUcomp65i_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR BLOOD THINNING Q65I IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294802.v2.p1" var_name="AFUcomp65j_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR STROKE Q65J IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="95">N</enum><enum count="2">Y</enum></stats></total></variable><variable id="phv00294802.v2.p1.c1" var_name="AFUcomp65j_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR STROKE Q65J IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="95">N</enum><enum count="2">Y</enum></stats></total></variable><variable id="phv00294802.v2.p1.c2" var_name="AFUcomp65j_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR STROKE Q65J IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294803.v2.p1" var_name="AFUcomp65k_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR MINI-STROKE OR TIA Q65K IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>32</male><female>64</female></sex></subject_profile><stats><stat n="96" nulls="312730"/><enum count="96">N</enum></stats></total></variable><variable id="phv00294803.v2.p1.c1" var_name="AFUcomp65k_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR MINI-STROKE OR TIA Q65K IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>32</male><female>64</female></sex></subject_profile><stats><stat n="96" nulls="312343"/><enum count="96">N</enum></stats></total></variable><variable id="phv00294803.v2.p1.c2" var_name="AFUcomp65k_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR MINI-STROKE OR TIA Q65K IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294804.v2.p1" var_name="AFUcomp65l_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR LEG PAIN OR CLAUDICATION Q65L IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>32</male><female>64</female></sex></subject_profile><stats><stat n="96" nulls="312730"/><enum count="91">N</enum><enum count="5">Y</enum></stats></total></variable><variable id="phv00294804.v2.p1.c1" var_name="AFUcomp65l_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR LEG PAIN OR CLAUDICATION Q65L IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>32</male><female>64</female></sex></subject_profile><stats><stat n="96" nulls="312343"/><enum count="91">N</enum><enum count="5">Y</enum></stats></total></variable><variable id="phv00294804.v2.p1.c2" var_name="AFUcomp65l_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR LEG PAIN OR CLAUDICATION Q65L IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294805.v2.p1" var_name="AFUcomp65m_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR DEPRESSION Q65M IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312729"/><enum count="79">N</enum><enum count="18">Y</enum></stats></total></variable><variable id="phv00294805.v2.p1.c1" var_name="AFUcomp65m_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR DEPRESSION Q65M IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>64</female></sex></subject_profile><stats><stat n="97" nulls="312342"/><enum count="79">N</enum><enum count="18">Y</enum></stats></total></variable><variable id="phv00294805.v2.p1.c2" var_name="AFUcomp65m_V2" calculated_type="string" reported_type=""><description>G. Interview. MEDS FOR DEPRESSION Q65M IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294806.v2.p1" var_name="AFUcomp66a_V2" calculated_type="string" reported_type=""><description>G. Interview. REGULARLY TAKE MEDICINE FOR PAIN OR INFLAMMATION THAT DOES NOT CONTAIN ASPIRIN Q66A IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>67</female></sex></subject_profile><stats><stat n="100" nulls="312726"/><enum count="68">N</enum><enum count="32">Y</enum></stats></total></variable><variable id="phv00294806.v2.p1.c1" var_name="AFUcomp66a_V2" calculated_type="string" reported_type=""><description>G. Interview. REGULARLY TAKE MEDICINE FOR PAIN OR INFLAMMATION THAT DOES NOT CONTAIN ASPIRIN Q66A IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>33</male><female>67</female></sex></subject_profile><stats><stat n="100" nulls="312339"/><enum count="68">N</enum><enum count="32">Y</enum></stats></total></variable><variable id="phv00294806.v2.p1.c2" var_name="AFUcomp66a_V2" calculated_type="string" reported_type=""><description>G. Interview. REGULARLY TAKE MEDICINE FOR PAIN OR INFLAMMATION THAT DOES NOT CONTAIN ASPIRIN Q66A IN AFU V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294807.v2.p1" var_name="AFUcomp28c6_V2" calculated_type="string" reported_type=""><description>C. General Health. DATE YOU MOST RECENTLY VISITED FOR CANCER Q28C6 IN AFU V2-V3; Q2C6 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>14</male><female>15</female></sex></subject_profile><stats><stat n="29" nulls="312797"/><example count="5">14-Mar</example><example count="5">14-Jan</example><example count="4">14-Feb</example><example count="3">14-Apr</example><example count="3">13-Dec</example><example count="2">14-Jul</example><example count="2">13-Nov</example><example count="1">14-Jun</example><example count="1">13-Jan</example><example count="1">==/2013</example></stats></total></variable><variable id="phv00294807.v2.p1.c1" var_name="AFUcomp28c6_V2" calculated_type="string" reported_type=""><description>C. General Health. DATE YOU MOST RECENTLY VISITED FOR CANCER Q28C6 IN AFU V2-V3; Q2C6 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>14</male><female>15</female></sex></subject_profile><stats><stat n="29" nulls="312410"/><example count="5">14-Mar</example><example count="5">14-Jan</example><example count="4">14-Feb</example><example count="3">14-Apr</example><example count="3">13-Dec</example><example count="2">14-Jul</example><example count="2">13-Nov</example><example count="1">14-Jun</example><example count="1">13-Jan</example><example count="1">==/2013</example></stats></total></variable><variable id="phv00294807.v2.p1.c2" var_name="AFUcomp28c6_V2" calculated_type="string" reported_type=""><description>C. General Health. DATE YOU MOST RECENTLY VISITED FOR CANCER Q28C6 IN AFU V2-V3; Q2C6 IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294808.v2.p1" var_name="AFUcomp64f_V2" calculated_type="string" reported_type=""><description>F. Invasive Procedures. APPROXIMATE DATE FOR ANGIOPLASTY OR STENT Q64F IN AFU V2-V3; Q32F IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>10</male><female>1</female></sex></subject_profile><stats><stat n="11" nulls="312815"/><enum count="4">13-Dec</enum><enum count="2">14-Jul</enum><enum count="1">14-Feb</enum><enum count="1">14-Jun</enum><enum count="1">==/2013</enum><enum count="1">14-Mar</enum><enum count="1">14-Jan</enum></stats></total></variable><variable id="phv00294808.v2.p1.c1" var_name="AFUcomp64f_V2" calculated_type="string" reported_type=""><description>F. Invasive Procedures. APPROXIMATE DATE FOR ANGIOPLASTY OR STENT Q64F IN AFU V2-V3; Q32F IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><subject_profile><sex><male>10</male><female>1</female></sex></subject_profile><stats><stat n="11" nulls="312428"/><enum count="4">13-Dec</enum><enum count="2">14-Jul</enum><enum count="1">14-Feb</enum><enum count="1">14-Jun</enum><enum count="1">==/2013</enum><enum count="1">14-Mar</enum><enum count="1">14-Jan</enum></stats></total></variable><variable id="phv00294808.v2.p1.c2" var_name="AFUcomp64f_V2" calculated_type="string" reported_type=""><description>F. Invasive Procedures. APPROXIMATE DATE FOR ANGIOPLASTY OR STENT Q64F IN AFU V2-V3; Q32F IN SAF V2-V3 [Annual Follow-up Questionnaire Form, Version V2]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294809.v2.p1" var_name="AFUcomp3_V1" calculated_type="string" reported_type=""><description>D. Death Information. DEATH REPORTED BY Q3 IN AFU V1-V3; Q1 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>419</male><female>390</female></sex></subject_profile><stats><stat n="809" nulls="312017"/><enum count="510">A</enum><enum count="284">C</enum><enum count="15">B</enum></stats></total></variable><variable id="phv00294809.v2.p1.c1" var_name="AFUcomp3_V1" calculated_type="string" reported_type=""><description>D. Death Information. DEATH REPORTED BY Q3 IN AFU V1-V3; Q1 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>419</male><female>390</female></sex></subject_profile><stats><stat n="809" nulls="311630"/><enum count="510">A</enum><enum count="284">C</enum><enum count="15">B</enum></stats></total></variable><variable id="phv00294809.v2.p1.c2" var_name="AFUcomp3_V1" calculated_type="string" reported_type=""><description>D. Death Information. DEATH REPORTED BY Q3 IN AFU V1-V3; Q1 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294810.v2.p1" var_name="AFUcomp6_V1" calculated_type="string" reported_type=""><description>B. Death Information. ABLE TO ANSWER QUESTIONS ABOUT HOSPITALIZATION OCCURRED SINCE LAST CONTACT Q6 IN AFU V1-V3; Q4 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>412</male><female>383</female></sex></subject_profile><stats><stat n="795" nulls="312031"/><enum count="634">Y</enum><enum count="161">N</enum></stats></total></variable><variable id="phv00294810.v2.p1.c1" var_name="AFUcomp6_V1" calculated_type="string" reported_type=""><description>B. Death Information. ABLE TO ANSWER QUESTIONS ABOUT HOSPITALIZATION OCCURRED SINCE LAST CONTACT Q6 IN AFU V1-V3; Q4 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>412</male><female>383</female></sex></subject_profile><stats><stat n="795" nulls="311644"/><enum count="634">Y</enum><enum count="161">N</enum></stats></total></variable><variable id="phv00294810.v2.p1.c2" var_name="AFUcomp6_V1" calculated_type="string" reported_type=""><description>B. Death Information. ABLE TO ANSWER QUESTIONS ABOUT HOSPITALIZATION OCCURRED SINCE LAST CONTACT Q6 IN AFU V1-V3; Q4 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294811.v2.p1" var_name="AFUcomp6a_V1" calculated_type="string" reported_type=""><description>B. Death Information. SOMEONE ELSE COULD ANSWER QUESTIONS ABOUT HOSPITALIZATION OCCURRED SINCE LAST CONTACT Q6A IN AFU V1-V3; Q5 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>75</male><female>85</female></sex></subject_profile><stats><stat n="160" nulls="312666"/><enum count="141">N</enum><enum count="18">Y</enum><enum count="1">R</enum></stats></total></variable><variable id="phv00294811.v2.p1.c1" var_name="AFUcomp6a_V1" calculated_type="string" reported_type=""><description>B. Death Information. SOMEONE ELSE COULD ANSWER QUESTIONS ABOUT HOSPITALIZATION OCCURRED SINCE LAST CONTACT Q6A IN AFU V1-V3; Q5 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>75</male><female>85</female></sex></subject_profile><stats><stat n="160" nulls="312279"/><enum count="141">N</enum><enum count="18">Y</enum><enum count="1">R</enum></stats></total></variable><variable id="phv00294811.v2.p1.c2" var_name="AFUcomp6a_V1" calculated_type="string" reported_type=""><description>B. Death Information. SOMEONE ELSE COULD ANSWER QUESTIONS ABOUT HOSPITALIZATION OCCURRED SINCE LAST CONTACT Q6A IN AFU V1-V3; Q5 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294812.v2.p1" var_name="AFUcomp7_V1" calculated_type="string" reported_type=""><description>B. Death Information. HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT (DECEASED PARTICIPANTS) Q7 IN AFU V1-V3; Q6 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>343</male><female>309</female></sex></subject_profile><stats><stat n="652" nulls="312174"/><enum count="547">N</enum><enum count="105">Y</enum></stats></total></variable><variable id="phv00294812.v2.p1.c1" var_name="AFUcomp7_V1" calculated_type="string" reported_type=""><description>B. Death Information. HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT (DECEASED PARTICIPANTS) Q7 IN AFU V1-V3; Q6 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>343</male><female>309</female></sex></subject_profile><stats><stat n="652" nulls="311787"/><enum count="547">N</enum><enum count="105">Y</enum></stats></total></variable><variable id="phv00294812.v2.p1.c2" var_name="AFUcomp7_V1" calculated_type="string" reported_type=""><description>B. Death Information. HOSPITALIZED FOR HEART ATTACK SINCE LAST CONTACT (DECEASED PARTICIPANTS) Q7 IN AFU V1-V3; Q6 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><stats><stat n="0" nulls="387"/></stats></total></variable><variable id="phv00294813.v2.p1" var_name="AFUcomp71_V1" calculated_type="string" reported_type=""><description>H. Administration Information. AFU COMPLETION STATUS Q71 IN AFU V1-V3; Q33 IN SAF V1-V3; Q13 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>3562</male><female>5033</female></sex></subject_profile><stats><stat n="16154" nulls="296672"/><enum count="16126">A</enum><enum count="27">C</enum><enum count="1">B</enum></stats></total></variable><variable id="phv00294813.v2.p1.c1" var_name="AFUcomp71_V1" calculated_type="string" reported_type=""><description>H. Administration Information. AFU COMPLETION STATUS Q71 IN AFU V1-V3; Q33 IN SAF V1-V3; Q13 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>3555</male><female>5026</female></sex></subject_profile><stats><stat n="16126" nulls="296313"/><enum count="16098">A</enum><enum count="27">C</enum><enum count="1">B</enum></stats></total></variable><variable id="phv00294813.v2.p1.c2" var_name="AFUcomp71_V1" calculated_type="string" reported_type=""><description>H. Administration Information. AFU COMPLETION STATUS Q71 IN AFU V1-V3; Q33 IN SAF V1-V3; Q13 IN DEC V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="28" nulls="359"/><enum count="28">A</enum></stats></total></variable><variable id="phv00294814.v2.p1" var_name="AFUcomp4_SAFV1" calculated_type="string" reported_type=""><description>B. Death Information. TRACING SHEET INDICATE DOCTOR-HEART FAILURE OR CONGESTIVE HEART FAILURE? Q4 IN SAFV1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>2920</male><female>4222</female></sex></subject_profile><stats><stat n="11126" nulls="301700"/><enum count="10327">N</enum><enum count="799">Y</enum></stats></total></variable><variable id="phv00294814.v2.p1.c1" var_name="AFUcomp4_SAFV1" calculated_type="string" reported_type=""><description>B. Death Information. TRACING SHEET INDICATE DOCTOR-HEART FAILURE OR CONGESTIVE HEART FAILURE? Q4 IN SAFV1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>2913</male><female>4215</female></sex></subject_profile><stats><stat n="11103" nulls="301336"/><enum count="10305">N</enum><enum count="798">Y</enum></stats></total></variable><variable id="phv00294814.v2.p1.c2" var_name="AFUcomp4_SAFV1" calculated_type="string" reported_type=""><description>B. Death Information. TRACING SHEET INDICATE DOCTOR-HEART FAILURE OR CONGESTIVE HEART FAILURE? Q4 IN SAFV1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>7</male><female>7</female></sex></subject_profile><stats><stat n="23" nulls="364"/><enum count="22">N</enum><enum count="1">Y</enum></stats></total></variable><variable id="phv00294815.v2.p1" var_name="AFUcomp5_SAFV1" calculated_type="string" reported_type=""><description>B. Death Information. TRACING SHEET INDICATE DOCTOR-WEAK HEART OR FLUID ON THE LUNGS? Q5 IN SAF V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>2712</male><female>3998</female></sex></subject_profile><stats><stat n="10286" nulls="302540"/><enum count="10253">N</enum><enum count="33">Y</enum></stats></total></variable><variable id="phv00294815.v2.p1.c1" var_name="AFUcomp5_SAFV1" calculated_type="string" reported_type=""><description>B. Death Information. TRACING SHEET INDICATE DOCTOR-WEAK HEART OR FLUID ON THE LUNGS? Q5 IN SAF V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>2706</male><female>3991</female></sex></subject_profile><stats><stat n="10265" nulls="302174"/><enum count="10232">N</enum><enum count="33">Y</enum></stats></total></variable><variable id="phv00294815.v2.p1.c2" var_name="AFUcomp5_SAFV1" calculated_type="string" reported_type=""><description>B. Death Information. TRACING SHEET INDICATE DOCTOR-WEAK HEART OR FLUID ON THE LUNGS? Q5 IN SAF V1 [Annual Follow-up Questionnaire Form, Version V1]</description><total><subject_profile><sex><male>6</male><female>7</female></sex></subject_profile><stats><stat n="21" nulls="366"/><enum count="21">N</enum></stats></total></variable><variable id="phv00294816.v2.p1" var_name="Age" calculated_type="integer" units="Years" reported_type=""><description>Age at Contact</description><total><subject_profile><sex><male>6633</male><female>7854</female></sex></subject_profile><stats><stat n="312227" nulls="599" mean="65.96" sd="8.797" median="66" min="43" max="&gt;89"/><example count="13287">65</example><example count="13234">66</example><example count="13114">69</example><example count="13011">67</example><example count="12900">68</example><example count="12897">64</example><example count="12798">70</example><example count="12439">63</example><example count="11869">62</example><example count="11831">71</example></stats></total></variable><variable id="phv00294816.v2.p1.c1" var_name="Age" calculated_type="integer" units="Years" reported_type=""><description>Age at Contact</description><total><subject_profile><sex><male>6626</male><female>7846</female></sex></subject_profile><stats><stat n="311840" nulls="599" mean="65.96" sd="8.797" median="66" min="43" max="&gt;89"/><example count="13272">65</example><example count="13217">66</example><example count="13098">69</example><example count="12997">67</example><example count="12883">68</example><example count="12882">64</example><example count="12780">70</example><example count="12423">63</example><example count="11855">62</example><example count="11820">71</example></stats></total></variable><variable id="phv00294816.v2.p1.c2" var_name="Age" calculated_type="integer" units="Years" reported_type=""><description>Age at Contact</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="387" nulls="0" mean="64.75" sd="8.706" median="65" min="46" max="82"/><example count="18">70</example><example count="18">59</example><example count="17">68</example><example count="17">66</example><example count="16">69</example><example count="16">63</example><example count="15">64</example><example count="15">65</example><example count="15">60</example><example count="14">62</example></stats></total></variable><variable id="phv00294817.v2.p1" var_name="AFUcompFU" calculated_type="integer" reported_type=""><description>Follow-up days to contact since baseline</description><total><subject_profile><sex><male>6633</male><female>7854</female></sex></subject_profile><stats><stat n="312227" nulls="599" mean="4433" sd="2602" median="4343" min="0" max="9095"/><example count="272">371</example><example count="270">364</example><example count="269">370</example><example count="250">369</example><example count="241">3219</example><example count="238">377</example><example count="237">372</example><example count="235">378</example><example count="235">379</example><example count="233">375</example></stats></total></variable><variable id="phv00294817.v2.p1.c1" var_name="AFUcompFU" calculated_type="integer" reported_type=""><description>Follow-up days to contact since baseline</description><total><subject_profile><sex><male>6626</male><female>7846</female></sex></subject_profile><stats><stat n="311840" nulls="599" mean="4433" sd="2602" median="4343" min="0" max="9095"/><example count="272">371</example><example count="270">364</example><example count="268">370</example><example count="250">369</example><example count="241">3219</example><example count="238">377</example><example count="237">372</example><example count="234">378</example><example count="234">379</example><example count="232">375</example></stats></total></variable><variable id="phv00294817.v2.p1.c2" var_name="AFUcompFU" calculated_type="integer" reported_type=""><description>Follow-up days to contact since baseline</description><total><subject_profile><sex><male>7</male><female>8</female></sex></subject_profile><stats><stat n="387" nulls="0" mean="4837" sd="2665" median="4821" min="315" max="9031"/><example count="2">4418</example><example count="2">4738</example><example count="2">8954</example><example count="2">6564</example><example count="2">6112</example><example count="2">7213</example><example count="2">8381</example><example count="2">1462</example><example count="2">2176</example><example count="2">8322</example></stats></total></variable></data_table>
